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The changing landscape of oncology
Over the recent years, the treatment of patients with solid tumors has been subject to a 
paradigm shift. Whereas patients have traditionally been treated according to the organ 
the tumor originated from, new insights into the molecular mechanisms underlying 
progression and dissemination of cancer have caused us to increasingly relinquish 
this anatomical cancer subdivision. Specific factors, e.g. growth factor receptors and 
mutations in oncogenes, have been found to be involved in tumori- and mutagenesis, 
but have also been found to contribute to variable degrees across different tumors. In 
fact, every tumor seems to have its own genetic signature and no two tumors – within 
or between patients – are identical [1]. 
Although the development of small molecules targeting these factors has extended 
our arsenal of treatment options and has improved outcome for many patients, great 
challenges still remain. Targeted treatments have only been shown to be efficacious 
in patients whose tumors are positive for the targeted factor [2, 3], which requires us 
to incorporate molecular diagnostics into the clinical work-up in order to discriminate 
patients with a high likelihood of benefiting from a specific targeted treatment from 
patients unlikely to respond to treatment. However, the presence of a factor in tumor 
cells may not be stable, but may vary over time and between the different tumor 
sites within an individual patient (Figure 1) [4, 5]. This so-called temporal and spatial 
heterogeneity, respectively, results from the genomic instability that is characteristic for 
tumors and forces us to consider the dynamic changes in the molecular characteristics 
of a tumor with the interpretation of the molecular work-up. 
Already, the assessment of the presence of certain predictive factors, e.g. the estrogen 
receptor (ER) for the treatment of breast cancer patients with aromatase inhibitors or 
tamoxifen, the Human Epidermal Growth Factor Receptor 2 (HER2) for the treatment of 
breast cancer patients with trastuzumab or lapatinib [2, 6, 7], and BRAF mutations for the 
treatment of melanoma patients with vemurafenib [3], has been incorporated into clinical 
care. Notwithstanding clinical guidelines recommending the use of metastatic tissue [8, 
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Figure 1. Schematic representation of the development and dissemination of a tumor. The current main 
hypothesis of clonal evolution states that a primary tumor develops as one homogeneous clone from a single 
cell (left). Random genetic changes, such as mutations and amplifications, occur in the instable genome and 
result in genetically and phenotypically different subclones (middle). The primary tumor is now considered 
spatially heterogeneous. Although not all subclones may acquire the ability to metastasize like the blue, green, 
and yellow clones, they may release CTCs into the circulation as illustrated by the dark purple clone. The CTCs 
that survive in the blood stream and are able to colonize distant tissue may grow out to metastases. New 
genomic changes occurring in the proliferating metastatic cells may cause the characteristics of the metastatic 
sites to significantly differ from the primary tumor, giving rise to intertumoral or temporal heterogeneity. Also, 
the metastatic sites themselves can again become spatially heterogeneous due to the formation of different 
subclones, which all may shed CTCs into the circulation. PT = primary tumor; CTC = circulating tumor cell; M= 
metastasis.
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9], predictive factors are currently mostly determined on the primary tumor; tissue from 
a primary tumor is routinely available for most patients and taking biopsies of metastatic 
sites can be painful and is not without risk. However, the dynamic changes that occur 
in the molecular make-up of a tumor over time and under treatment pressure and the 
consequent heterogeneity between primary tumors and metastatic sites make primary 
tumor tissue less suitable for analysis, especially when metastatic disease develops after 
a latency period of months or even years after the initial presentation. For example, 
the expression of ER and HER2 – both important treatment targets for patients with 
metastatic breast cancer (MBC) – have been observed to be discordant between a distant 
metastasis and the primary tumor in 13-37% and 6-34% of the patients, respectively [10-
15]. In prostate cancer, AR mutations, amplifications, and splice variants have only rarely 
been found in primary tumors, but have been detected in the metastases from patients 
with metastatic castration-resistant prostate cancer (MCRPC) in frequencies of 30-60% 
[16-18]. Primary tumors and metastases from patients with metastatic colorectal cancer 
(MCRC) have found to be discordant in the mutational status of the KRAS oncogene in 
8-23% of the patients [19-21]. These examples underline the urgency for tools enabling to 
capture the extent of tumor heterogeneity and to monitor the molecular characteristics 
of a metastatic tumor in real-time.
Circulating tumor cells
The characterization of circulating tumor cells (CTCs) from the peripheral blood has been 
proposed as a minimally invasive tool to assess tumor characteristics at a specific point in 
time. After detachment from a solid tumor – either the primary tumor or a metastatic site 
(Figure 1) – CTCs float freely in the peripheral blood of patients with different forms and 
stages of epithelial cancer, where they can be captured after a simple venipuncture [22]. 
Although first described in the publication “A case of cancer in which cells similar to those 
in the tumours were seen in the blood after death” by Thomas Ashworth in 1869 [23], 
it took over a century to discover the clinical relevance of the drifting CTCs. Technical 
obstacles due to the rarity of CTCs in the circulation have mainly caused this time lag. Only 
on average one cell amidst a few billion hematological cells is a CTC, making detection 
extremely challenging. The first applied detection methods were reverse transcription 
polymerase chain reaction (RT-PCR), immunofluorescence (IF) and flow cytometry, but 
these techniques lacked the sensitivity to discover the clinical value of CTCs [24-26]. 
A boost in research occurred after the development of the first semi-automated CTC 
detection and enumeration platform: the CellSearch System (Janssen Diagnostics LLC, 
Raritan, NJ). Based on the expression of the Epithelial Cell Adhesion Molecule (EpCAM), 
epithelial cells are immunomagnetically enriched in this system, followed by IF staining to 
discriminate CTCs from the remaining leukocytes; CTCs stain positive for cytokeratin (CK)-
phycoerythrin (PE) and the double-stranded DNA stain 4’,6-diamidino-2-phenylindole 
(DAPI), but negative for cluster of differentiation molecule (CD) 45-allophycocyanin 
(APC), leukocytes on the other hand stain positive for CD45-APC and DAPI, but negative 
for CK-PE (Figure 2). All the enriched and stained cells are thereafter transferred to a 
cartridge, which is scanned by digital fluorescence microscopy. After analysis and 
processing, a selection of images positive for both CK-PE and DAPI is presented to the 
operator for further assessment (Figure 3). All cells with a round to oval morphology, a 
diameter ≥4 µm, an intact cell membrane, and a nucleus which overlaps ≥50% with the 
cell membrane are counted, leading to the final enumeration of the CTCs present in the 
sample of 7.5 mL peripheral blood. 
In 2004, the United States Food and Drug Administration (FDA) provided clearance for 
the clinical use of a CTC count from 7.5 mL of blood by the CellSearch System following 
the demonstration of a strong, independent prognostic value of CTCs in patients with 
MBC [27]. In this study, it was found that patients with a favorable CTC count of <5/7.5 
mL of blood before the start of systemic therapy as well as during treatment had a 
longer median progression-free and overall survival (PFS and OS, respectively) than the 
patients with an unfavorable count of ≥5 CTCs/7.5 mL of blood. Moreover, it was shown 
that switches from favorable to unfavorable CTC counts or vice versa during treatment 
predicted for treatment resistance or response, respectively, as early as after the first 
cycle of chemotherapy [28]. The prediction of treatment resistance by changes in CTC 
counts was shown to be more accurate at an earlier stage than the conventional methods 
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using radiology or serum cancer antigens [29]. Similar results have been observed in 
patients with MCRPC, where treatment response evaluation by CTC counts was shown 
to be more accurate than radiology, bone scintigraphy, and serum levels of prostate-
specific antigen (PSA) [30]. Over the years, the prognostic value of CTCs enumerated 
by the CellSearch System has been confirmed for many other types of epithelial cancers 
[26], including primary breast cancer (PBC, [31, 32]), MCRC [33]), lung cancer [34, 35], 
melanoma [36], pancreatic cancer [37], esophageal cancer [38], and hepatocellular 
cancer [39].   
The commercial availability of the CellSearch system has led to an exponential increase 
in the number of publications on the clinical value of CTCs over the past years (Figure 
4). While studies initially focused on the prognostic value of CTCs before and during 
treatment, this has swiftly shifted to the predictive value and the utility of CTCs for well-
considered targeted treatment decisions. With a short circulating half-life of only a few 
hours [40, 41], CTCs may form an invaluable source of real-time information on metastatic 
tumor characteristics, thereby potentially offering a minimally invasive alternative for 
tissue biopsies. Importantly, expanded knowledge of the biological behavior of CTCs will 
be needed to allow for full appreciation of the clinical relevance of CTCs. For example, 
after detachment from a solid tumor, CTCs have to survive in the circulation. In order to 
do so, they are thought to change their epithelial phenotype to a more mesenchymal-like 
phenotype through a process called epithelial-to-mesenchymal transition (EMT) [42]. In 
this process, expression levels of cell-adhesion proteins like EpCAM and E-cadherin are 
downregulated, and mesenchymal proteins like N-cadherin and vimentin are upregulated 
[43]. Subsequently, before extravasation from the circulation and the formation of new 
metastases, CTCs are supposed to undergo the reverse process of mesenchymal-to-
epithelial transition (MET) [42]. These biological changes in CTCs will have to be taken 
into consideration with the use of CTCs as “liquid biopsy”. 
Unfortunately, research on the biology of CTCs and the predictive value of CTC 
characteristics remains hampered by technical issues. The generally low number of 
A.
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D.
Anti-EpCAM antibodies 
with iron 
nanoparticle Biotin - streptavidin Fluorescent antibodies
EpCAM
Figure 2. The enrichment and detection of CTCs from peripheral blood as done by the CellSearch System. A 
sample of 7.5 mL whole blood is inserted into the CellSearch AutoPrep System (A). In this system, plasma is as-
pirated and anti-EpCAM antibodies to which an iron nanoparticle is bound are added together with biotin and 
streptavidin (B). After binding of the anti-EpCAM antibodies, the EpCAM-positive CTCs present in the blood 
become magnetic. The biotin-streptavadin network with binding of additional anti-EpCAM ferrofluid antibod-
ies further strengthen the magnetism, which makes the isolation of even 1 CTC in 7.5 mL blood possible. After 
an incubation step against a strong magnet (C), all magnetic cells plus a surplus of trapped leukocytes remain 
while the other cells are washed away. To discriminate between CTCs and the remaining leukocytes, fluores-
cent antibodies are added (D). After scanning by a fluorescence microscope, the CTC count from the initial 7.5 
mL blood can be determined.
Figure 3. Examples of two presented CK-PE and DAPI positive events present in a CellSearch cartridge after 
CellSearch enrichment, staining and scanning by the CellTracks Analyzer digital fluorescence microscope. The 
final selection and enumeration of the CTCs from 7.5 mL blood has to be done manually by counting all CK-PE/
DAPI positive and CD45-APC negative, intact cells that are larger than 4 µm. The upper row shows an CTC, 
which has been selected for couting. The lower row shows a cell that stains dimly for CK-PE, but brightly for 
CD45-APC. This cell is a leukocyte and is therefore not counted. The FITC channel is left open for additional 
staining and characterization of the CTCs, for example for the expression of HER2. 
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CTCs present in a blood sample and the large surplus of leukocytes that remain even 
after enrichment require characterization assays to be extremely sensitive and specific. 
The characterization of CTCs for the presence of proteins [44-46], DNA mutations [19, 
47], amplifications [48], and specific gene transcripts [49, 50] has proven feasible, but 
prospective clinical trials investigating the clinical relevance of the presence of these 
factors are still scarce. Attempts have been made to increase the CTC capture rate, for 
example by using other capture markers besides EpCAM [24]. Also, methods have now 
become available enabling the interrogation of pure CTC fractions or even single CTCs 
[51, 52]. Such technologies will likely help to further improve our understanding of CTCs 
and to determine the position of CTCs in clinical care.
Scope of this thesis
The studies described in this thesis focused on the technical aspects of CTC characterization 
and the clinical significance of CTCs in terms of the prognostic and predictive value. In 
chapter 2 a study is described in which a new approach to improve the CTC detection 
rate of the CellSearch System in patients with locally advanced breast cancer was tested. 
Also, the associations between CTC counts and outcome to neoadjuvant chemotherapy 
were investigated. In chapter 3 an overview is provided of the currently available CTC 
characterization methods along with their advantages and disadvantages. Besides, the 
different studies investigating the clinical value of CTC characteristics for patients with 
breast cancer are summarized as an indication of where we stand in this field. Chapter 
4 contains a study in which the expression levels of tumor-associated genes were 
determined in the CellSearch-enriched CTCs from patients with MBC. The resulting gene 
expression profiles were compared to the primary tumors with the aim to investigate to 
what extent CTCs differ from the primary tumors. The discordance in the expression of the 
endocrine treatment target ER between the CTCs and the corresponding primary tumor 
was also analyzed separately given its direct clinical relevance. Lastly, the prognostic 
value of discordant CTC profiles for OS was investigated. In chapter 5, the alterations 
in the expression of tumor-associated genes in CTCs were explored further, this time 
in patients with MCRC. The gene expression profiles of matching primary tumors, liver 
metastases, and CTCs were compared, allowing us to investigate whether CTCs more 
closely resembled the metastases than the primary tumor. In chapter 6, recent studies 
investigating the prognostic and predictive value of CTCs for the treatment of patients 
with MCRPC are summarized. More specifically, recommendations are given how to use 
CTCs as a tool for optimal sequencing of the new treatment options that have become 
available over the past decade. In chapter 7, an approach is described to measure the 
presence of the androgen receptor splice variant 7 (AR-V7) in the CTCs from patients with 
MCRPC. The presence of AR-V7 in CTCs measured by the AdnaTest (Qiagen, Hannover, 
GE) has been shown to be a prognostic factor under treatment with abiraterone or 
enzalutamide [53]. The aim of the study described in chapter 7 was to evaluate the 
prognostic value of the presence of AR-V7 for response to cabazitaxel and to explore 
whether CTCs can aid in treatment decision-making in this setting. Lastly, in chapter 8, 
the results obtained from the studies described in this thesis are put into perspective, 
and recommendations and future directions are given.  
Figure 4. The number of publications in PubMed from 1990 until April 2016 as indexed by the terms “circulating 
epithelial cells” or “circulating tumor cells” at July 1st, 2016. A further increase is expected for the remainder 
of 2016.
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Circulating tumor cells (CTCs) are detected by the CellSearch System in 20-25% of 
primary breast cancer (PBC) patients. To improve CTC detection, we investigated 
melanoma cell adhesion molecule (MCAM) as enrichment marker next to epithelial 
cell adhesion molecule (EpCAM) and tested the clinical relevance of MCAM-positive 
CTCs in patients with HER2-negative stage II/III pBC starting neoadjuvant chemo-
therapy (NAC) in the NEOZOTAC trial. Using the CellSearch System, EpCAM-positive 
and MCAM-positive CTCs were separately enriched from 7.5 mL blood, at baseline 
and after the first NAC cycle. Circulating endothelial cells (CECs) were measured 
using flow cytometry. Primary objective was to improve the CTC detection rate to 
≥40% combining EpCAM/MCAM. Correlations of CTC and CEC counts and patho-
logical complete response (pCR) were also explored. At baseline, we detected Ep-
CAM-positive and MCAM-positive CTCs in 12 of 68 (18%) and 8 of 68 (12%) patients, 
respectively. After one cycle, this was 7 of 44 (16%) and 7 of 44 (16%) patients, re-
spectively. The detection rate improved from 18% at baseline and 16% after one cycle 
with EpCAM to 25% (P=0.08) and 30% (P=0.02), respectively, with EpCAM/MCAM. No 
patients with MCAM-positive CTCs versus 23% of the patients without MCAM-posi-
tive CTCs at baseline achieved pCR (P=0.13). EpCAM-positive CTCs and CEC counts 
were not correlated to pCR. Combined EpCAM/MCAM CellSearch enrichment thus 
increased the CTC detection rate in stage II/III pBC. We found no associations of 
CTC and CEC counts with pCR to NAC. The clinical relevance MCAM-positive CTCs 
deserves further study. 
ABSTRACT
Introduction
A circulating tumor cell (CTC) count from peripheral blood as measured by the Food and 
Drug Administration (FDA)-approved CellSearch System (Janssen Diagnostics, Raritan, 
NJ) is a strong prognostic factor in both primary and metastatic breast cancers [1]. 
Although 70% of the patients with metastatic breast cancer (MBC) have ≥1 CTC/7.5 mL 
of blood, in primary breast cancer (PBC) this proportion is only as low as 20-25% [1-6]. In 
both cases, the presence of CTCs is associated with poor prognosis. For MBC, patients 
with ≥5 CTCs/7.5 mL blood have significantly shorter median progression-free survival 
(PFS) and overall survival (OS) compared with patients with <5 CTCs [1,7,8]. For PBC, 
patients with ≥1 CTC do significantly worse concerning disease-free survival (DFS) and OS 
compared with patients without CTCs [1,3,5-7]. 
Improvements in the detection of CTCs can be made. The CellSearch System relies on 
the expression of the epithelial cell adhesion molecule (EpCAM; CD326) on CTCs and 
misses EpCAM-negative CTCs [8-11]. We showed that particularly breast cancer cell lines 
with epithelial-to-mesenchymal transition (EMT) features lack expression of EpCAM 
and are therefore not detected by the CellSearch System [9,12]. Because cells that have 
undergone EMT probably represent an aggressive, clinically relevant subpopulation of 
CTCs [10], we aimed to detect EpCAM-negative CTCs by alternative approaches. We found 
melanoma cell adhesion molecule (MCAM; CD146) to be expressed on EpCAM-negative 
breast cancer cell lines and tested its use as enrichment marker next to EpCAM. In a small 
series of MBC patients, MCAM-positive CTCs were detected in 9 out of 20 patients (45%), 
suggesting that CTC detection can be improved using this dual enrichment approach [9]. 
Besides CTCs, circulating endothelial cells (CECs) have been proposed as a prognostic 
marker in breast cancer [13]. Being sloughed off the vessel wall, they are a putative 
marker of angiogenesis and vascular damage. Accordingly, increased CEC counts are 
found in patients with different solid malignancies, including breast cancer [13]. However, 
the clinical value of CEC counts before start of and changes during treatment remain to 
be investigated.
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In this study we used an EpCAM/MCAM CellSearch enrichment approach to improve CTC 
detection in patients with stage II/III breast cancer starting neoadjuvant chemotherapy 
(NAC). Primary objective was to improve the CTC detection rate from approximately 
20% to 40% of patients. Secondary objectives were to determine baseline CEC counts 
and changes of CTCs and CECs during NAC, and to investigate associations between 
the presence and dynamics of EpCAM-positive and MCAM-positive CTCs and CECs with 
pathological complete response (pCR) to NAC.
Patients and methods
Patients
As a side-study to the NEOZOTAC trial – a multicenter, randomized phase III trial 
initiated by the Dutch Breast Cancer Research Group (BOOG; ref 14) – patients with 
HER2-negative stage II/III breast cancer who provided additional informed consent for 
CTC blood sampling were enrolled. Patients were treated with neoadjuvant docetaxel/
doxorubicin/cyclophosphamide (TAC) ± zoledronic acid (ZA) and underwent surgery 
afterwards. Pathological responses on primary tumors and lymph nodes were scored 
by a pathologist at the Leiden University Medical Center, Leiden, The Netherlands. 
The definition for pCR was a total absence of invasive tumor cells. This side-study was 
approved by the Erasmus MC (METC 10-229) and local Institutional Review Boards.
Blood draws and sample processing
Before start of and after the first NAC cycle, 2x10 mL blood was drawn into CellSave 
preservative tubes (Janssen Diagnostics). All samples were processed within 96 hours 
at the central laboratory, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 
Two CTC enumerations, both from 7.5 mL of blood, were done using the CellSearch 
System as described before [9]. In brief, EpCAM-positive and MCAM-positive CTCs 
were enumerated in two separate runs using the CellSearch Epithelial Cell Kit (Janssen 
Diagnostics). For the MCAM enrichment, anti-MCAM ferrofluid-bound antibodies from 
the CellSearch Circulating Endothelial Cell kit (Janssen Diagnostics) were used and 
fluorescein isothiocyanate (FITC)-conjugated CD34 (BD Biosciences, clone 8G12) was 
added as extra marker to exclude a subset of cytokeratin (CK)-18 expressing CECs [9]. 
Nucleated, EpCAM or MCAM-enriched cells, positive for CK8/18/19, and negative for 
CD45 and CD34 for the MCAM-positive cells were considered CTCs. To enable distinction 
between EpCAM-positive and MCAM-positive CTCs separate EpCAM- and MCAM-
enrichments were run. Combined EpCAM/MCAM CTC counts were calculated afterwards, 
using the sum of both separate enrichments. 
The enumeration of CECs was done from 4 mL of blood using a flowcytometric assay 
with CD34+/DNA+/CD146+/CD45- as CEC phenotype, as described in full detail before [14]. 
Immunohistochemistry on primary tumor tissue
Expression of EpCAM and MCAM was evaluated on diagnostic core needle biopsies 
of primary tumors taken before NAC. Slides were incubated with anti-MCAM (1:100, 
clone N1238; Abcam, Cambridge, UK) or anti-EpCAM (1:500, clone VU1D9; Cell Signaling 
Technologies, Beverly, MA), followed by the Envision System (DAKO, Glostrup, Denmark) 
and counterstaining with hematoxylin. Scoring of staining intensity (negative/weak/
moderate/strong) and estimation of the percentage of positive tumor cells were done 
by a well-trained technician and pathologist. 
Statistics
The primary objective of this study was to improve the CTC detection rate in patients with 
PBC using the EpCAM/MCAM enrichment approach. The overall relapse rate in breast 
cancer approximates 40% [15]. Since this study included patients with a poor prognosis, 
we deemed an improvement in CTC detection rate from 20 to 25% with EpCAM [2,3,6] 
to ≥40% using the extended approach clinically relevant. In patients with stage II/III PBC 
starting NAC, EpCAM-positive CTCs have before been detected in 46/213 (22%) [2] and 
22/97 (23%) [5]. Using these numbers, with an alpha of 0.05 and power 0.80, we had 
to enroll 57 patients. Secondary objectives included (i) assessment of CEC counts at 
baseline and changes thereof during NAC, and (ii) associations of CTCs and CEC numbers 
and changes thereof with pCR to NAC.
Standard statistical tests were applied: binomial tests for percentages, Pearson’s 
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Chi-square tests for categorical variables, and Student t or Mann-Whitney U tests for 
continuous variables. Changes in CEC counts were tested by the Wilcoxon signed rank 
test. Binomial tests were one-sided, all other tests were two-sided. We considered a 
P<0.05 as statistically significant. Analyses were performed using SPSS 21 (IBM, Armonk, 
NY, USA). 
Results
From December 2010 until May 2012, 81 patients were recruited from the NEOZOTAC trial 
[16]. Only patients with both EpCAM and MCAM enumerations available were used in the 
analyses, leaving 68 evaluable patients at baseline – thus meeting our power calculations 
– and 39 patients after one NAC cycle (Figure 1). The characteristics of the 68 patients are 
summarized in Table 1 and specified per patient in Supplementary Table S1. 
CTC counts
At baseline, 12 patients (18%) had ≥1 EpCAM-positive CTC(s) (median 1, range 1 – 4) and 
8 (12%) had ≥1 MCAM-positive CTC(s) (median 1, range 1 – 5). Five patients (7%) had 
MCAM-positive CTCs only. The CTC detection rate increased from 18% with EpCAM alone 
to 25% when considering all EpCAM-positive and/or MCAM-positive CTCs (P=0.08). The 
comparison between EpCAM-positive and MCAM-positive CTCs is shown in Table 2A. 
After the first NAC cycle, we detected EpCAM-positive CTCs in 6 patients (15%; median 
1, range 1 – 7) and MCAM-positive CTCs in 6 patients (15%; median 1, range 1 – 4). Only 
one patient had both five EpCAM-positive CTCs and one MCAM-positive CTC. The CTC 
detection rate at this time point significantly increased from 16% with EpCAM only, to 30% 
using EpCAM/MCAM combined (P=0.02; Table 2B).
Comparing CTC counts at baseline and after the first cycle, 5 patients (13%) switched from 
CTC-negative to positive when considering EpCAM-positive CTCs. Three of these patients 
did not have any MCAM-positive CTCs at both time points, whereas 2 had one MCAM-
positive CTC after the first NAC cycle, of whom 1 had no MCAM-positive CTCs at baseline. 
In 5 other patients we detected MCAM-positive CTCs after the first NAC cycle, whereas 
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there were none detectable at baseline. None of these patients had EpCAM-positive 
CTCs at baseline or after the first cycle. One patient (3%) had MCAM-positive CTCs at 
both time points and also turned positive for EpCAM-positive CTCs during NAC. Figure 
2 (left three bars) shows the observed directions of changes in CTC counts during NAC.
Endothelial cell counts
At baseline and after the first cycle, CECs were enumerated in 68 and 42 patients, 
respectively (Figure 1). Median CEC counts were 44.5/4 mL blood (range 3-1,475) at 
baseline and 144.5/4 mL blood (range 9-807) after the first cycle. In the 42 patients with 
CEC counts at both time points available we observed a significant median increase 
during the first NAC cycle from 31.5 to 144.5 CECs (P<0.001; Figure 3). In 10 patients (24%), 
CECs decreased during treatment. 
Associations with clinical parameters
We found no associations between the presence of EpCAM-positive and/or MCAM-
positive CTC(s) at baseline and clinical characteristics (Table 1). Fourteen of the 68 
patients (21%) achieved a pCR to NAC. The presence of EpCAM-positive CTC(s) at baseline 
was not correlated with pCR. Interestingly, none of the 8 patients with ≥1 MCAM-positive 
CTC(s) at baseline achieved pCR compared to 14 of the 60 patients (23%) without MCAM-
positive CTCs (P=0.13). Changes of either EpCAM-positive or MCAM-positive CTCs during 
NAC were not associated with pCR (Figure 2, middle and right bars). 
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56 12 68 37 7 44
Table 2. Observed CTC counts after EpCAM versus MCAM enrichment in patients with both enumerations 
available at baseline (A.), and after the first cycle of NAC (B.). Both enrichments were done from 7.5 mL of 
blood in separate runs and compared afterwards. A positive CTC count means ≥1 CTC/7.5 mL.
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Median CEC counts at baseline were 61.5/4 mL in the 14 patients with pCR compared with 
40.5 in the 54 patients without pCR (P=0.37). In the 42 patients with both CEC counts 
available, comparable median increases were observed between patients with and 
without pCR to NAC (Figure 3). The pCR rate in patients with decreasing CEC counts was 
2/10 (20%), which was not different from the 7 of the 32 patients (22%; P=0.90) with pCR 
and increasing CEC counts.  
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Expression of EpCAM and MCAM in primary tumors
Core needle biopsies taken before NAC were collected from 65 patients. In 5 patients, 
no invasive tumor or too few tumor cells were present for reliable evaluation, leaving 
60 tumors for the evaluation of EpCAM expression. All tumors were positive for EpCAM, 
but seven tumors showed an EpCAM-negative focus and six had an EpCAM-weak focus. 
Expression of MCAM could be assessed in 59 tumors and was found positive in 11 (19%; 
Supplementary figure S1, Supplementary Table S1). The expression of EpCAM/MCAM in 
primary tumors was not correlated to the presence of MCAM-positive CTCs at baseline. 
No MCAM-positive CTCs were detected in patients with MCAM-positive tumors. We 
detected MCAM-positive CTCs in 14% of the patients with an EpCAM-negative focus in 
the primary tumor compared with 33% of the patients with an EpCAM-weak focus and 6% 
of the patients with homogeneously EpCAM-positive tumors.
Discussion
In this study, we investigated MCAM as additional CellSearch enrichment marker next 
to EpCAM to improve the CTC capture rate in stage II/III breast cancer. At baseline, 
the CTC detection rate increased from 18% using EpCAM only to 25% using both MCAM 
and EpCAM. After one NAC cycle we observed a significant increase from 16% to 30%. 
Nevertheless, the primary goal to improve the detection rate to ≥40%, at beforehand 
defined as clinically relevant, was not met. 
Neither the presence of EpCAM-positive or MCAM-positive CTCs at baseline, nor 
changes of CTCs after the first NAC cycle correlated with clinicopathological parameters. 
Interestingly, none of the patients with MCAM-positive CTCs at baseline achieved 
pCR compared with 23% of the patients without MCAM-positive CTCs. Although not 
statistically significant, this difference may point to a prognostic unfavorable value of 
MCAM-positive CTCs and deserves further study. The pCR rate between patients with 
and without EpCAM-positive CTCs was similar. Baseline CEC counts and changes of either 
CECs or CTCs during NAC were not associated with pCR in our patient group. Associations 
with clinical outcome in terms of DFS and OS will have to be awaited. 
Three other studies investigated the predictive and/or prognostic values of CTCs in the 
neoadjuvant setting (Table 3; refs. [2,5-7,17]). The 11 to 23% of the patients found CTC-
positive by EpCAM enrichment in these trials compares well with the 18% we found using 
the EpCAM enrichment only. Also in agreement with our findings, neither the presence 
of CTCs before or after NAC, nor changes during treatment correlated with pCR 
[2,5,17]. Importantly, in the REMAGUS02 trial, pCR was no prognostic factor for distant 
metastasis-free survival (DMFS) and OS, whereas the baseline CTC count was [6,7]. The 
presence of CTCs thus might outperform pCR as prognostic factor in patients treated 
with NAC, possibly as indicator of the presence of micrometastases.
Increasing the CTC capture rate from peripheral blood will probably improve the 
prognostic and predictive value of CTC enumeration. Because MCAM is an EMT-inducer 
[18,19], it might be a valuable enrichment marker for mesenchymal CTCs. Epithelial and 
mesenchymal CTCs were found to co-occur in patients with MBC, but mesenchymal cells 
Reference Trial
Detection  
platform
Blood 
volume 
(mL)
N
CTC positive 
patients Correla-
tion with 
pCR
DMFS OSpre 
NAC
post 
NAC
Pierga et al. 
(2008) [5]
REMAGUS02 CellSearch 7.5 115 23% 17% No
HR 5.0  
(95% CI 1.4-17; 
P=0.01)  
36 mo FU 
HR 9.0  
(95% CI 1.8-45; 
P=0.007)  
36  mo FU
Bidard et al. 
(2009, 2013) 
[6,7]
- HR 2.4  
(95% CI 0.9-6, 
P=0.06)  
70  mo FU
- HR 3.0  
(95 CI 1.0 - 9.5; 
P=0.05)  
70 mo FU
Riethdorf et 
al. (2010) [2]
GeparQuattro CellSearch 7.5 287 22% 11% No NR NR
Azim et al. 
(2013) [17]
NeoALLTO
CellSearch 
after Ficoll 
density 
gradient 
separation
22.5 51 11% 13% No NR NR
Table 3. Overview of relevant literature concerning the prognostic value of CTCs in patients with PBC treated 
with NAC.
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showed to be better capable in predicting treatment failure [10]. Previously, we showed 
that the CellSearch System misses EpCAM-negative breast cancer cell lines with EMT 
features and that recovery of these cell lines improves using MCAM, which is frequently 
expressed on these cell lines [9,12]. We investigated the dual EpCAM/MCAM enrichment 
approach in patients with MBC and detected MCAM-positive CTCs in 9 of 20 patients 
(45%) [9]. Although associations with clinical outcome were not investigated, we 
hypothesized that MCAM-positive CTCs represent the mesenchymal, more aggressive 
subtype of CTCs. An upregulation of EMT-related transcription factors in CTCs during NAC 
has also been reported, possibly as a survival mechanism for CTCs during chemotherapy 
[20]. More insight into the process of EMT and the phenotype of mesenchymal CTCs 
will be required to investigate the clinical relevance of mesenchymal CTCs. Besides a 
loss of EpCAM, we found a downregulation of cytokeratins. Instead we found CD49f 
to be upregulated. Combining cytokeratin staining with CD49f in the CellSearch System 
resulted in improved recovery of cell lines with EMT features [21]. The value of CD49f 
on the recovery of MCAM-positive CTCs and the clinical value thereof will be subject in 
a future study. 
Little is known about the prognostic value of CECs in breast cancer. Research in this field 
is greatly hampered by the lack of consensus on CEC phenotype. Consequently, different 
CEC definitions are handled and observed CEC counts using the different techniques 
are a 1,000-fold apart. Nonvalidated methods also showed to count macroparticles and 
large platelets as CECs, leading to incomparable results [13,22]. Technical obstacles have 
to be taken before concluding on the clinical value of CEC counts. Using a thoroughly 
validated flowcytometric method to measure CECs in 4 mL of peripheral blood [15], we 
found increasing CEC numbers during NAC, but no associations with pCR to NAC. The 
increase in CECs probably represent vascular damage due to NAC [13]. Whether this is 
associated with long-term vascular complications warrants additional studies. 
In conclusion, using MCAM as additional enrichment marker next to EpCAM in the 
CellSearch System might improve the detection of CTCs in stage II/III breast cancer. 
Whether the detection of MCAM-positive CTCs and changes thereof during treatment of 
localized or metastatic breast cancer are of clinical relevance in terms of clinical outcome 
deserves further investigation. 
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Supplementary Figure S1. Examples of EpCAM and MCAM staining in primary tumor tissues from core needle 
biopsies taken before start of NAC at 200x and 600x (inserts) magnification. A and B. Tumor with EpCAM-
positive (asterisk) and EpCAM-negative (arrow) foci. Both foci show moderate positivity for MCAM as can 
be deduced from the brown membrane staining. C and D. Strongly EpCAM-positive tumor surrounded by 
EpCAM-negative stroma. This tumor shows no staining for MCAM. As a positive control, staining can be found 
in MCAM-positive endothelium of small vasculature in the surrounding stroma (arrows). E and F. Strongly 
EpCAM-positive tumor, also positive for MCAM. The surrounding infiltrate is negative for both EpCAM and 
MCAM. Vasculature surrounded by infiltrate (arrow as example) is positive for MCAM.
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TOWARDS A PERSONALIZED BREAST CANCER TREATMENT 
APPROACH GUIDED BY CIRCULATING TUMOR CELL 
CHARACTERISTICS
Wendy Onstenk, Jan-Willem Gratama, John A. Foekens, and Stefan Sleijfer
Cancer Treatment Reviews, 2013; 39(7): p. 691-700.
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Circulating tumor cells (CTCs) can be found in the peripheral blood of patients with 
different solid tumors, including breast cancer. A CTC count is a strong established 
prognostic factor in various stages in several tumor types. Besides that, characteriza-
tion of CTCs is expected to become an invaluable tool to predict treatment response 
and personalize cancer treatments. Likely, CTCs are shed by different tumor lesions 
and may therefore provide a comprehensive view of tumor characteristics at a cer-
tain time-point, including inter- and intratumoral heterogeneity. Obtained through 
a simple venipuncture, CTCs could this way serve as a “liquid biopsy”. However, iso-
lation and subsequent characterization of CTCs is technically extremely challenging, 
mainly due to the small number of cells amidst a large majority of leukocytes. A wide 
range of assays have been developed, but only the CellSearch System (Veridex, Rari-
tan, NJ, USA) has obtained FDA clearance for CTC enumeration so far. For character-
ization purposes, no assay has been validated at all. Nevertheless, the first studies 
investigating the clinical value of CTC characteristics have been performed. Here, we 
review these clinical studies. The various techniques used to interrogate CTCs are 
briefly described and an overview of the clinical relevance of CTC characterization in 
breast cancer is given.
ABSTRACT
Introduction
In today’s clinical oncology the dogma is shifting to personalizing treatments. Here, 
treatments are deliberately chosen based on tumor cell characteristics, thereby selecting 
agents that specifically target factors essential in the biology of the tumor. Successful 
examples of this approach include the use of imatinib in gastro-intestinal stromal tumors 
(GIST), vemurafenib in BRAFV600-mutated melanoma, and crizotinib in non-small cell 
lung cancer with EML4-ALK translocations. However, eventually resistance to targeted 
agents emerges due to the genomic instability of cancer and inter- and intratumoral 
heterogeneity. This eventually leads to survival and growth of resistant tumor cell clones 
under the pressure of treatment [1,2]. Consequently, differences arise in the molecular 
make-up of a tumor over time. Treatment decisions thus must be made on the basis of 
tumor cell characteristics, not only just prior to treatment initiation, but also repetitively 
during treatment to adapt systemic therapy when necessary.
In metastatic breast cancer (MBC), two proteins are essential for treatment decision 
making: the human epidermal growth factor receptor-2 (HER2) and the estrogen receptor 
(ER). Presence of these predictive factors is usually assessed on primary tumor tissue in 
standard daily practice. However, it is increasingly recognized that primary tumors and 
the different metastatic lesions can greatly differ in molecular characteristics, including 
differences in HER2 and ER expression [1,3]. In the metastatic setting such predictive 
factors thus should be determined in metastatic tissue rather than falling back on the 
primary tumor. Since taking biopsies from metastases is often painful and frequently 
technically not possible, circulating tumor cells (CTCs) from peripheral blood form an 
attractive alternative for the assessment of predictive factors. A CTC count is a strong 
prognostic factor at all time-points during treatment in MBC [4] and characterization of 
CTCs could even be of greater importance. As CTCs may be released by several separate 
tumor lesions, they possibly provide a comprehensive view of tumor characteristics, 
including inter- and intratumoral heterogeneity. Furthermore, CTCs are obtained through 
a simple venipuncture, which enables repetitive and real-time monitoring of a tumor’s 
characteristics, thereby serving as a “liquid biopsy”.
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Isolation of CTCs from peripheral blood is still technically extremely challenging 
(reviewed in [5]). With respect to CTC enumeration, the CellSearch System (Veridex 
LLC, Raritan, NJ) is the only Food and Drug Administration (FDA)-cleared technique, 
whereas characterization assays have not yet been validated at all. But despite this lack 
of validated characterization assays, the first studies investigating the clinical value of 
CTC characterization have already been performed. In this review, advances in the field 
of CTC characterization in breast cancer are discussed. It is beyond the scope of this 
review to address all the available characterization techniques and the accompanying 
technical issues. Instead, we focus on the clinical relevance of CTC characterization in 
breast cancer and provide a short overview of the techniques used so far to investigate 
the clinical value of CTC characteristics. 
CTC characterization methods
Characterization of CTCs is technically challenging for two main reasons: the low number 
of cells and the leukocyte background. Using the CellSearch System, CTCs are detectable 
in 70% of MBC patients, but only in 50% a number of ≥5 CTCs/7.5 mL blood is found [6]. 
In primary breast cancer (PBC), ≥1 CTC(s)/7.5 mL of blood can be found in only 24% of 
the patients [7]. Part of the explanation for the low numbers of detectable CTCs is that 
most isolation assays still rely on an epithelial cell adhesion molecule (EpCAM)-based 
enrichment step. However, EpCAM-negative CTCs exist, for example due to epithelial-
to-mesenchymal-transition (EMT). In this process, CTCs lose their epithelial phenotype, 
including the expression of EpCAM and cytokeratins (CKs) [8,9]. These CTCs may thus 
be missed by currently available assays, which all are based on EpCAM-positivity of 
the tumor cells. Furthermore, the enriched CTCs that are isolated are outnumbered 
by a 1,000 - 10,000-fold excess of “contaminating” leukocytes. Highly sensitive assays 
are thus needed to characterize small numbers of CTCs in enriched samples, and the 
presence of leukocytes may yield false-positive findings in such assays. Over the years, 
many new methods have been developed to characterize CTCs on the level of protein 
expression, mRNA expression and chromosomal abnormalities. However, none of these 
assays have yet been validated and they all have their advantages and disadvantages 
(Table 1). Below the techniques are described that have been used to investigate the 
clinical value of CTCs. It is beyond the scope of this review to provide a full overview of 
all possible characterization techniques.
Table 1. Summary of currently used CTC characterization methods.
Method Advantages Disadvantages
Protein expression
Immunofluorescence CTC count can be obtained in the same assay
No cut-off at the sample level available 
due to heterogeneity between CTCs in one 
sample
Heterogeneity between cells can 
be assessed Limited possibilities for multiplexing
Cut-off defined at the cell-level 
by comparison with cell line cells 
for HER2
Interactions between proteins 
can be studied
mRNA expression
Polymerase chain 
reaction (PCR)
Multiplexing possible up to a 
large number of genes
No information on CTC cell count in a 
sample
Only small reaction volumes 
required Information on heterogeneity is lost
Severely hampered by contaminating 
leukocytes
Chromosomal abnormalities
Fluorescence in situ 
hybridization (FISH)
CTC count can be obtained in the 
same assay
Lower sensitivity for small genes due to the 
large size of FISH probes
Heterogeneity between cells can 
be assessed
Knowledge needed of possibly altered 
genes for design of probes
Limited possibilities for multiplexing
Protein expression
The most validated, and the only currently commercially available characterization assay, 
is immunofluorescence staining of HER2 using the CellSearch System, using the fourth 
spare filter on the CellTracks Analyzer digital microscope. Fluorescein isothiocyanate 
(FITC)-labeled monoclonal antibodies directed against HER2 are added simultaneously 
with anti-CK, anti-CD45 and DAPI - used for the discrimination of CTCs from leukocytes- 
and CTC enumeration and characterization for HER2 expression are simultaneously 
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carried out on the microscope. Using this assay, overexpression on the protein level 
has shown to correlate well with gene amplification when assessed in parallel by 
fluorescence in situ hybridization (FISH) on cytospun CTCs obtained from cell lines and 
patient samples [10-14]. The direct comparison of immunocytochemistry with FISH led 
to a 0-3 immunofluorescence intensity score, where 0 and 1+ stand for HER2-negative 
CTCs and 2+ and 3+ indicate HER2-positivity [13,14]. Recently, an automated approach 
has been proposed using a dynamic cut-off that differs per sample. For this, an algorithm 
is applied that measures the intensity of HER2 immunofluorescence staining of both the 
CTCs and the leukocytes in a sample. Only CTCs with an HER2 intensity staining greater 
than the 91st percentile of the intensity staining of all leukocytes in that same sample 
are considered HER2-positive [15]. However, heterogeneity in HER2 expression exists 
between the different CTCs within one sample, likewise tumor cells within primary tumors 
and metastases.[1-3] This heterogeneity makes it difficult to assess HER2-positivity for 
the whole sample [10,13-18]. Different cut-offs for HER2-positivity have been proposed 
on the sample-level, including ≥1 CTC 2+ or 3+ [14,16], ≥50% or ≥75% of CTCs positive for 
HER2 in a sample[11,15] and a calculated score using immunofluorescence intensity and 
the percentage of positive cells [10]. Importantly, studies to compare and validate the 
proposed sample-level cut-offs with respect to clinical outcomes have not been carried 
out so far. 
Next to HER2, other proteins can be stained using the CellSearch system, e.g. the human 
epidermal growth factor receptor-1 (EGFR/HER1).[19] A protocol to develop and optimize 
a user-defined assay has recently been published [20]. Other methods have also been 
used to stain CTCs by immunofluorescence, mostly on cytospins after density gradient 
centrifugation or immunomagnetical isolation [12,17,18,21-24].
Instead of measuring total protein levels, newly developed assays claim to only measure 
the activated, phosphorylated portion [25,26]. Only the Collaborative Enzyme Enhanced 
Reactive (CEER)-immunoassay has been applied on CTCs [26]. This assay was used to 
measure phosphorylated HER2 (pHER2) using two detection antibodies, one against 
HER2 and the other against the phosphorylation site. Both antibodies are labeled with 
enzymes that only create a fluorescent signal when in close proximity, thus only creating 
a signal when a phosphotyrosine molecule is bound to HER2. However, only a proof-of-
principle study on CTCs has been performed thus far [26]. 
mRNA expression
Many studies characterized CTCs by looking at mRNA expression using reverse 
transcription polymerase chain reaction (RT-PCR) [16-18,21,24,27-42]. Most of them used 
the commercially available AdnaTest (AdnaGen AG, Langenhagen, Germany) [16,24,31,35-
40], where HER2 mRNA is measured as one of the three tumor-associated transcripts 
for the detection of CTCs together with EpCAM and mucin 1 (MUC1). At the same time 
presence of HER2 transcripts can be used for characterization, qualifying a sample HER2-
positive above the cut-off of >0.15 ng/μL. It is also possible to measure the expression of 
other genes, for example those coding for ER and phosphoinositide 3-kinase (PI3K) [31].
Gene-expression profiling of CTCs after CellSearch or other enrichment approaches is also 
possible. Our group has developed an assay to measure the expression of 96 genes in as 
little as 1 CTC after CellSearch processing [32,33]. Given the large surplus of leukocytes, 
which is still left after enrichment, we selected genes that are not or only at low levels 
expressed in leukocytes. Among the selected genes in our panel are the genes coding for 
ER, EGFR, HER2, HER3 and the fibroblast growth factor receptor-4 (FGFR4). Several other 
assays have been designed to measure mRNA levels, mostly using multiplex quantitative 
RT-PCR after immunomagnetical enrichment using anti-EpCAM-labeled capture beads 
[27-30,34] or a density-gradient separation step [13,17,18,21,40-42]. 
Chromosomal abnormalities
On the DNA level, FISH on CTCs can show chromosomal aberrations, such as gene 
amplifications and translocations. One of the first studies on CTCs used FISH to evaluate 
aneusomy and prove the malignant origin of CTCs [43]. Subsequently, other studies used 
FISH on CTCs, mainly to investigate amplifications of the ERBB2 gene, coding for HER2 
[10-14,17,23,24,40,41,44-47]. Most of these studies used cytospins after either enrichment 
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through CellSearch, immunomagnetical beads or density gradient isolation. However, 
since CTCs are lost during the spinning process, fixation and FISH inside the CellSearch 
cartridge might be preferred [10,48]. A protocol to fix cells and perform FISH inside a 
CellSearch cartridge has been published [48].
Optimal characterization assay?
Obtaining a comprehensive view of the characteristics of the few CTCs present in 
a sample is feasible. However, choices have to be made when it comes to the assays 
that can be applied, as only a limited amount of cells is available and not all assays work 
well together or successively. It is possible to combine immunofluorescence-based 
assays for detection of protein expression and FISH, but one has to consider that only a 
limited number of fluorophores can be used due to the spectral overlap. Using PCR for 
multiplexing is easier, but since a sample has to be lysed, other assays can no longer be 
applied. Besides that, PCR-based assays are severely hampered by the contribution of 
the large background of leukocytes present after any enrichment approach. With the 
current state of the art, the combination of an immunomagnetical enrichment followed 
by immunofluorescence and image cytometry seems to be the most informative assay 
for CTC characterization. The most complete picture is obtained of both the number 
of cells present in a sample and the characteristics of these cells, including intensity of 
staining and heterogeneity between different CTCs. However, in the near future single 
cell genomic profiling assays will become available [49]. These will probably further 
boost CTC characterization options as they are able to provide lots of information on for 
example mutational status, copy number variations and heterogeneity at once. 
Clinical significance of CTC characterization
Human Epidermal Growth Factor Receptor-2 (HER2)
In approximately 10-15% of the primary breast tumors HER2 is overexpressed, thereby 
offering an important treatment target both in patients with PBC and MBC. For the latter, 
HER2 status is still assessed on primary tumor tissue, even though the primary tumor 
often has surgically been removed years before the diagnosis of metastatic disease, 
and in spite of the fact that studies have shown that significant discrepancies can exist 
between primary tumors and metastases [1-3]. Probably, CTC characteristics resemble 
the characteristics of the metastases better than the primary tumor does [12,50,51]. 
Significant differences exist in the expression of targetable receptors between the 
primary tumor and CTCs, among which HER2 [1-3], and therefore, the presence of HER2-
positive CTCs could be a better indication for anti-HER2 treatments, irrespective of the 
HER2-status of the primary tumor. 
Reported HER2-positivity rates in CTCs lie between 19-90%, an imprecise estimate due to 
differences in isolation and characterization methods and applied cut-offs (Table 2) [10-
12,14-18,21,22,24,26,27,29,30,33,41,52-56]. The fact that positivity rates for HER2 on CTCs 
exceed 15% in all studies suggests discrepant expression of HER2 compared to the primary 
tumor in a proportion of patients. Indeed, such discrepancies have been reported. Meng 
et al. [12] selected 29 patients with HER2-negative PBC or MBC and detectable CTCs after 
an EpCAM-based immunomagnetical enrichment. Amplification of HER2 was assessed 
by FISH and actually found in 9/24 patients (38%), suggesting an acquisition during 
tumor progression. Ever since, discordances between primary tumors and CTCs have 
been reported by multiple groups using different assays and seem to occur both ways, 
i.e. HER2-positive primary tumors with HER2-negative CTCs, and HER2-negative primary 
tumors with HER2-positive CTCs (Table 2) [10-17,22,26,31,33,37,53,56,57].
In contrast to most other studies, Mayer et al. [45] found a high overall HER2 concordance 
rate between primary tumor and CTCs of 93%. Using 10 different capture markers, 
immunofluorescence staining for several CKs and FISH, they observed a proportion of 
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) cells that had the morphology of a CTC, but were negative for both CK and the pan-
leukocyte marker CD45. These cells were considered CK-negative CTCs since they 
showed a similar HER2 amplification patterns compared to the CK-positive portion of 
CTCs. Loss of HER2 on CTCs could thus also be caused by assays relying on the expression 
of CK, and missing CK-negative CTCs.
Only a few studies investigated the clinical value of HER2 expression on CTCs. Several 
groups found that presence of HER2-positive CTCs, irrespective of the HER2-status of the 
primary tumor, is an adverse prognostic factor for disease-free survival (DFS) and OS in 
PBC [41,56] and MBC [47] (Table 3). Bozionellou et al. [40] selected 30 PBC/MBC patients 
that had just completed a treatment line and still had detectable CK-19-positive CTCs and/
or bone marrow disseminated tumor cells (DTCs) as assessed by RT-PCR after density 
gradient centrifugation. Irrespective of the HER2-status of the primary tumor, they 
treated all patients with trastuzumab, a monoclonal antibody that targets HER2. While 
HER2 mRNA was detected in the enriched samples in 25/30 patients (83%) before start 
of trastuzumab, afterwards this was only in 33%. Trastuzumab thus possibly eliminated 
CTCs in 50% of the patients, although the significance with respect to clinical outcome 
parameters, such as progression or DFS, had not been investigated. Georgoulias et al. 
[18] continued on this concept and randomized 75 patients with HER2-negative PBC 
and persisting CK-19-positive CTCs after adjuvant treatment between six cycles of 
trastuzumab monotherapy (N=36) or observation (N=39). At the end of the trastuzumab 
treatment, 23/32 (72%) of patients with a successful CTC enumeration had turned CTC-
negative compared to only 7/27 (26%) in the observational arm. A good quality cytospin 
for HER2 immunofluorescence was available of 57 patients and in 51 patients (90%) 
HER2-positive CTCs were detected. Patients treated with trastuzumab had a significantly 
better DFS, with 11% relapses compared to 38% in the observational group. This study 
suggests that trastuzumab has clinically relevant anti-tumor activity in patients with a 
HER2-negative primary tumor. 
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negative primary tumor, pHER2 was detected on CTCs. Interestingly, Kim’s work shows 
that HER2 apparently can be activated despite the fact that it is not overexpressed and 
can be overexpressed but not activated.  
In conclusion, discrepancies exist in the expression of HER2 on CTCs compared to 
the primary tumor and involve losses and gains of HER2 in similar probabilities. These 
discrepancies may partially be due to different techniques to measure HER2 in primary 
tumors and CTCs and the lack of highly sensitive and specific methods to reliably measure 
the HER2-status of CTCs. However, at least part of the discrepancies is due to biological 
reasons, justifying further research as this could have large clinical implications. We are 
currently investigating differences in gene expression profiles between the primary 
tumor, CTCs and lymph node metastases in patients with metastatic breast cancer to 
further address this issue. 
So far, only three relatively small, prospective clinical trials investigated the efficacy 
of anti-HER2-treatments against HER2-positive CTCs [18,40,46]. However, given the 
small number of patients and the differences in patient groups, study design, and used 
techniques, no firm conclusions can be drawn. To do so, more, larger prospective trials 
are needed, some of which have already started. The DETECT III and the TREAT-CTC trials 
are examples here; the first investigating efficacy of lapatinib added to standard first-line 
chemotherapy in patients with HER2-negative MBC and HER2-positive CTCs as assessed 
by the CellSearch system (trial number NCT01619111), and the latter investigating efficacy 
of trastuzumab versus observation in HER2-negative PBC with detectable CTCs by the 
CellSearch system after (neo)adjuvant chemotherapy (trial number NCT01548677). 
To further address the question whether the HER2-status of CTCs can aid us in the 
personalization of therapy, we will have to await the results from these and other well-
designed studies to come. 
In another prospective trial, Pestrin et 
al. [46] selected 96 patients with HER2-
negative MBC and detectable CTCs by 
the CellSearch system. Only 7 patients 
had HER2-positive CTCs and were 
treated with single-agent lapatinib to 
evaluate efficacy of HER2 inhibition in 
this patient group; one patient showed 
disease stabilization and the rest 
progressed. Unfortunately, due to the 
small number of patients, no efficacy 
analysis could be done. 
Early attempts have been made to 
measure pHER2 on CTCs, since this 
might be a more accurate predictor 
of sensitivity to anti-HER2 treatments 
than HER2 overexpression alone 
[58]. Kim et al. [26] used a CEER-
immunoassay to measure HER2 and 
pHER2 on CellSearch isolated CTCs 
from 27 patients with PBC/MBC. In 7/7 
patients with HER2-positive CTCs and 
a HER2-negative primary tumor, CTCs 
were positive for pHER2. On the other 
hand, in only 4/6 patients with HER2-
positive CTCs and a HER2-positive 
primary tumor pHER2 was detected. 
Besides, in 3/17 (18%) of the patients 
with HER2-negative CTCs and a HER2-
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Estrogen receptor (ER)
As the target of hormonal treatment, accurate information on the expression of ER on 
metastases is important. Similar to HER2, the presence of ER-positive CTCs could be an 
indication for hormonal treatments, irrespective of the ER-status of the primary tumor. 
However, less is known about the expression of ER in CTCs; only a few exploratory 
studies, using both immunofluorescence and PCR-based methods, have been carried 
out (Table 4). In these studies, positivity rates for the expression of ER in patients with 
detectable CTCs lie between 18-57% [27,29,31,33,35,38,39,57]. On average, this proportion 
is lower than the approximate 70% of primary tumors that is positive for ER, suggesting 
discrepant ER expression patterns between primary tumors and CTCs. While loss and 
gain of HER2 amplification seem both as likely to occur, for ER this is different. In all but 
one study, loss of ER from an ER-positive primary tumor to ER-negative CTCs is more 
frequently observed than a gain of ER on CTCs in patients with ER-negative primary 
tumors. In MBC, compared to the primary tumor, a loss of ER in CTCs was observed in 33-
77% of the patients, whereas a gain of ER in CTCs was only found in 0-40% [27,31,33,38,57]. 
In PBC, this difference is less obvious, with reported rates of 67-80% for a loss and 50-60% 
for a gain of ER, respectively.[39,57] In a study performed by our group, we found a loss 
of ER in 11/30 (37%) MBC patients, while in a single patient (1/6, 17%) there was a gain [33]. 
However, as in most studies, the obtained discrepancy rates resulted from a comparison 
of two different assays to measure the expression of ER: mRNA expression in CTCs by RT-
PCR versus protein expression in the primary tumor assessed by immunohistochemistry. 
To make a fair comparison we next measured the expression of ER on the mRNA level in 
both CTCs and corresponding primary tumors in 8 patients [33]. Again, a loss of ER in the 
CTCs was seen in 3/8 patients (38%), whereas a gain was only seen in one patient (13%). 
Our results appear to correspond with the results obtained by others, supporting the 
hypothesis that expression of ER in CTCs can be discrepant and is mainly lost over time. 
Studies on the clinical consequences of ER-status conversion in CTCs are still lacking. 
Only one study so far investigated changes in the expression of ER in CTCs under the 
pressure of treatment. In this study, 30 mL of blood was drawn from 98 patients with 
PBC at baseline and either after completion of neoadjuvant or 3 cycles of adjuvant 
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chemotherapy. In all samples, CTCs were isolated and characterized by density gradient 
centrifugation, immunomagnetical cell sorting using anti-CK-7/8/18/19-antibodies and 
immunofluorescence [23]. Comparing the pre- and after treatment samples, in 2/8 
patients with an ER-positive tumor and ER-positive CTCs at baseline, a conversion to 
ER-negative CTCs was observed. Although the method of isolation is not optimal - the 
authors describe recovery rates of only up to 60% - and although this study only included a 
small number of patients, the observation of loss of ER under pressure of chemotherapy 
warrants further investigation.
Before conducting clinical studies on the predictive value of ER-expression in CTCs, 
important technical issues should be solved first. No assay, either immunofluorescence 
or PCR-based, has been validated in any way and nothing is known about a cut-off value 
for ER-positivity on the cell-level let alone on the sample-level. Proposed cut-offs are any 
staining in >10% of all CTCs in a sample on the protein-level or >0.6 ng/µL of ER transcripts 
on the mRNA-level [31,57]. However, heterogeneity in the expression of ER in CTCs 
within a single patient has been observed, similar to the situation in primary tumors and 
metastatic lesions where ER positivity can also be heterogeneous [3,23]. It will therefore 
be necessary to establish a valid and clinically relevant cut-off level. 
New predictive factors
Currently, HER2 and ER are the only validated predictive factors used to tailor treatments 
in breast cancer. However, not all patients respond well to anti-HER2 and hormonal 
treatments, even when clinically indicated. To better predict resistance to these 
treatments, other predictive factors are needed, which are sought in parallel signaling 
pathways, such as the EGFR-pathway, or proteins downstream of these pathways, such 
as PI3K. 
Expression of EGFR has been detected on 38-86% of the CTCs in patients with both PBC 
and MBC [19,22,23]. Furthermore, Kallergi et al. [22] found evidence for activation of 
the EGFR pathway in a proportion of CTCs. After density gradient centrifugation and 
cytospinning, CTCs were stained for the expression of EGFR, phosphorylated EGFR 
(pEGFR) and the downstream proteins phosphorylated PI3K (pPI3K) and phosphorylated 
Akt (pAkt) by immunofluorescence. They found EGFR and pEGFR-positive CTCs in 6/16 
PBC patients and 7/16 MBC patients with detectable CTCs; 2/6 and 6/7 patients with EGFR-
positive CTCs, respectively, were also positive for pEGFR. When EGFR expression of CTCs 
was compared with that of the primary tumor, a loss of EGFR-expression was seen in 
1/3 of PBC patients and 1/1 MBC patient; in increment in EGFR expression was seen in 2/9 
patients and 3/9 patients, respectively. In >80% of patients also pPI3K and pAkt were 
positive. Altogether, the authors concluded that expression of EGFR in combination with 
pEGFR, pPI3K and pAKT suggests an activated pathway and a possible functional role in 
the biology of cancer cells. 
Several other factors that may be helpful for treatment decision-making in breast cancer 
include factors activated by chemotherapy-induced cell damage. Examples are excision 
repair cross-complementing protein 1 (ERCC1), which is involved in the repair of DNA-
adducts formed by platinum-based chemotherapy and has been associated with cisplatin 
resistance [59], and gamma-H2AX, which is involved in the repair of DNA double-strand 
breaks (DSB) and has been associated with resistance to chemotherapy-agents inducing 
DSB [60]. Both proteins can be detected in CTCs [57,60]. In the case of irreparable DNA 
damage, apoptosis pathways are activated and caspases start to cleave CK. Fragments 
of CK-18 can be measured as the M30 protein and have been associated with response 
to chemotherapy [61]. Staining of CTCs for M30 using the CellSearch system is possible 
[20,61]. All three proteins, ERCC1, gamma-H2AX and M30, are upregulated in response 
to DNA damage, thus after administration of chemotherapy. Although these factors are 
not genuine predictive factors that could predict sensitivity at forehand, they could still 
increase cancer treatment efficacy by detecting ineffective regimens at an early time-
point. Whether this will provide additional information over simply the changes in CTC-
counts during treatment, which also indicate treatment response or resistance, will have 
to be proven.
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Discussion
We increasingly appreciate that cancer is a heterogeneous and dynamic disease that, 
due to clonal heterogeneity [1,2], continuously changes its genetic and molecular make-
up over time and under the pressure of treatment. For a genuine personalized treatment 
approach it will therefore be crucial to identify accurate predictive factors to inform us 
at any time-point which pathways are activated, how to inhibit them and whether this is 
successful or if other pathways are being upregulated thereby causing resistance. 
For several reasons CTCs provide an excellent basis for the assessment of predictive 
factors; at first, they are easily accessible via a simple blood draw as opposed to painful and 
cumbersome tissue biopsies. Thus, they provide the possibility for repetitive measurements 
and enable real-time monitoring of tumor characteristics. Second, CTCs are likely shed 
from the different tumor lesions present within a patient and the heterogeneity found 
between the different CTCs in a sample supposedly represents an individual’s inter- and 
intratumoral heterogeneity [10,14,16-18,21,23,37,57]. Third, CTCs provide a basis to obtain 
a complete molecular picture. Analysis on circulating cell free DNA (cfDNA) can reveal 
the presence of actionable mutations and can even predict treatment resistance months 
before radiological progression of disease in the case of resistance-causing mutations 
[62,63]. But as discussed in this review, CTCs offer the great advantage over cfDNA 
approaches that the expression of proteins and mRNA as well as chromosomal aberrations, 
such as mutations and amplifications, can be assessed at the single-cell level in parallel. 
Before CTCs can be applied to guide treatment decisions, major technical hurdles have 
to be overcome first, of which the most important and urgent one is the lack of a reliable 
isolation method. In only 70% of the patients with MBC we are able to detect CTCs and in 
most cases only in very small numbers [6]. Nevertheless, the first studies investigating 
predictive factors on CTCs have already been conducted. At first these focused solely on 
technical issues how to characterize CTCs, but now also the first prospective clinical trials 
have been initiated. Most studies investigated HER2 expression and almost all found 
discrepancies between the CTCs and the primary tumor in a proportion of patients, losses 
and gains at similar rates. Fewer studies focused on the expression of ER in CTCs. It seems 
that loss of ER expression in CTCs in patients with ER-positive primary tumors is quite 
common, though its clinical relevance remains to be unraveled. Technical difficulties can 
partly underlie the observed discrepancies. However, a plausible biological explanation 
would be that ER-negative CTCs are shed by ER-negative metastases that have been 
selected under pressure of hormonal treatment, and that CTCs this way truly reflect the 
characteristics of the ER-negative metastases. Early attempts have also been made to 
investigate new, potentially predictive factors in CTCs, for example EGFR and proteins 
involved in DNA damage repair, but these are still proof-of-principle studies. 
Due to the many different isolation and characterization techniques employed in the 
different studies performed so far, obtained results can hardly be compared and it is 
impossible to draw firm conclusions. Clearly, consensus on the techniques to be used 
in clinical trials is needed. Characterization of CTCs is technically very challenging due 
to the low detectable numbers among an abundance of leukocytes; to overcome these 
problems numerous assays have been developed. Immunocytochemistry for now 
probably is the most usable assay as it provides the most comprehensive picture: on 
CTC count, intensity of staining and heterogeneity in expression between the different 
CTCs in one sample; this in contrast to PCR, where cells are lysed and all information on 
CTC count and heterogeneity is lost. For HER2, immunocytochemistry has been validated 
by comparing in parallel protein overexpression with gene amplification as assessed by 
FISH in both cell lines and patient samples [10-14]. This led to a 0-3+ scoring for CTCs 
based on the intensity of staining, but due to the heterogeneity observed between CTCs 
a sample-level cut-off is needed next to a cell-level cut-off [10,13,14]. The need for cut-offs 
also applies to ER, although in this case we will have to begin by defining and validating 
a cell-level cut-off.  
In conclusion, characterization of CTCs as a tool for a personalized cancer treatment 
approach is still in its infancy. Importantly, technical issues have to be solved first, 
meaning that validated assays and validated cut-offs are urgently needed before 
predictive factors on CTCs can reliably be studied. Despite that, promising results have 
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already been obtained, which show that HER2 can be both lost and gained on CTCs and 
ER is mainly lost during disease progression. Whether patients with metastatic disease 
should be treated based on the expression of predictive factors on CTCs irrespective 
of the status of the primary tumor remains to be investigated. Possibly, in the near 
future CTCs will prove to be inestimable tools that help improve the prognosis of cancer 
patients by telling when patients need to be treated with which targeted agents and 
when to switch to another agent.  
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Before using circulating tumor cells (CTCs) as liquid biopsy, insight into molecular 
discrepancies between CTCs and primary tumors is essential. We characterized 
CellSearch-enriched CTCs from 62 metastatic breast cancer (MBC) patients with ≥5 
CTCs starting first-line systemic treatment. Expression levels of 35 tumor-associat-
ed, CTC-specific genes, including ESR1, coding for the estrogen receptor (ER), were 
measured by reverse transcription quantitative polymerase chain reaction and cor-
related to corresponding primary tumors. In 30 patients (48%), gene expression pro-
files of 35 genes were discrepant between CTCs and the primary tumor, but this had 
no prognostic consequences. In 15 patients (24%), the expression of ER was discrep-
ant. Patients with ER-negative primary tumors and ER-positive CTCs had a longer 
median TTS compared to those with concordantly ER-negative CTCs (8.5 versus 2.1 
months, P = 0.05). From seven patients, an axillary lymph node metastasis was avail-
able. In two patients, the CTC profiles better resembled the lymph node metastasis 
than the primary tumor. Our findings suggest that molecular discordances between 
CTCs and primary tumors frequently occur, but that this bears no prognostic con-
sequences. Alterations in ER-status between primary tumors and CTCs might have 
prognostic implications.
ABSTRACT
Introduction
Over the past decade, the concept of tumor heterogeneity between primary tumors 
and metastases has increasingly been acknowledged. Under the influence of time and 
treatment, tumor cell characteristics, including the expression of treatment targets such 
as the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) in 
breast cancer, can vary between the primary tumor and distant metastatic sites [1-6]. 
Besides intertumor or temporal heterogeneity, even cell clones within one tumor site 
can differ in characteristics, giving rise to intratumor or spatial heterogeneity. Tumor 
heterogeneity may form the basis of treatment resistance and is therefore important to 
take into account in treatment decision-making. 
Nevertheless, the choice for palliative treatments in metastatic breast cancer (MBC) 
is still generally based on primary tumor characteristics. Although a re-evaluation of 
ER and HER2 expression on a tumor tissue biopsy at the time of metastatic disease 
is recommended in guidelines [7], this is frequently omitted as obtaining tissue from 
metastases can be challenging or even impossible. Therefore, better and more patient-
friendly tools are urgently needed to analyze characteristics of metastases before start 
of and repetitively during treatment. 
Analysis of circulating tumor cells (CTCs) might be an attractive means to assess the 
characteristics of metastases. Being present in the peripheral blood, CTCs can easily be 
obtained through a venipuncture and as such form a promising alternative for biopsies 
from metastatic lesions [8,9]. However, before we can fully appreciate the potential 
clinical value of CTC characterization, we need to learn more about the biology and 
to what extent CTCs – as suggested representation of metastatic cells – differ in their 
characteristics from primary tumors. In this study, we used the CellSearch System 
(Janssen Diagnostics, Raritan, NJ) to isolate CTCs from MBC patients followed by gene 
expression profiling of 35 epithelial, tumor-associated, and CTC-specific genes [10]. 
The main objective of this study was to compare the overall molecular CTC profile to 
the corresponding primary tumor profile and to assess the proportion of patients with 
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discordant molecular make-up. A profile from an axillary lymph node metastasis taken 
at the time of primary tumor resection was also available for comparison in a subset 
of patients. The expression of ER in CTCs and discordances with the primary tumor 
were investigated separately. Additionally, we explored the prognostic significance of 
observed discrepancies between primary tumor and CTC profiles.  
Figure 1. Study flowchart. In total 262 patients from an ongoing prospective clinical trial were evaluated for 
eligibility for this study. After excluding patients not meeting our inclusion criteria (right boxes), 62 pairs of CTC 
and FFPE primary tumor profiles remained for the subsequent analyses.
Materials and Methods
Wherever possible, the data are reported conform to the reporting recommendations 
for tumor marker prognostic studies (REMARK; [11]). A study flowchart is presented in 
Figure 1. 
Patients
We retrospectively selected patients from a clinical trial enrolling MBC patients starting 
first-line systemic treatment, either endocrine or chemotherapy according to the 
physician’s decision [10,12]. Blood for enumeration and characterization of CTCs was 
drawn before the start of systemic treatment. Clinical data were collected from patient 
charts. All patients with a CTC count ≥5/7.5 mL blood who were included in the clinical 
trial between February 2008 and February 2012 were selected for the current study. 
Patients were recruited from six hospitals in the Rotterdam region. The Erasmus MC 
and local Institutional Review Boards approved the study (METC 06-248). All patients 
provided written informed consent. 
Sample processing
Enumeration and characterization of CTCs using the CellSearch System and the 
generation of cDNA, linear preamplification, and reverse transcription quantitative 
polymerase chain reaction (RT-qPCR; using Taqman Gene Expression Assays; Applied 
Biosystems, Carlsbad, CA) were performed as described in detail before [10,12].
Archived formalin-fixed paraffin embedded (FFPE) primary tumors and axillary lymph 
node metastases were collected from pathology laboratories. Only paraffin blocks 
with ≥30% tumor cells on hematoxylin and eosin slides were selected. Isolation of RNA 
from FFPE samples was done using the High-Pure RNA Paraffin Kit (Roche Applied 
Science, Penzberg, Germany) according to the manufacturer’s instructions. Quantity 
and quality checks of isolated RNA were performed using the Nanodrop 1000-v.3.7 
(Thermo Scientific, Wilmington, USA), the MultiNA Microchip Electrophoresis system 
(Shimadzu, Kyoto, Japan), and multiplexed RT-qPCR for reference genes. 
Patients assessed for 
eligibility
N = 262
<5 CTC
N = 151
Assessed for availability of 
primary tumor
N = 89
CTC draw not before start of 
first-line palliative treatment 
N = 13
No CTC gene expression profile 
available 
N = 9
RNA isolated from primary 
tumor
N = 69
Insufficient RNA quantity or 
quality
N = 7
Primary tumors profiled
N = 62
No primary tumor available or 
<30% tumor cells
N = 20
Excluded patients
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In all CTC and FFPE tumor samples, we measured our previously described panel of 
55 epithelial tumor- and CTC-specific genes. These genes had been selected based on 
literature for involvement in tumorigenesis and/or mutagenesis along with absent or low 
expression by leukocytes. Consequently, our panel consists of clinically relevant genes 
that are reliably measurable in ≥5 CTCs by RT-qPCR [10,12]. To confirm similarly good 
assay performance on CTC and FFPE tumor samples, we compared expression levels 
between nine paired fresh frozen and FFPE primary tumor samples and only continued 
with the 20 genes that significantly correlated (Pearson correlation P>0.05; Table 1).
Normalization and statistical analysis
Expression levels of individual genes in CTC and tumor samples were quantified 
relative to the average Cq of three reference genes (GUSB, HMBS, and HPRT1) 
using the ΔCq method [13]. Samples with an average reference gene Cq>26 were 
considered to be of insufficient RNA quality and excluded from further analysis. 
To correct for the leukocyte background in the CTC samples, the median ΔCq of 
each gene transcript in 31 CellSearch enriched healthy blood donor samples was 
used as cut-off. All ΔCq values below this cut-off were considered undetectable. A 
compare batches (ComBat) normalization was conducted to enable comparison of 
corresponding profiles and limit technical variations [14-16]. 
We used a Pearson correlation analysis to compare the overall expression levels of 35 
genes in primary tumors to corresponding CTCs. To enable further statistical testing 
two groups were formed of concordant and discordant profiles, based on all Pearson 
correlation coefficients of 62 primary tumors x 62 CTC samples. Among these 3,844 
correlations were 62 corresponding primary tumor/CTC pairs of the same patient and 
Table 1 (right page). Selection of genes from our previously described [10] CTC-specific panel of 55 tumor-
associated gene transcripts. Based on Pearson’s correlation, genes that significantly correlated (P<0.05) 
between nine paired fresh frozen and FFPE primary tumor samples were selected for further comparison 
between FFPE primary tumor tissues and the fresh frozen CTC samples. Twenty assays performed poorly in 
the comparison between fresh frozen and FFPE samples, leaving 35 genes suitable for comparison of paired 
primary tumor tissues and CTC samples.  
Gene Pearson r P value In 35 gene panel?
FOXA1 0.99 <0.05 Yes
ITGA6 0.99 <0.05 Yes
KRT19 0.99 <0.05 Yes
IL17BR 0.98 <0.05 Yes
PKP3 0.98 <0.05 Yes
CXCL14 0.97 <0.05 Yes
KRT17 0.97 <0.05 Yes
EEF1A2 0.96 <0.05 Yes
IGFBP2 0.96 <0.05 Yes
EPCAM 0.96 <0.05 Yes
TFF1 0.96 <0.05 Yes
CEP55 0.96 <0.05 Yes
ESR1 0.96 <0.05 Yes
PLAU 0.95 <0.05 Yes
SPDEF 0.95 <0.05 Yes
DUSP4 0.94 <0.05 Yes
KRT7 0.93 <0.05 Yes
AGR2 0.93 <0.05 Yes
SCGB1D2 0.93 <0.05 Yes
FGFR4 0.92 <0.05 Yes
TFF3 0.91 <0.05 Yes
ERBB4 0.91 <0.05 Yes
PTRF 0.91 <0.05 Yes
CRABP2 0.90 <0.05 Yes
LAD1 0.90 <0.05 Yes
FKBP10 0.87 <0.05 Yes
CCND1 0.85 <0.05 Yes
PIP 0.84 <0.05 Yes
TSPAN13 0.84 <0.05 Yes
DTX3 0.83 <0.05 Yes
MUC1 0.83 <0.05 Yes
S100A7 0.83 <0.05 Yes
ACTA1 0.82 <0.05 Yes
IGFBP4 0.82 <0.05 Yes
MELK 0.82 <0.05 Yes
TOX3 0.81 >0.05 No
CEACAM5 0.77 >0.05 No
MUCL1 0.76 >0.05 No
PLOD2 0.73 >0.1 No
TIMP3 0.73 >0.1 No
DTL 0.69 >0.1 No
CLDN3 0.69 >0.1 No
KRT18 0.69 >0.1 No
SCGB2A2 0.67 >0.1 No
ERBB3 0.66 >0.1 No
IGFBP5 0.64 >0.1 No
CD24 0.63 >0.1 No
KIF11 0.62 >0.1 No
SEPP1 0.59 >0.1 No
FEN1 0.57 >0.1 No
KPNA2 0.39 >0.1 No
CTTN 0.35 >0.1 No
FGFR3 0.35 >0.1 No
S100A16 0.35 >0.1 No
MKI67 0.26 >0.1 No
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3,782 non-corresponding pairs of different patients. The mean correlation coefficient 
from corresponding samples from one patient was 0.72, which was significantly higher 
than the 0.54 from non-corresponding pairs from different patients (P<0.0001; Figure 
2A). The top 10% strongest correlations among all 3,844 pairs were arbitrarily chosen as 
concordant pairs, leading to a cut-off of r=0.74. 
To determine the ER-status of CTCs, we first established an mRNA cut-off value for ER-
positivity by comparing ESR1 expression levels in primary tumors with known ER-status 
from routine pathological reports. ER-positivity was defined as immunohistochemical 
staining in >10% of tumor cells. Expression levels of ESR1 in 61 primary tumors (one 
tumor’s ER-status was unknown) correlated with ER-status from the pathology reports 
and led to a reliable ESR1 cut-off in our patient cohort (Figure 3). All subsequent analyses 
were based on the ESR1 expression levels both in the primary tumors and CTCs.
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Figure 2.A. Scatterplot showing Pearson correlation coefficients of 3,782 non-matching primary tumor – CTC 
pairs of different patients (left side) and 62 matching primary tumor – CTC pairs (right side). The matching pairs 
correlated significantly better. The top 10% highest correlation coefficients are shown in light blue. Horizontal 
lines represent the means. The reported P value is from an independent samples t test. B. Histogram showing 
the distribution of all 3,844 matching and non-matching correlation coefficients. The top 10% with cut-off r=0.74 
was chosen to define patients with concordant, highly correlating primary tumor versus CTC gene expression 
profiles. This cut-off was subsequently used to define two patient groups of concordant and discordant profiles 
among the 62 study patients.
Figure 3. Determination of an mRNA cut-off value to assess ER positivity in CTC samples. This cut-off was 
based on ESR1 expression levels in 61 primary tumors with known ER-status as assessed by routine pathology. 
Tumors were scored as ER-positive by the pathologist when >10% of tumor cells showed nuclear staining by 
immunohistochemistry. The optimal cut-off for ESR1 expression was found with a sensitivity and specificity of 
100%.
The Datan Framework GenEx Pro package version 5.4.1 software (MultiD Analyses AB, 
Göteborg, Sweden), SPSS 20.0 (IBM Corporation, Armonk, NY), and R version 3.0.1 
(http://www.R-project.org/) were used to analyze gene expression levels. ComBat 
normalization was done using the Surrogate Variable Analysis package within R. 
Standard statistical testing was done using SPSS 20.0 (IBM Corporation, Armonk, NY). 
Differences in continuous variables were tested using Student’s t test or non-parametric 
Mann-Whitney U, depending on the distribution. Categorical variables were tested by 
chi-square tests. Correlations were tested either by Pearson (gene expression data) or 
Spearman correlation (CTC count). Clinical outcome was expressed as time-to-treatment 
switch (TTS: the interval between start of first-line and second-line treatment or death, 
whichever comes first) and overall survival (OS: the interval between start of first-line 
treatment and death or last known to be alive). Associations with clinical outcome were 
visualized in Kaplan-Meier plots and tested by log-rank tests. All statistical tests were 
two-sided and P<0.05 was considered statistically significant. 
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All patients Concordant profiles
Discordant  
profiles P value
N 62 100% 32 100% 30 100%
Age at MBC (mean ± sd)       59.8 ± 12.6        62.1 ± 11.4        57.4 ± 13.4 0.14
Tumor classification 0.46
T1 - 2 47 76% 23 72% 24 80%
T3-4 15 24% 9 28% 6 20%
Lymph node metastases 0.14
N0 16 26% 11 34% 5 17%
N+ 43 69% 19 59% 24 80%
Nx 3 5% 2 6% 1 3%
Bloom and Richardson grade 0.63
1 6 10% 4 13% 2 7%
2 38 61% 18 56% 20 67%
3 18 29% 10 31% 8 27%
Tumor histology 0.98
Ductal 37 60% 19 59% 18 60%
Lobular 12 19% 7 22% 5 17%
Mixed ductal/lobular 6 10% 3 9% 3 10%
Other 7 11% 3 9% 4 13%
Hormone receptor expression
ER positivea 49 79% 26 81% 23 77% 1.00
PR positiveb 34 55% 17 53% 17 57% 0.79
HER2 positivec 15 24% 5 16% 10 33% 0.07
Triple negative 10 16% 5 16% 5 17% 1.00
Menopausal status at primary diagnosis 0.19
Premenopausal 24 39% 10 31% 14 47%
Postmenopausal 35 56% 21 66% 14 47%
Unknown 3 5% 1 3% 2 7%
(Neo)adjuvant treatmentd
None 25 40% 21 66% 16 53% 0.44
Chemotherapy 29 47% 16 50% 13 43% 0.62
Anthracyclines 27 44% 15 47% 12 40%
Taxanes 7 11% 2 6% 5 17%
Other 2 3% 1 3% 1 3%
Hormonal therapy 28 45% 15 47% 13 43% 0.80
Tamoxifen 25 40% 14 44% 11 37%
Aromatase inhibitors 8 13% 5 16% 3 10%
Trastuzumab 2 3% - 2 7% 0.23
Interval between primary tumor and metastases 0.28
< 1 year or synchronous 17 27% 6 19% 11 37%
1 – 5 years 22 36% 13 41% 9 30%
≥ 5 years 23 37% 13 41% 10 33%
Location of metastasese 0.58
Bone 47 76% 23 72% 24 80%
Visceral 46 74% 25 78% 21 70%
Secondary breast tumor/local relapse 5 8% 2 6% 3 10% 0.67
First-line systemic treatment for MBCd
Chemotherapy 42 68% 20 63% 22 73% 0.42
Anthracyclines 7 11% 3 9% 4 13%
Taxanes 27 44% 14 44% 13 43%
Other 17 27% 9 28% 8 27%
Hormonal therapy 29 47% 16 50% 13 43% 0.62
Tamoxifen 8 13% 4 13% 4 13%
Aromatase inhibitors 21 34% 12 38% 9 30%
Targeted therapy 25 40% 11 34% 14 47% 0.26
Trastuzumab 15 24% 5 16% 10 33%
Bevacizumab 7 11% 4 13% 3 10%
Other 5 8% 3 9% 2 7%
Baseline CTC count (median, IQR) 29.5 (11 - 98.5) 48.5 (12.0 - 154.3) 18 (9 - 68.8) 0.07
Primary tumor tissue
Median % invasive cells (IQR) 60 (44 - 75) 60 (41 - 79) 60 (44 - 75) 0.75
Median % infiltrate (IQR) 15 (7 - 29) 16 (5 - 30) 15 (10 - 25) 0.98
Median % normal tissue (IQR) 15 (10 - 25) 10 (10 - 20) 16 (10 - 25) 0.18
Table 2. Clinicopathological characteristics of all patients and tumors.
RESULTS
Gene expression profiles of CTCs, primary tumor, and lymph node metastasis
We selected 62 patients for the current study from the 262 evaluated for eligibility 
(Figure 1). Clinicopathological characteristics of these patients are shown in Table 2. The 
median interval between resection of the primary tumor and start of first-line palliative 
treatment was 33 months (interquartile range (IQR) 0 – 88 months). Thirty-seven 
patients (60%) had received (neo)adjuvant treatment in the form of chemotherapy 
(N=29), hormonal treatment (N=28), and/or trastuzumab (N=2). The median follow-up 
time of the 19 patients still alive at the time of analysis was 31.2 months (range 19 – 59 
months). In Supplementary Table S1, characteristics and prior treatments are specified 
per patient. 
The main objective of this study was to assess the proportion of patients with 
discrepancies in overall molecular characteristics between CTCs taken before the start 
of first-line therapy for metastatic disease and corresponding primary tumors. Based on 
the expression of the 35 selected genes, we found discordant profiles in 30 patients 
(48%). No differences were found in clinicopathological characteristics between patients 
with concordant and discordant profiles (Table 2). More patients in the discordant 
group had synchronous metastases or an interval between primary tumor surgery and 
CTC draw <1 year compared to patients in the concordant group, but this difference 
did not reach statistical significance (37% versus 19%; P=0.28). Twenty-one patients with 
concordant (66%) versus 16 patients with discordant profiles (53%) had received (neo)
adjuvant treatment (P=0.44). However, patients with discordant profiles tended to have 
lower CTC counts (median 18 versus 48.5, P=0.07), and more often HER2-positive primary 
tumors (33% versus 16%, P=0.07).
We tested whether differences in sample input may have confounded the analyses. In the 
primary tumors, the median percentage of tumor cells, infiltrate and normal tissue was 
comparable between patients with concordant or discordant profiles (Table 2). Although 
CTC counts in the group of patients with concordant profiles were higher, there was 
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only a weak correlation between CTC counts and the correlation coefficients of primary 
tumor versus CTC profiles (Spearman r = 0.25, P = 0.05). Furthermore, in patients with 
CTC counts greater than the overall median of 29.5 we still found discordant profiles 
in 36% of patients (Figure 4). Therefore, we concluded that CTC counts were no major 
contributor to the observed discrepancies in gene expression profiles.
r = 0.25
P = 0.05
.74
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discordant profiles
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Figure 4. Correlation plot of baseline CTC counts versus Pearson correlation coefficients of the CTCs versus 
the primary tumor gene expression profiles in all 62 patients. The four quadrants are based on the median CTC 
count of 29.5 (vertical line) and the cut-off of r = 0.74 of concordant or discordant CTC versus primary tumor 
profiles (horizontal line). Only a weak influence of CTC counts on observed discordances was found. In patients 
with a CTC count higher than the median of 29.5 we still observed  a discordance rate of 36%. The reported r and 
P values are from Spearman correlation. 
Additional gene expression profiles from axillary lymph node metastases taken at 
the time of primary tumor resection were available from seven patients (Figure 5). 
These profiles closely matched the primary tumor profiles in all seven patients. In two 
patients (nrs. 4 and 5) the CTC profile was discordant from the lymph node metastasis. 
Interestingly, in two other patients (nrs. 1 and 7) the CTC profiles better correlated with 
the lymph node metastasis profiles than with the primary tumor profiles. 
Discrepancies in ER expression
Being an important treatment target, we had special interest for discrepancies in ER-
status between CTCs and primary tumors. Applying the established cut-off value for 
ESR1, we found ER-positive CTCs in 48 patients (77%). Compared to the corresponding 
primary tumors, we observed discrepancies in ER-status in 15 of 62 patients (24%; Table 3). 
Expression of ER was gained in 7 out of the 13 patients (54%) with originally ER-negative 
primary tumors, whereas it was lost in 8 out of the 49 patients (16%) with ER-positive 
primary tumors. The length of the interval until first-line treatment for metastatic disease 
had no influence on the occurrence of ER-switches, although a non-significant association 
toward more switches in patients with ER-positive primary tumors and longer intervals 
was observed (table 4). Of the 49 patients with ER-positive primary tumors, 27 had 
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Figure 5. Correlation matrix based on the expression of 35 
tumor-associated, CTC-specific genes in seven FFPE primary 
tumors, lymph node metastases, and corresponding CTC 
samples taken at the time of metastatic disease. Numbers 
below the matrix are the Pearson correlation coefficients of 
the vertical FFPE primary tumor or lymph node metastasis 
with the corresponding CTC sample (visualized in yellow 
boxes). Asterisks indicate discordant profiles based on the 
top 10% correlation coefficients with cut-off r=0.74 (Figure 
2). In patients 5 and 7 the CTC profiles were discordant 
from the primary tumor profiles; in patients 4 and 5 the 
CTC profiles were discordant from the lymph node profiles. In patients 1 and 7 the CTCs correlated better with 
the lymph node metastases than with the primary tumors, as can be concluded from the more intense red 
color (arrows). Red color represents correlation coefficients higher than the median, black corresponds to 
the median, and green stands for correlation coefficients lower than the median. CTC = circulating tumor cells; 
LNM = lymph node metastasis; PT = primary tumor.
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received adjuvant hormonal therapy. 
Six patients thereafter switched from 
an ER-positive primary tumor to ER-
negative CTCs (22%) compared to two 
of the 22 patients that had not received 
endocrine therapy before (9%; P=0.20). 
Associations with clinical outcome
In all 62 patients, the median TTS was 
8.7 (95% CI 7.2 – 10.2) months with a median OS of 23.0 (95% CI 13.7 – 32.4) months. We 
found no difference in TTS or OS between patients with concordant or discordant CTC 
versus primary tumor profiles (log-rank P=0.95 and P=0.50, respectively, Figure 6A and 
B). 
In our exploratory analyses, a statistically significant difference in median TTS by ER-
status of CTCs versus primary tumors was observed (P=0.001; Figure 6C). Patients with 
ER-negative tumors and discordant ER-positive CTCs (N=7) had improved TTS (median 8.5 
months (95% CI 0.0 – 22.7) over those with concordant ER-negative CTCs (N=6; median 
2.1 months (95% CI 0.0 – 8.8); P=0.05). Based on the ER-status of the primary tumor, 20 
patients received palliative hormonal treatment only (not preceded by chemotherapy). 
ER-status Primary Tumor
ER-negative ER-positive
No switch switch Total No switch switch Total
In
te
rv
al
Synchronous or <1 
year
1
(33%)
2
(67%)
3
(100%)
13
(93%)
1
(7%)
14
(100%)
1 – 5 years
4
(50%)
4
(50%)
8
(100%)
12
(86%)
2
(14%)
14
100%)
>5 years
1 
(50%)
1
(50%)
2
(100%)
16
(76%)
5
(24%)
21
(100%)
Linear-by-linear association P = 0.69 P = 0.19
Table 4. Discrepancies in ER/ESR1 expression between primary tumors and corresponding CTCs according to 
the interval between primary tumor surgery and start of first-line treatment for metastatic disease.
A.
Concordant proﬁles
Discordant proﬁles
Log-rank P = 0.95
B.
Concordant proﬁles
Discordant proﬁles
Log-rank P = 0.50
Numbers at risk
Concordant
Discordant
32
30
24
21
15
17
9
9
4
5
Numbers at risk
Concordant
Discordant
32
30
12
13
5
6
1
3
1
1
2
4
C. D.
  
Remain ER+ 
ER+ to ER- 
ER- to ER+ 
Remain ER- 
95% CI
8.8 - 10.9
1.7 - 11.7 
0.0 - 22.7
0.0 - 8.8
Median
9.8
6.7
8.5
2.1
P-value
0.05]
] 0.31
  N  
Remain ER+ 41
ER+ to ER- 8
ER- to ER+ 7
Remain ER- 6
95% CI
22.5 - 37.0
0.0 - 59.0 
3.9 - 18.9
0.0 - 14.9
Median
29.8
21.1
11.4
6.8
P-value
0.39]
] 0.51
Overall log-rank P < 0.001Overall log-rank P = 0.001
Numbers at risk
Remain ER+
ER+ to ER-
ER- to ER+
Remain ER- 
41
8
7
6
20
2
3
0
10
1
0
0
4
0
0
0
2
0
0
0
Numbers at risk
Remain ER+
ER+ to ER-
ER- to ER+
Remain ER- 
41
8
7
6
32
7
4
2
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0
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2
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2
0
0
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2
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FIGURE 6. ABOVE: Time-to-treatment-switch (TTS; A.) and overall survival (OS; B.) of all 62 patients according 
to concordant or discordant primary tumor versus corresponding CTC gene expression profiles. No significant 
differences were observed in median TTS and OS. BELOW: Time-to-treatment-switch (C.) and overall survival 
(D.) as a function of the ER-status of CTCs versus the primary tumors. Patients at risk at various time points are 
indicated below the plots. Reported P values between two groups are from Log-rank tests and between four 
groups from Log-rank tests for trend.
Out of these, the three patients with ER-negative CTCs had shorter TTS of 1.0, 4.4, and 
6.7 months compared to the 17 patients with concordant ER-positive CTCs, for whom 
median TTS was 12.4 months. However, formal statistical tests are not meaningful due 
to the small patient numbers. 
ER-status
CTCs 
negative positive
pr
im
ar
y 
tu
m
or
 negative 6 7 13
positive 8 41 49
 14 48 62
Table 3. Discrepancies in ER/ESR1 expression between 
primary tumors and corresponding CTCs.
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Differences in OS were mainly driven by the ER-status of the primary tumor and no 
differences between the concordant and discordant groups were observed within the 
group of patients with ER-positive or ER-negative primary tumors (P=0.51 and P=0.39, 
respectively, Figure 6D). 
Discussion
In this study, we compared gene expression profiles of CTCs taken at the time of 
metastatic disease to the corresponding primary breast tumors. We assessed the degree 
of molecular discordance and found that gene expression profiles of 35 epithelial tumor-
associated, CTC-specific genes in CTCs differed from the corresponding primary tumor in 
48% of MBC patients. Patients with concordant and discordant profiles did not differ in 
clinicopathological characteristics.
Differences in sample input can largely influence the results obtained and confound 
the discrepancies in gene expression profiles observed. To ascertain reliable CTC-
driven gene expression profiles, only patients with a CTC count ≥5 were included in this 
study. Importantly, even after CellSearch enrichment, CTCs are left in a background of 
leukocytes that may influence expression levels of certain genes [12]. To circumvent 
this, we selected genes based on literature for their involvement in tumori- and/or 
mutagenesis and absent or low level expression in leukocytes. Although limiting the 
choice of genes, this assured reliable CTC-driven profiles in patients with ≥5 CTCs [10]. 
A normalization step using healthy blood donors further limited leukocyte contribution 
to the CTC gene expression profiles. The assays used on the CTC samples were also 
applied to the FFPE samples and a normalization step was applied to eliminate technical 
variations. We cannot exclude influence of other cell types – such as stromal tissue – on 
the profiles obtained from primary tumors since these tissues were not macrodissected. 
However, only epithelial tumor cell-associated gene transcripts were measured, limiting 
the contribution of stromal cells. The median percentage of tumor cells was 60% in 
patients with concordant and discordant profiles. Although patients with concordant 
profiles had higher CTC counts, we only found a weak correlation between CTC counts 
and profile correlation coefficients maximally explaining 6% of the variance in observed 
discrepancies. Besides, profiles were still discordant in 36% of the patients with CTC 
counts greater than the overall median. Altogether, differences in sample input did not 
seem to cause the observed discrepancies in molecular characteristics between primary 
tumors and CTCs. 
The high proportion of patients with discordant profiles underscores the importance of 
considering tumor heterogeneity in the clinics. Reassessment of ER and HER2-status of 
metastatic disease is recommended in clinical guidelines [7], but still frequently omitted 
due to the invasive nature of tissue biopsies. Furthermore, a biopsy from one metastatic 
site can lead to false conclusions since spatial and temporal heterogeneity is disregarded. 
A “liquid biopsy” using CTC characteristics constitutes an easily accessible and patient-
friendly way to repetitively monitor metastatic tumor cell characteristics – probably of 
multiple metastatic sites – throughout the course of treatment. Although no distant 
metastatic tissue was available from the patients included in our study, an axillary lymph 
node metastasis taken at the time of primary tumor resection was available from seven 
patients. In all seven patients, this profile correlated well with the primary tumor; in two 
patients there was a discordant profile with CTCs. Interestingly, in two other patients, 
CTCs better resembled the lymph node metastasis than the primary tumor. Future 
studies should focus on the comparison between primary tumors, distant metastases, 
and CTCs to establish whether we can use CTCs as direct derivatives of distant metastatic 
lesions. 
Several studies investigated differences in characteristics between primary breast tumors 
and metastatic sites, especially for the treatment targets ER and HER2. Conversion rates 
for ER and HER2 generally lie around 15% [4,5,17-21]. Discordances between primary 
tumors and CTCs have been investigated less extensively. Reported discrepancy rates 
for ER vary between 21 and 79% of patients, with losses of ER more frequently being 
encountered than gained ER expression [reviewed in [9]]. Based on the expression of 
ESR1 in CTCs, we observed discrepancies in ER-status compared to the primary tumor 
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in 24% of cases. Unexpectedly, an upregulation of ESR1 was more frequently observed 
than a downregulation. However, given the small number of patients with ER-negative 
primary tumors these numbers have to be interpreted with caution. In patients with 
ER-positive disease, an association was observed of longer disease-free intervals with a 
higher chance of switch in ER-status. Furthermore, ER-negative CTCs were found in 22% 
of patients who had received adjuvant endocrine treatment compared to 9% of patients 
who had not. However, both observed differences did not reach statistical significance. 
In the overall group of 62 patients, discordances in ER-status were of prognostic 
significance for TTS, but not for OS. This is likely due to the diluting effects of subsequent 
chemotherapeutic treatments on OS. Unfortunately, too few patients received palliative 
endocrine therapy not preceded by chemotherapy to allow for statistical testing. The 
results observed in this study might indicate a predictive and prognostic value of ER-
switches, especially in ER-positive patients, worthwhile of exploring further. 
Discordant overall molecular profiles between CTCs and primary tumors had no 
prognostic significance in our study. This lack of prognostic value might be influenced 
by the choice of genes in our panel. Although selected from literature for involvement 
in tumor development and progression, the predictive and/or prognostic value of 
most genes remains largely unknown. Alternatively, changes in gene expression can 
be induced by factors present in the circulation, but not in the tumor. These changes 
might then reflect a difference in environment rather than true tumor evolution and this 
way might bear no prognostic information. Notwithstanding, our patient group is too 
small to investigate the prognostic significance of 35 individual genes and therefore we 
decided to only use the composite molecular profile of all 35 genes. Biological changes 
in individual genes and pathways therefore remain to be investigated, preferentially also 
by comparison with metastatic tissue.   
Discrepancies in HER2-status between CTCs and primary tumors have been reported in 
19-90% of patients [9]. Unfortunately, we were not able to reliably measure ERBB2 mRNA 
expression levels in CTCs since ERBB2 is also expressed at low levels by leukocytes. This 
again points to the technical issues surrounding CTC isolation and characterization, 
which greatly hamper research in this field. 
Several limitations apply to our results. Although the use of a validated and FDA-
approved system for clinical use is a strength, the EpCAM-dependency of the used 
CellSearch System is a weakness. Previously, we showed that the CellSearch system 
does not detect mesenchymal transitioned breast cancer cell lines with only low or no 
expression of EpCAM [22]. We therefore only compared characteristics of epithelial 
CTCs to the primary tumors. The complex mechanisms of molecular changes in CTCs, 
including epithelial-to-mesenchymal transition, remain to be unraveled further. Since 
single cell information was lost during RT-qPCR, we were unable to explore the extent 
of heterogeneity between single CTCs. Also, the expression of ER was investigated on 
the mRNA instead of the usual protein level. In our group of patients we found a perfect 
correlation between protein and mRNA expression for ER in primary tumor tissues. 
However, whether this applies to the CTCs remains unknown. Furthermore, sampling 
bias in tissue biopsies and technical factors, such as the limited sensitivity of currently 
available assays, need to be considered when comparing the results obtained from 
different studies [23]. 
Conversions in receptor status between primary tumors and metastatic sites are of 
prognostic significance. Patients who lose expression of a receptor have shorter median 
OS compared to patients with sustained expression [1,4,5]. Amir et al. [21] investigated 
the impact of discordance in ER and HER2 status on patient management by reporting the 
results of metastatic tissue biopsies to the treating physicians. Changes in therapy were 
reported in 14% of patients and mostly concerned addition of trastuzumab in patients 
with a gain of HER2 and a switch from endocrine treatment to chemotherapy in patients 
with a loss of ER. To fully appreciate the clinical relevance of ER and HER2 expression in 
CTCs of MBC patients, well-designed prospective clinical trials are needed to investigate 
whether treatment decisions in MBC should be based on CTC characteristics. The first 
trials assessing this have already been initiated [24-26].
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In conclusion, overall CTC characteristics and the expression of ER in CTCs differ from 
the primary tumor in a significant proportion of MBC patients. Conversions in ER-status 
between primary tumors and CTCs might be of prognostic significance and may impact 
treatment decision-making. To fully appreciate the value of CTC characterization, 
technical challenges have to be overcome first. An urgent need for validated 
characterization assays exists to open the path to larger prospective trials investigating 
the clinical value of CTC characteristics. Potentially, CTCs might become an invaluable 
tool for a personalized cancer treatment approach and thereby improve the prognosis 
of MBC patients. 
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CTCs are a promising alternative for metastatic tissue biopsies for use in precision 
medicine approaches. We investigated to what extent the molecular characteristics 
of circulating tumor cells (CTCs) resemble the liver metastasis and/or the primary 
tumor from patients with metastatic colorectal cancer (MCRC). Methods: patients 
were retrospectively selected from a prospective study. Using the CellSearch 
System, CTCs were enumerated and isolated just prior to liver metastasectomy. A 
panel of 25 CTC-specific genes was measured by RT-qPCR in matching CTCs, primary 
tumors, and liver metastases. Spearman correlation coefficients were calculated 
and considered as continuous variables with r=1 representing absolute concordance 
and r=-1 representing absolute discordance. A cut-off of r>0.1 was applied in order to 
consider profiles to be concordant. Results: the CTC profiles were concordant with 
the liver metastasis in 17/23 patients (74%) and with the primary tumor in 13 patients 
(57%). The CTCs better resembled the liver metastasis in 13 patients (57%), and the 
primary tumorin five patients (22%). The correlations were not associated with 
clinical parameters. Nine genes (CDH1, CDH17, CDX1, CEACAM5, FABP1, FCGBP, IGFBP3, 
IGFBP4, and MAPT) displayed significant differential expressions, all of which were 
downregulated, in CTCs compared to the tissues in the 23 patients. Conclusions: 
in the majority of the patients, CTCs reflected the molecular characteristics of 
metastatic cells better than the primary tumors. Genes involved in cell adhesion and 
epithelial-to-mesenchymal transition were downregulated in the CTCs. Our results 
support the use of CTC characterization as a liquid biopsy for precision medicine. 
ABSTRACT
Introduction
The treatment of metastatic colorectal cancer (MCRC) increasingly depends on the 
tumor’s molecular characteristics. For example, inhibition of the Epidermal Growth 
Factor Receptor (EGFR) by cetuximab or panitumumab was shown to be futile in the 30-
60% of MCRC patients with KRAS or NRAS mutated tumors, and as such, these treatments 
are now indicated only for patients with wild-type tumors [1,2]. Other tumor cell 
characteristics besides gene mutations may further affect patient outcome, as evidenced 
by a recent study showing the ability of a gene expression profile to predict outcome to 
chemotherapy in MCRC patients [3]. One may argue that treatment decisions are best 
based on the composite picture of several molecular features, including DNA mutations 
and transcription levels. 
Blood sampling for circulating tumor cells (CTCs) has widely been proposed as a “liquid 
biopsy” to guide treatment decisions. In addition to the CTC count, which is strongly 
prognostic for survival in patients with MCRC as determined by the CellSearch System 
(Janssen Diagnostics, Raritan, NJ) [4], CTCs are generally thought to provide a real-
time picture of different tumor characteristics, including the extent of heterogeneity at 
specific moments [5]. However, solid proof that CTCs can indeed function as surrogates 
for metastatic tissue is currently lacking, since research on the biology and predictive 
value of CTCs is hampered by technical difficulties. The characterization of CTCs is very 
challenging due to the rarity of CTCs in the circulation and the large background of 
leukocytes in which they are left even after CellSearch enrichment [6-9]. In this study, 
we used our previously described approach to reliably measure the expression of tumor-
associated genes in CellSearch-enriched CTCs to compare the molecular characteristics 
of CTCs with the primary tumor and a liver metastasis from patients with MCRC. We 
investigated whether the characteristics of CTCs taken at the time of metastatic disease 
were closer to the liver metastasis or the primary tumor and, in this respect, whether or 
not we can use CTCs as surrogates for metastatic tissue biopsies. 
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Patients and Methods
Patients
Patients were retrospectively selected from a previously reported prospective clinical 
trial investigating the prognostic value of CTC enumeration for the one-year recurrence 
rate in patients with MCRC undergoing a liver metastasectomy [10]. The selection of 
patients for the current study is shown in Figure 1. The Erasmus MC Review Board 
approved the study (METC 06-089). All patients provided written informed consent.
Sample collection and processing
Archived formalin-fixed paraffin-embedded (FFPE) primary tumors and liver metastases 
were collected from pathology laboratories. The High-Pure RNA Paraffin Kit (Roche 
Applied Science, Penzberg, Germany) was used according to the manufacturer’s 
instructions to isolate RNA from tumors with ≥30% tumor cells on haematoxylin and eosin 
(HE) staining. The details of blood sampling and processing for the CTC enumeration 
and characterization have been described before [10,11]. In brief, two samples of 30 mL 
blood in CellSave (Janssen Diagnostics, Raritan, NJ) and EDTA tubes were taken just prior 
to liver surgery and processed <24 h using the CellSearch System. The higher volume of 
blood used to enumerate CTCs from when compared to the usual 7.5 mL was part of the 
design of the original study and has been described before [11]. After a modified Ficoll 
density-gradient separation, mononuclear cells were collected and processed by the 
CellSearch System using the Epithelial Cell Kit for the CTC enumeration and the Profile 
Kit for the CTC isolation (both kits Janssen Diagnostics, Raritan, NJ). The isolation of 
mRNA from CTC samples was performed using the AllPrep DNA/RNA Micro Kit (Qiagen, 
Venlo, The Netherlands). 
The gene expression profiles from all the CTC samples from all patients included in the 
prospective trial were determined in our previous study [9]. A panel of 34 CTC-specific 
genes was identified and proved to be reliably measurable in CTCs in the background 
of leukocytes. The genes had been selected based on literature for their association 
with MCRC development and progression. They were tested for absent or low-level 
Figure 1. Study flowchart and the selection of patients for the analyses. The selection of patients available 
with a gene expression profile from the CTCs, the primary tumor, and the liver metastasis was based on the 
presence of sufficient epithelial signals in the CTC samples, as a measure for the presence of CTCs amongst 
the leukocytes. Of the 36 patients, 23 were designated as having an “HBD”-unlike and reliably CTC-driven 
profile. These patients were included in the analyses to compare the gene expression profiles of the CTCs to 
the primary tumors and the liver metastases. 
expression in leukocytes, thereby rendering them measurable in the few CTCs present 
in the CellSearch-enriched samples. For the current study, we used the same panel of 34 
genes for the selected primary tumor and liver metastasis tissues. The Taqman-based RT-
qPCR assays used on the CTC samples were tested for performance on FFPE tumor tissue 
by comparing a separate group of 15 patient-matched fresh-frozen (FF) and FFPE tumor 
tissues. Only assays with significantly correlating expression levels (linear correlation 
r>0.7, P<0.05) were included in the final gene panel, which resulted in 25 of the 34 genes 
suitable for use in the comparison of the CTC, primary tumor, and metastasis profiles 
(Table 1). 
Next, we selected patients with truly CTC-driven profiles from the total of 36 with 
available tissue profiles. Stochastic variations occurring in small numbers, such as CTC 
numbers from blood, limited the use of the CTC count to select patients with presumed 
circulating tumor content in the blood tube used for profiling. Instead, we constructed 
All patients with a CTC profile 
of sufficient QQ
N = 133
FFPE primary tumor and metastasis 
 30% tumor cells 
N = 36
Patients with  HBD-unlike 
CTC profile
N = 23
No availability of both 
FFPE tissues
N = 67
<30% tumor cells in primary 
tumor and/or metastasis
N = 30
 HBD-alike  CTC profile
N = 13
Excluded patients
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Pt ID Gene Name
Included 
in final 
panel?
CTC - PT CTC - M M - PT
Mean 
Δrank P
Mean 
Δrank P
Mean 
Δrank P
1 AGR2 Yes -2.39 0.43 -2.09 0.45 -0.3 0.9
2 AKR1C3 Yes -2.3 0.45 -3.39 0.29 1.09 0.73
3 CD44 No*
4 CDH1 Yes -10.52 0.02 -11.26 0.001 0.74 0.85
5 CDH17 Yes -8.17 0.03 -7.91 0.05 -0.26 0.89
6 CDH5 Yes 1.48 0.61 1.04 0.66 0.43 0.88
7 CDX1 Yes -11.09 0.001 -11.13 0.004 0.04 0.98
8 CEACAM5 Yes -11.09 0.002 -11.17 0.004 0.09 0.97
9 COL4A1 Yes -3 0.21 -3.04 0.32 0.04 0.98
10 CXCL1 Yes -4.43 0.12 0 1 -4.43 0.19
11 EGFR No*
12 FABP1 Yes -7.35 0.02 -7.35 0.02 0 1
13 FCGBP Yes -11.26 0.02 1.13 0.68 -12.39 0.004
14 GPX2 Yes -0.96 0.75 -1.78 0.48 0.83 0.76
15 HOXB9 No*
16 IGFBP3 Yes -11.09 0.003 -11.09 0.002 0 1
17 IGFBP4 Yes -7.61 0.02 -6.43 0.08 -1.17 0.73
18 IGFBP5 Yes -1 0.65 -1 0.63 0 1
19 KRT19 Yes -1.09 0.7 -1.09 0.65 0 1
20 KRT20 Yes -4.26 0.14 -3.61 0.23 -0.65 0.75
21 KRT8 No*
22 LAD1 Yes -2.48 0.38 -2.48 0.22 0 1
23 MACROD1 Yes -1.3 0.72 -2.35 0.45 1.04 0.72
24 MAPT Yes -14.48 0.001 -12.52 0.003 -1.96 0.52
25 NQO1 No*
26 PRSS8 Yes -1.52 0.54 -1.52 0.51 0 1
27 RARRES2 Yes -5 0.1 -5 0.11 0 1
28 REG1A No*
29 S100A16 No*
30 S100P Yes 1.17 0.68 3.65 0.17 -2.48 0.06
31 SATB2 No*
32 SLC6A8 No*
33 TRIM2 Yes -5.7 0.08 -5.7 0.06 0 1
34 TSPAN8 Yes -1.96 0.48 -1.3 0.57 -0.65 0.81
an epithelial score comprising the sum of the 34 epithelial genes’ measured expression 
levels in a CellSearch-enriched sample multiplied by the z-value from non-parametric 
comparisons of the median Cq values between the 23 patients with ≥3 CTCs and 30 HBDs 
from the previous study [9]. 
∑ 3 4 g e n e s = - ( - 2 . 2 8 * A G R 2 + 2 . 6 1 * A K R 1 C 3 - 3 . 5 6 * C D 4 4 + 2 . 2 8 * C D H 1 - 2 . 5 3 * C D H 1 7 -
2 . 7 3 * C D H 5 - 2 . 6 8 * C D X 1 - 1 . 9 5 * C E A C A M 5 - 2 . 3 8 * C O L 4 A 1 + 3 . 0 9 * C X C L 1 - 1 . 6 4 * E G F R -
4 . 3 8 * FA B P 1 + 2 . 3 9 * F C G B P - 3 . 9 8 * G P X 2 - 1 . 6 2 * H O X B 9 + 2 . 5* I G F B P 3 + 2 . 6 2 * I G F B P 4 -
2.77*IGFBP5-3.1*KRT19-3.34*KRT20-3.69*KRT8-3.74*LAD1+1.08*MACROD1+2.84*M
APT+2.51*NQO1-3.25*PRSS8-1.89*RARRES2-2.21*REG1A-3.94*S100A16+1.94*S100P-
2.7*SATB2+2.32*SLC6A8-2.7*TRIM2-3.27*TSPAN8)
The epithelial score had a strong correlation with the CTC count from the parallel 
enumeration blood tube (Spearman r=0.76, P<0.001, Figure 2A), indicating that the score 
did indeed reflect the epithelial input into the PCR. A cut-off score to identify patients with 
CTC-driven gene expression profiles was then determined from the Receiver Operating 
Characteristics (ROC) curve of the 23 patients with ≥3 CTCs versus 30 HBDs (Figure 2B). 
The optimal cut-off yielded a sensitivity of 91% and a specificity of 93% to discriminate 
patients from HBDs and was used to select patients with an “HBD-unlike” profile for the 
current study (Figure 2C and D).
Table 1 (left page). List of the 34 genes that made up our CTC-specific gene panel that proved to be reliably 
measurable in CTCs in a background of leukocytes [9]. To allow for comparison between the FF CTC samples 
and the FFPE tumor samples, all Taqman assays were tested on matching FF and FFPE primary tumors from 
15 patients. Only genes with correlating expression levels in the matching tissues (linear correlation r>0.7 and 
P<0.05) were included in the final gene panel. In total, 25 of the 34 genes were deemed reliably measurable 
in all samples and tissues and these genes were used to compare the characteristics of the CTCs to the 
corresponding FFPE primary tumor and liver metastasis. All individual gene expression levels were ranked over 
the 23 patients per sample and Δranks of one gene between two corresponding samples from a patient were 
calculated. The mean Δranks for the 25 genes across the 23 patients are shown in columns 4 (mean difference 
between the CTCs and the primary tumors), 6 (mean difference between the CTCs and the liver metastases), 
and 8 (mean difference between the primary tumors and the liver metastases). The mean Δranks were then 
tested by one-sample t tests with 1,000k bootstrapping against the 0 value; the resulting P values can be found 
in the columns 5, 7, and 9. Where there was no significant difference in the average expression of a gene 
between two samples, the mean Δrank would be close to and not statistically significantly different from 0. 
CTC= circulating tumor cells; M = metastasis; PT = primary tumor.
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Normalization and statistical analysis
Three reference genes (GUSB, HMBS, HPRT1) were used as controls for sufficient overall 
mRNA quality (average reference gene Cq<26 in 92% of the samples in total). Following 
the ΔCq method, expression levels were normalized relative to the average Cq of the 
reference genes [12]. The median ΔCq of each gene transcript from the 30 HBDs was used 
as the cut-off to correct for the leukocyte background in the CTC samples, as previously 
described [7,9]. Different normalization approaches were tested in the first attempt to 
directly compare the gene expression levels of the CTC and FFPE samples. However, non-
measurable levels in the CTC samples distorted these normalization procedures, forcing 
us to continue non-parametrically by separately ranking the Cq values of individual genes 
across the patients for the CTC, primary tumor, and liver metastasis samples separately. 
The three resulting ranks per gene per patient were visualized in heatmaps (Figure 3). 
Spearman correlation coefficients were calculated between the 25 gene profiles and 
considered as continuous variables with r=1 representing absolute concordance and r=-1 
representing absolute discordance. A cut-off value to cite two profiles as concordant 
was chosen based on the mean of all correlation coefficients; the mean r was 0.1 and, 
consequently, all profiles with r>0.1 were considered concordant. Differences between 
categorical variables were tested by χ2 or Fisher exact tests. The differences in gene 
Figure 2 (left page). The selection of patients with CTC-driven profiles from the blood samples of the total 36 
selected patients. Only patients with sufficient epithelial input were included in the analyses to compare gene 
expression profiles with CTCs, the primary tumor, and a liver metastasis. A. An epithelial score was calculated 
by adding the expression levels of the 34 CTC-specific genes multiplied by the z-value from the comparison 
between 23 patients with ≥3 CTCs and using the 30 HBDs from the prior study [9] as a weighing factor. The 
epithelial scores from the 23 patients with ≥3 CTCs and the 30 HBDs strongly correlated with the CTC count 
from the blood tube taken in parallel with the tubes for the characterization of CTCs (r=0.76, P<0.001). B. A 
Receiver Operating Characteristics (ROC) curve was constructed from the epithelial scores of the 23 patients 
with ≥3 CTCs and the 30 HBDs. The optimal cut-off value resulted in a sensitivity of 91% and a specificity of 93% 
to discriminate patients from HBDs. C. Line graph showing the epithelial scores of the 23 patients and the 30 
HBDs. The dashed line shows the optimal cut-off value from the ROC curve. Two patients were assigned as 
HBDs, one of whom had a CTC count of 35. Most probably this is the result of a technical error in the enrichment 
of the CTCs or the gene profiling. Two HBDs had an epithelial score slightly above the cut-off value and were 
assigned as patients. D. The epithelial scores were calculated for the patients selected for the current study 
with FFPE primary tumors and liver metastases. Of the 36 patients, 23 had a score above the cut-off and were 
designated as having an “HBD”-unlike profile. These patients were included in the analyses to compare the 
gene expression profiles of the CTCs to the primary tumors and the liver metastases. 
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expression between two samples were tested by one-sample t tests. All statistical 
tests were two-sided and performed with 1,000k bootstrapping to correct for multiple 
testing; P<0.05 was considered statistically significant. The Datan Framework GenEx Pro 
package version 5.4.1 software (MultiD Analyses AB, Göteborg, Sweden) and SPSS 21.0 
(IBM Corporation, Armonk, NY) were used for the analyses. The manuscript was written 
to conform with the reporting recommendations for tumor marker prognostic studies 
(REMARK; [13]).
Results
A total of 142 patients were included in the original prospective study investigating the 
prognostic value of the CTC count [10]. Archived FFPE primary tumor and liver metastasis 
tissues with ≥30% tumor cells on HE slides were available from 36 patients (Figure 1). 
However, the calculated epithelial score from the CTC sample was below the cut-off 
in 13 patients, leaving 23 patients with a reliable CTC-driven gene expression profile 
suitable for comparison with the primary tumor and liver metastasis (Figure 2D). The 
characteristics of these patients are shown in Table 2. 
To compare the concordance of the three profiles per patient, heatmaps were 
constructed and Spearman correlation coefficients over the 25 ranks were calculated 
(Figure 3; Table 3). With a cut-off of r>0.1, the CTC profiles were concordant with the 
liver metastasis in 17 patients (74%) and with the primary tumor in 13 patients (57%). The 
primary tumor and metastasis profiles were concordant in 16 of the 23 patients (70%). 
Comparing the correlation coefficients from the correlation between the CTC versus 
primary tumor profiles and the CTC versus liver metastasis profiles with an error margin 
of ∆r>0.1, the CTCs more closely resembled the metastasis in 13 patients (57%) and the 
primary tumor in five patients (22%; Table 3). In the remaining five patients, the ∆r was 
≤0.1 and/or both coefficients were ≤0.1. In patients 1 and 20, the CTCs neither resembled 
the primary tumor nor the liver metastasis. In patients 9, 14, and 17, both correlations 
seemed similar and the CTCs seemed to reflect both the characteristics from the primary 
tumor as well as the liver metastasis. 
N %*
Total 23 100%
Age at inclusion (mean ± sd) 68 ± 10
Sex  (Male / female) 16 / 7 70% / 30%
Location primary tumor
Right hemicolon 6 26%
Left hemicolon / sigmoid 12 52%
Rectum 5 22%
Staging
T2 3 13%
T3 16 70%
T4 2 9%
Unknown 2 9%
N0 9 39%
N1-2 11 49%
Unknown 3 11%
Differentiation
Well differentiated 1 4%
Moderately differentiated 15 65%
Poorly differentiated 1 4%
Unknown 6 26%
Presentation with metastases
Synchronous 12 52%
Metachronous 11 48%
Median interval (IQR ) 25 (17 – 39)
Liver metastases only 21 91%
Dukes classification at first diagnosis
A 1 4%
B 4 17%
C 5 22%
D 12 52%
Unknown 1 4%
Prior chemotherapy
Neoadjuvant 1 4%
Adjuvant 3 11%
Induction 7 30%
Primary tumor in situ at CTC draw 4 17%
Number of CTCs before liver surgery (median, IQR) 1 (0-3)
≥3 CTCs 6 26%
IQR = interquartile range; sd = standard deviation. 
* Percentages do not always add up to 100% due to rounding.
We next examined whether clinicopathological parameters were associated with the 
strength of the correlations. The primary tumor was still in situ at the time of liver surgery 
and CTC sampling in five patients (Table 3). Here, the CTCs could be theoretically derived 
from both the primary tumor and the metastases. In two patients, the CTCs seemed to 
share characteristics with both the primary tumor and the liver metastasis, as defined by 
a positive correlation of r>0.1 with both the primary tumor and the liver metastasis. In 
Table 2. Clinicopathological characteristics of the 23 patients with “HBD-unlike” profiles.
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Figure 3. Heatmaps showing the ranks per gene, per sample, per patient. The expression levels for individual 
genes were ranked per sample over the 23 patients; undetectable expression levels were given a rank 
number of 30. Red represents higher than median gene expression levels, white represents the median gene 
expression, and yellow represents expression levels below the median or wholly undetectable.
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patients 10 and 19, the CTCs correlated with the liver metastasis only, whereas in patient 
18, the CTC characteristics correlated with the primary tumor only. No associations of 
the correlations’ strength were observed regarding time or pattern of presentation with 
metastasis, the number of metastases, prior chemotherapy, or age (Table 4). 
Lastly, we investigated the 25 individual genes for differences in expression levels 
between the three tumor compartments. For this, we calculated the difference between 
Pt 
ID
Spearman r CTCs 
closest 
to
Clinical parameters
PT-CTC M-CTC PT-M CTC count
PT in 
situ
Prior 
chemo
Presentation 
with M
Number 
of M
1 0.08 0.08 0.55 Neither 0 N N Synchr 3
2 -0.18 0.12 -0.13 M 2 N Y Metachr 1
3 0.17 0.32 -0.21 M 0 N Y Synchr 1
4 -0.41 0.17 0.15 M 7 N Y Metachr 1
5 0.05 0.12 0.50 M 8 N Y Synchr 1
6 0.23 -0.45 0.01 PT 1 N N Synchr 1
7 0.33 0.43 -0.10 M 1 N N Metachr 1
8 0.24 0.37 0.42 M 0 Y N Synchr 2
9 0.20 0.21 -0.01 Both 0 N N Metachr 1
10 -0.11 0.28 0.26 M 0 Y N Synchr 1
11 0.13 0.42 0.43 M 0 Y N Synchr 2
12 0.13 0.03 0.54 PT 0 N Y Synchr 7
13 0.05 0.43 0.55 M 2 N Y Synchr 2
14 0.15 0.12 -0.38 Both 0 N Y Metachr 2
15 0.58 0.30 0.14 PT 8 N N Metachr 1
16 0.15 -0.09 0.77 PT 3 N N Metachr 1
17 0.25 0.31 0.59 Both 2 N N Synchr 2+
18 0.19 0.08 0.12 PT 0 Y Y Synchr 4+
19 -0.14 0.13 0.16 M 1 Y N Synchr 1
20 -0.15 0.04 0.16 Neither 0 N N Metachr 1
21 0.33 0.44 0.58 M 3 N N Metachr 2
22 -0.02 0.35 0.16 M 6 N Y Metachr >10
23 0.06 0.56 -0.06 M 1 N Y Metachr 3
Table 3. Correlation coefficients from Spearman correlation analyses comparing the ranked 25 gene profiles 
from the CTCs, the primary tumor, and the liver metastasis per patient. The cut-off value of r>0.1 was used to 
consider two profiles concordant. To assess whether a CTC profile was closer to the liver metastasis than to 
the primary tumor, the difference between the correlation coefficients of the CTCs versus the primary tumor 
and the CTCs versus the liver metastasis had to be >0.1. The clinical parameters tested for the associations with 
the strength of correlation have been specified per patient. CTC= circulating tumor cells; M = metastasis; PT = 
primary tumor; Synchr = synchronous; Metachr = metachronous.
the ranks of two samples (∆rank) per gene per patient and the mean of the ∆ranks over 
the 23 patients. This resulted in three mean ∆ranks per gene (CTC-primary tumor, CTC-
metastasis, metastasis-primary tumor; Table 1). In an instance where a gene was not 
differentially expressed between two tumor compartments, the mean ∆rank would be 
close to and not statistically significantly different from zero. A one-sample t test against 
0 was applied to determine whether genes were significantly over- or under-expressed 
(Table 1). The expression levels between the primary tumor and the liver metastases 
were overall similar; only FCGBP was downregulated in the liver metastases. In the CTCs, 
however, a larger number of genes was downregulated. In comparison to the primary 
tumor, the expression of CDH1, CDH17, CDX1, CEACAM5, FABP1, FCGBP, IGFBP3, IGFBP4, and 
MAPT were downregulated. Compared to the liver metastases, downregulations of the 
same genes were observed, with the exceptions of FCGBP and IGFBP4.
N
CTC - PT CTC - M M - PT
Mean r P Mean r P Mean r P
Mean all patients 23 0.10 0.21 0.23
Synchronically metastasized 11 0.11
0.90
0.18
0.50
0.33
0.12
Metachronically metastasized 12 0.09 0.24 0.12
Solitary metastasis 12 0.06
0.33
0.13
0.10
0.14
0.18
Multiple metastases 11 0.14 0.29 0.32
Mean primary tumor in situ 5 0.06
0.60
0.26
0.47
0.28
0.47
Mean primary tumor resected 18 0.11 0.19 0.21
Prior chemotherapy received 10 0.02
0.10
0.23
0.69
0.12
0.17
No chemotherapy received 13 0.16 0.19 0.30
Linear correlations
Age 23 0.27 0.22 -0.02 0.94 -0.15 0.49
Interval between surgery for PT 
and M 12 0.16 0.61 0.24 0.45 -0.44 0.15
Table 4. Associations between clinical parameters and the strength of the correlation between two tumor 
samples (CTCs versus primary tumor, CTCs versus liver metastasis, or liver metastasis versus primary tumor). 
For the categorical variables, the reported r values are the mean correlation coefficients from the Spearman 
rank correlation of the 25 gene profiles. The P values are from independent samples t tests. For the continuous 
variables of age and interval between the two surgeries, the reported r and P values are from linear correlations 
between the variables and correlation coefficients from the 25 gene profiles. CTC= circulating tumor cells; M = 
metastasis; PT = primary tumor.
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Discussion
In this study, we observed that the molecular characteristics of CTCs obtained just prior 
to liver metastasectomy well reflected the characteristics of (one of) the liver metastasis 
and were generally closer to the metastasis than the primary tumor in patients with 
MCRC. Based on the expression of 25 CTC-specific and tumor-associated genes, we 
found the CTC profiles to correlate with the liver metastasis in 74% of the patients and 
with the primary tumor in 57% of the patients. No associations were observed between 
the strength of the correlations and clinicopathological characteristics. 
To gain insight into the molecular changes occurring during tumor progression, we 
investigated the differences in the expression levels of the 25 individual genes between 
the three tumor compartments. Nine genes were downregulated in the CTCs, three 
of which (CDH1, CDH17, CEACAM5) are involved in cell adhesion. Downregulation of 
CDH1, encoding E-Cadherin, is a well-recognized event in the progression of epithelial 
cancers and the induction of epithelial-to-mesenchymal transition (EMT) [14,15]. The 
loss of epithelial markers, including E-cadherin, together with an overexpression 
of mesenchymal markers has been consistently observed in CTCs and is thought to 
reflect EMT as a means for CTCs to survive in the circulation [16-19]. Downregulation 
of insulin growth factor binding proteins 3 (IGFBP3) and 4 (IGFBP4), both proliferation-
inhibiting and apoptosis-inducing factors, may help CTCs to survive [20]. Additionally, 
IGFBP3/4 may play a role in EMT through interactions with the EMT-inducer transforming 
growth factor β (TGF-β) [20,21]. The significance of the downregulation of CDX1, FABP1, 
and MAPT in CTCs is unknown, although associations between the losses of these 
genes and the development and progression of colon cancer have been described [22-
29]. Altogether, most of the downregulated genes in the CTCs seem to act as tumor 
suppressors, cell adhesion molecules, or have an involvement in EMT, a process that 
has well-acknowledged relevance for the survival and dissemination of CTCs [14,15]. The 
observed downregulations thus seem to have a functional role in CTC biology.
Several studies have compared the characteristics of CTCs to the primary tumors in 
different solid tumors, including MCRC. For example, mutations in the KRAS oncogene 
were found to be discordant between CTCs and primary tumors from MCRC patients in 
6-55% of patients [30-34]. This discordance has been interpreted as tumor heterogeneity 
and a reflection of the characteristics of metastatic lesions instead of the primary tumor 
by the CTCs. However, solid proof that CTCs can indeed function as surrogates for 
metastatic tumor cells and thus prove to be a reliable alternative for tissue biopsies is 
lacking. Few studies have made direct comparisons between CTCs, the primary tumor, 
and distant metastatic tissue. In a study on metastatic breast cancer, the expression of 
the estrogen receptor was concordant between the CTCs and the primary tumor in 15 
of the 22 (68%) patients and between the CTCs and the metastases in 10 of the 12 (83%) 
patients [35]. Notably, in the two patients where the metastasis was discordant from 
the primary tumor, the CTCs reflected the characteristics of the metastasis. In MCRC, 
the profiles from single CTCs – obtained with a micromanipulator after CellSearch-
enrichment, followed by whole genome amplification, array comparative genomic 
hybridization and ultradeep sequencing – were compared to the primary tumors and 
distant metastatic sites of three patients [36]. In one patient, the copy number profile 
of a single CTC was 73% concordant with the liver metastasis, and 70% with the primary 
tumor. In the second patient, the CTCs were much closer to the primary tumor, while in 
the third patient all three profiles closely matched. These results seem comparable to the 
results from our study in that they support the hypothesis that CTCs are representative 
for metastatic tissue.        
Still, our analyses should be considered exploratory since formal statistical analyses were 
restricted by the sample size and lack of preliminary data needed for upfront power 
calculations. Technical issues – mainly caused by the rarity of CTCs in the blood stream 
and the leukocyte contamination even after CellSearch enrichment – limited the number 
of genes that could be measured and compared. Nevertheless, we were able to build 
a CTC-specific gene panel through selection of MCRC-associated genes from literature 
and testing for absent or low-level expression in leukocytes. Tumor heterogeneity and 
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sampling bias could also be an influence on the results. Only one liver metastasis was 
profiled per patient, even from patients in whom multiple metastases were present. 
The number of CTCs that were detected was low and, due to stochastic variations, 
only a subset of CTCs from the total circulating CTC pool may have been interrogated. 
Furthermore, the biological behaviors of tumor subclones may differ, whereby smaller, 
but more aggressive clones may shed more CTCs than an abundant, but more indolent 
clone, which might be overrepresented in a tissue biopsy. To address the aforementioned 
issues, future studies should incorporate more extensive sampling of tumor tissues 
and compare the profiles to single CTC profiles, preferably though an RNA sequencing 
approach to gain better insight into oncogenic and mutagenic genes and pathways. 
In conclusion, CTCs from the majority of patients with MCRC reflected the characteristics 
of the liver metastasis, supporting the use of CTCs as a surrogate for metastatic biopsies. 
The CTCs, overall, resembled the molecular characteristics of the liver metastasis 
better than the primary tumor. Several CTC-specific changes occurred and seemed to 
primarily represent EMT-related downregulations of cell-adhesion and tumor suppressor 
genes, which could have a biological function for CTC survival and migration. Our 
results support the hypothesis that CTCs may become a valuable tool for precision 
medicine by functioning as a liquid biopsy and providing real-time information on tumor 
characteristics.
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The presence of the androgen receptor splice variant 7 (AR-V7) in circulating 
tumor cells (CTCs) from patients with metastatic castration-resistant prostate 
cancer (MCRPC) was recently demonstrated to be associated with resistance to 
abiraterone and enzalutamide. Cabazitaxel might, however, remain effective in 
AR-V7-positive patients. Objective: to investigate the association between AR-V7 
expression in CTCs and resistance to cabazitaxel. Design, setting, and participants: 
we selected patients with MCRPC from the multicenter, randomized, phase 2, 
open-label study in MCRPC on the pharmacodynamic effects of budesonide on 
cabazitaxel (Jevtana; CABARESC).   Before the start of the first and third cabazitaxel 
cycle, CTCs were enumerated using the CellSearch System. In patients with ≥10 CTCs 
in 7.5 mL blood at baseline, the expression of AR-V7 was assessed by quantitative 
polymerase chain reaction. Outcome measures and statistical analysis: the primary 
endpoint was the assocation between the AR-V7 status and the CTC response rate 
(decrease to fewer than five CTCs in 7.5 mL blood during treatment). Secondary 
endpoints were the prostate-specific antigen (PSA) response rate (RR) and overall 
survival (OS). Analyses were performed using chi-square and log-rank tests. Results 
and limitations: AR-V7 was detected in 16 of 29 patients (55%) with ≥10 CTCs and was 
more frequently found in abiraterone pre-treated patients (5 of 5 (100%) treated 
versus 7 of 20 (35%) untreated; P = 0.009). We found no differences in CTC and PSA 
RR. The presence of AR-V7 in CTCs was not associated with progression-free survival 
(hazard ratio (HR) 0.8; 95% confidence interval (CI) 0.4-1.8) or OS (HR 1.6; 95% CI 0.6-
4.4). Conclusions: the response to cabazitaxel seems to be independent of the AR-
V7 status of CTCs from MCRPC patients. Consequently, cabazitaxel might be a valid 
treatment option for patients with AR-V7-positive CTCs. 
ABSTRACT
Introduction
Several new treatment options have become available for patients with metastatic 
castration-resistant prostate cancer (MCRPC). Abiraterone and enzalutamide, both 
acting on androgen receptor (AR) signaling, improve overall survival (OS) both in the 
pre- and post-docetaxel setting [1-6]. Cabazitaxel, the next-generation taxane, has 
been developed to overcome docetaxel resistance and improves OS in MCRPC patients 
pretreated with docetaxel [3,7]. With the arrival of these treatments, the question of 
how to optimally sequence treatment lines for MCRPC patients has arisen. Preclinical and 
clinical data indicate cross-resistance between abiraterone, enzalutamide, and docetaxel 
[8-12]. However, patients pretreated with abiraterone, enzalutamide, and docetaxel still 
appear to benefit from cabazitaxel [7,13,14]. Reliable predictive factors reflecting tumor 
characteristics in real-time are thus urgently needed to guide treatment selection. 
A circulating tumor cell (CTC) count from peripheral blood before and during treatment 
is an independent prognostic factor for progression-free survival (PFS) and OS in 
MCRPC, and it outperforms prostate-specific antigen (PSA) measurements as an early 
treatment response marker [15-19]. The presence of the AR splice variant 7 (AR-V7), 
coding for a truncated and constitutively active androgen receptor (AR), in CTCs has 
been found to be associated with resistance to enzalutamide and abiraterone but not 
to taxanes, mainly docetaxel [20,21]. We investigated the association of AR-V7 in CTCs 
with the response to cabazitaxel in docetaxel pretreated MCRPC patients. We set up a 
highly specific reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) 
assay to measure messenger RNA (mRNA) expression levels of wild-type AR (AR-WT) 
and AR-V7 in CTCs enriched by the CellSearch System (Janssen Diagnostics LLC, Raritan, 
NJ, USA). Extensive and robust data are available concerning the clinical relevance of 
CTCs enumerated by this relatively widely available US Food and Drug Administration 
(FDA)-cleared technique. Next, we explored associations between the presence of AR-
V7 in CTCs taken before the start of cabazitaxel and the outcome to cabazitaxel.    
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Patients and Methods
Patients
Patients with MCRPC were recruited from an ongoing multicenter, randomized phase 2 
trial, investigating the effects of budesonide on cabazitaxel toxicity (CABARESC, Dutch 
Trial Registry no. NTR2991). All patients had progressive disease after docetaxel (three 
rising PSA measurements ≥2 weeks apart, PSA rise ≥2.0 μg/L, or radiologic progression). 
Full inclusion criteria are listed in Supplement 1. All patients received 25 mg/m2 of 
cabazitaxel until progression, unacceptable toxicity, or the maximum of 10 cycles. The 
collection of CTC samples was a side study of the CABARESC trial. For this study, we 
selected patients who had been included between August 2012 and August 2014 with ≥10 
CTCs in 7.5 mL blood before the start of cabazitaxel to ensure robust and CTC-specific 
downstream analysis. The Erasmus Medical Center and local institutional review boards 
approved the study (METC 11-324). All patients provided written informed consent. 
Sample Processing
Before the start of the first and the third cycle of cabazitaxel, CTCs were enumerated from 
7.5 mL blood drawn in a CellSave tube using the CellSearch System. Characterization of 
CTCs was done before the first cycle of cabazitaxel from 7.5 mL ethylenediaminetetraacetic 
acid (EDTA) blood, which was processed using the CellSearch Profile Kit. After RNA 
isolation, cDNA generation, and preamplification, expression levels of AR-WT and AR-V7 
were measured by RT-qPCR in an 11% aliquot of the original starting material using Taqman 
Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA) (Supplementary Table 
1). Details on sample processing are available in Supplement 2. 
The performance of the assays was tested through the analysis of 17 healthy blood donors 
(HBDs) and prostate (22RV1, LNCaP, PC3, and VCaP) and breast (CAMA1, MDA-MB-415, 
MDA-MB-453, MPE600, SUM185PE, and ZR75.1) cancer cell lines (Supplementary Table 
1 and 2). A total of 100 cell-line cells were spiked in 7.5 mL HBD blood and CellSearch-
enriched to serve as negative and positive controls: 22RV1 (WThigh/V7high), CAMA1 (WTlow/
V7neg), LNCaP (WThigh/V7low), MDA-MB-415 (WTlow/V7neg), MDA-MB-453 (WTlow/V7neg), 
MPE600 (WTlow/V7neg), PC3 (WTneg/V7neg), SUM185PE (WTlow/V7low), VCaP (WThigh/V7high), 
ZR75.1 (WTlow/V7low). All samples were processed in a similar way to the patient blood 
samples.  
Normalization and Statistical Analysis
Samples with an average cycle threshold for quantification (Cq) <26.5 for the three 
reference genes (gluceronidase, beta [GUSB]; hydroxymethylbilane [HMBS]; and 
hypoxanthine phosphoribosyltransferase 1 [HPRT1]) and an average Cq of the two 
epithelial genes <26.5 (epithelial cell adhesion molecule [EPCAM]; and keratin 19, type 1 
[KRT19]) were considered evaluable. To correct for CTC count and epithelial tumor cell 
input, Cq values of AR-V7 and AR-WT were normalized to the average Cq value of the 
epithelial genes (Spearman’s r [rs] with CTC count 0.7; P<0.01; Supplementary Figure 
1A). Final epithelial tumor cell input in the aliquot of RNA used was calculated using 
the equation derived from the regression line of the correlation between the epithelial 
genes and the CTC count, thereby taking into account that only 11% of the originally 
isolated RNA from all CTCs in the sample was used for the characterization of AR-V7 
status (Supplementary Figure 1A). A cut-off value for positivity for AR-V7 was determined 
based on the cell line and HBD experiments (Supplement 2). 
The primary endpoint of this study was to compare the CTC response rate (CTC RR), 
defined as a decrease to fewer than five CTCs in 7.5 mL blood during treatment, between 
patients with AR-V7-positive and AR-V7-negative CTCs. Secondary objectives were the 
PSA RR (30% or 50% decline in PSA level from baseline to 12 weeks or earlier in case of 
treatment discontinuation), best PSA response during treatment, PFS (interval between 
registration and progression of disease or death), and OS (interval between registration 
and death). Associations between PFS or OS and the CTC response during treatment 
were analyzed after the second blood draw. Patients without events were censored at 
the last date recorded to be progression-free and/or alive. Reported end points were 
based on the Prostate Cancer Working Group 2 (PCWG2) guidelines [22]. 
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The main hypothesis stated that there would be no difference in response to cabazitaxel 
by the presence or absence of AR-V7. Since limited data regarding the prevalence of 
AR-V7 was available at the time of study design, no formal sample size calculations 
were performed. Therefore, our analyses were exploratory. Differences in the primary 
objective, CTC RR, and secondary objective, PSA-RR, were analyzed using the chi-square 
or Fisher exact tests. Survival was analyzed using Cox regression models and visualized 
in Kaplan-Meier plots. Other applied tests were the Student t test, the Mann-Whitney U 
test, and Pearson or the Spearman correlation, depending on the variable or distribution 
of a variable. All statistical tests were two-sided and performed using the SPSS 21.0 
software package (IBM Corporation, Armonk, NY, USA). A P value <0.05 was considered 
statistically significant. 
Results
AR-WT and AR-V7 in CTCs
We first tested the sensitivity and specificity of our assays by comparing RNA fractions 
isolated from pure and spiked-in breast and prostate cancer cell-line cells before and 
after CellSearch enrichment (Supplementary Table 1 and 2). The AR-V7 status could be 
reliably determined in three or more spiked-in epithelial cells. The cut-off was confirmed 
in our clinical samples, in which two patients with RNA from three CTCs in the used 
aliquot were positive for AR-V7; none of the patients with fewer than three CTCs were 
positive for AR-V7 (Supplementary Table 2). The leukocyte background did not influence 
the outcomes of our analyses (Supplementary Figure 1B and 3C). Of the 17 HBDs tested, 
16 were negative for the expression of AR-WT and AR-V7 (Supplementary Table 2). One 
67-year-old male HBD had detectable AR-WT in his peripheral blood. Since this donor was 
anonymous, no follow-up or further diagnostics were done. 
We next selected patients with ≥10 CTCs at baseline to limit stochastic variations 
between the CTC enumeration and isolation tubes and to assure epithelial input. Twenty-
nine patients with sufficient RNA quality and quantity and sufficient epithelial cell input in 
the CTC samples were identified (Figure 1). Table 1 shows all patient characteristics. Five 
Figure 1. Study flow chart showing the selection of patients for the analyses. Cq = cycle threshold for 
quantification; CTC = circulating tumor cell.
patients had received abiraterone before enrollment. The expression of AR-WT in CTCs 
was detected in all patients, whereas AR-V7 was detected in 16 patients (55%). All five 
patients who had previously been treated with abiraterone expressed AR-V7 compared 
to seven of the 20 patients (35%) who had not received abiraterone (P = 0.01). We found 
no significant correlation between the expression levels of AR-V7 and AR-WT in CTCs (rs 
= 0.3, P = 0.12; Supplementary Figure 2A) and no difference in AR-WT expression levels 
between patients with and without AR-V7 in the CTCs (P = 0.2; Supplementary Figure 2B). 
AR-V7 and Response to Cabazitaxel
The primary endpoint of this study was the CTC RR, defined as a decrease to fewer than 
five CTCs per 7.5 mL blood after two cabazitaxel cycles, determined by the presence 
or absence of AR-V7 in baseline CTCs. A secondary CTC sample was available from 25 
patients. In three patients, the second draw was missed and one patient died after the 
second cycle because of a non-disease-related event. The overall CTC RR to cabazitaxel 
was 5 of 25 patients (20%). Fifteen patients had AR-V7-positive and ten had AR-V7-
All available patients
N = 76
< 10 CTC at baseline
N = 32
  10 CTC at baseline
N = 44
Sufficient mRNA quality 
and quantity
N = 29
Mean Cq reference 
genes >26.5
N = 3
CTC count after 2 cycles
N = 25
Mean Cq epithelial 
genes >26.5
N = 12
Second blood draw 
missed
N = 4 
Excluded patients
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negative CTCs. The CTC RRs in both AR-V7-positive and AR-V7-negative patient groups 
were 20% (Table 2). Sequential PSA levels during cabazitaxel treatment for evaluation of 
the PSA-RR were available from 26 patients. Five (17%) and three patients (10%) achieved 
a ≥30% and ≥50% PSA response, respectively, after 12 weeks of treatment. At the end of 
treatment, the best PSA response was ≥30% in seven patients (24%) and ≥50% in three 
patients (10%). The 30% and 50% PSA RRs after 12 weeks and at the end of treatment in 
patients with and without AR-V7 in CTCs were not statistically different (Table 2, Figure 
AR-V7 in CTCs at baseline
All patients Absent Present P value*
N 29 100% 13 100% 16 100%
Age at registration  
(mean ± SD) 70 ± 7 68 ± 9 71 ± 6 0.3
WHO performance score 0.4
0 11 38% 6 46% 5 31%
1 18 62% 7 54% 11 69%
Type of castration 0.4
Surgical 4 14% 1 8% 3 19%
LHRH agonist 25 86% 12 92% 13 81%
Number of prior chemotherapy lines 0.9
One (docetaxel) 27 93% 12 92% 15 94%
Two 2 7% 1 8% 1 6%
Prior antiandrogens for MCRPC
Abiraterone 5 17% 0 0% 5 31% 0.009
Orteronel 3 10% 3 23% 0 0% 0.09
Baseline chemistry** 
Lactate dehydrogenase  
(U/L , median (IQR))
453  
(309 – 635)
431  
(310 – 616)
456  
(287 – 674) 0.9
Alkaline phosphatase  
(U/L , median (IQR))
163  
(106 – 375)
160  
(96 – 358)
228  
(107 – 384) 0.7
Prostate specific antigen (μg/L, 
median (IQR))
321  
(76 – 649)
107  
(68 – 439)
475  
(78 – 885) 0.08
Baseline CTC count  
(median (IQR))
100  
(50 – 243)
94  
(38 – 260)
110  
(52 – 254) 0.6
ALP = alkaline phosphatase; AR-V7 = androgen receptor splice variant 7; CTC = circulating tumor cell; IQR = 
interquartile range; LDH = lactate dehydrogenase; LHRH = luteinizing hormone-releasing hormone; MCRPC = 
metastatic castration-resistant prostate cancer; PSA = prostate-specific antigen; SD = standard deviation; WHO 
= World Health Organization.
* Reported P values are from independent samples Student t test (age), nonparametric Mann-Whitney U test 
(baseline chemistry and CTC count) and chi-square tests (categorical variables). IQR: interquartile range; sd: 
standard deviation. 
** Upper limit of normal: LDH, 247 U/L; ALP 114 U/L; PSA 6.4 μg/L.
Table 1. Patient characteristics in all patients, AR-V7-negative patients, and AR-V7-positive patients.
A. CTC response B. PSA response at week 12 C. Best PSA response
No Yes No ≥30% * ≥50% No ≥30%* ≥50%
AR-V7
No 8 2 9 3 2 7 4 2
Yes 12 3 12 2 1 12 3 1
Fisher’s exact 
P = 1
χ2  
P = 0.7
χ2  
P = 0.6
Table 2. Presence of AR-V7 in CTCs at baseline versus (A.) CTC response to cabazitaxel after two cycles, (B.) PSA 
response after 12 weeks of treatment, and (C.) best PSA response at the end of treatment. 
CTC = circulating tumor cell; PSA = prostate-specific antigen. 
*Numbers include patients with ≥50% PSA response. Sequential PSA values from three patients were missing 
(two AR-V7-positive and one negative). One AR-V7-positive patient discontinued treatment after two cycles of 
cabazitaxel and was not included in the analysis for PSA response after 12 weeks. The AR-V7-negative patient 
was still undergoing treatment and thus was included only in the analysis for PSA response after 12 weeks.
2). We found no statistical difference in CTC RR and PSA RR between patients that had or 
had not received abiraterone before cabazitaxel.
AR-V7 and Survival
At the time of analysis, four patients were still receiving cabazitaxel treatment. The 
median follow-up time from the date of registration for the 12 patients still alive was 
7 months (range 2–27 months). The median OS in all 29 patients was 10 months (95% 
confidence interval (CI) 5-14); median PFS was 5 months (95% CI 2-8). The five patients with 
a CTC response to cabazitaxel had significantly longer OS than the 20 patients without 
a CTC response (hazard ratio (HR): 0.1, 95% CI 0.01-0.9; P = 0.04), but had a comparable 
PFS (HR: 0.7, 95% CI 0.2-2.0; P = 0.5). The presence of AR-V7 in CTCs at baseline was not 
associated with PFS (HR: 0.8; 95% CI 0.4-1.8; P = 0.6) or OS (HR: 1.6; 95% CI 0.6-4.4; P = 0.4; 
Figure 3). Treatment with abiraterone before or after cabazitaxel had no influence on OS 
(Supplementary Figure 3). 
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Figure 2. Waterfall plots of PSA responses to cabazitaxel treatment (A.) after 12 weeks and (B.) at the end of 
treatment. The dashed lines represent 30% and 50% decreases in PSA level relative to the baseline level. No 
differences in PSA responses were observed between AR-V7-positive and AR-V7-negative patients. Sequential 
PSA values from three patients were missing (two AR-V7-positive and one negative). One AR-V7-positive 
patient discontinued treatment after two cycles of cabazitaxel and was not included in the analysis for PSA 
response after 12 weeks. The AR-V7-negative patient was still undergoing treatment and thus was included only 
in the analysis for the PSA response after 12 weeks. CTC = circulating tumor cell; PSA = prostate-specific antigen.
* patients who had received treatment with abiraterone before cabazitaxel. 
Figure 3. (A.) Progression-free and (B.) overall survival as a function of the presence of AR-V7 in CTCs at 
baseline. The reported P value is from a log-rank test. 
AR-V7 = androgen receptor splice variant 7; CI = confidence interval; HR = hazard ratio.
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Discussion
The presence of AR-V7 in CTCs of MCRPC patients is associated with resistance to 
enzalutamide or abiraterone but not to taxanes [20,21]. In these studies, CTCs were 
enriched using an mRNA-based method; limited data exist about the method’s clinical 
relevance in MCRPC. We explored the feasibility of the characterization of the presence 
of AR-V7 in CTCs captured by the CellSearch System, which obtained FDA clearance for 
clinical use of the CTC count. We set up a robust RT-qPCR assay that reliably detects AR-
V7 in three or more CTCs and investigated the association between the AR-V7 status of 
CTCs and outcome to cabazitaxel. In contrast to docetaxel, no cross-resistance seemed 
to emerge among cabazitaxel, abiraterone, and enzalutamide [8,14]. Consequently, we 
hypothesized that patients with AR-V7-positive CTCs would still benefit from cabazitaxel. 
The prevalence AR-V7 in our cohort of 29 docetaxel-pretreated MCRPC patients with 
≥10 CTCs per 7.5 mL blood was 55%, which seems higher than the 29% in the previously 
reported enzalutamide/abiraterone cohort [20}, but comparable to the 46% in the prior 
taxane cohort [21]. We confirmed the higher prevalence of AR-V7 in abiraterone-resistant 
patients. In line with our hypothesis, we found indications that the presence of AR-V7 in 
CTCs taken prior to treatment might not be associated with the outcomes of cabazitaxel 
treatment in terms of CTC RR, PFS, and OS. The CTC RR, defined as a decrease to fewer 
than five CTCs in 7.5 mL during treatment, has been shown to be a robust surrogate end 
point for PFS and OS in several prior studies [15-19,23]. 
The lack of an association between AR-V7 in CTCs and outcome is in agreement with 
the findings in 37 patients starting treatment with docetaxel (N=30) or cabazitaxel 
(N=7) [21], and contrasts with the results in patients treated with enzalutamide or 
abiraterone [20]. However, comparisons have to be made with caution because of the 
differences in methodology and patient selection. In the previous studies, CTCs were 
detected using the AdnaTest (AdnaGen, Langenhagen, Germany), whereas we used 
the CellSearch System. Both methods immunomagnetically enrich CTCs based on the 
expression of EpCAM, but there are important differences to consider; for example, the 
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AdnaTest also enriches CTCs expressing the human epidermal growth factor receptor 2 
(HER2). Although frequently detected on breast cancer CTCs [24], the expression and 
clinical relevance to prostate cancer CTCs is unclear. After enrichment, the CellSearch 
identifies a CTC as an intact, nucleated cell with expression of cytokeratin as assessed 
by immunofluorescence. In the AdnaTest, all morphological information is lost after 
lysis of the enriched cells, so CTC enumeration is not possible. The presence of CTCs is 
assumed by the presence of the epithelial gene transcripts, thereby disregarding other 
characteristics such as the presence of a nucleus or intact cell membrane. Considering the 
differences in methodology, the AdnaTest and the CellSearch System might not detect 
comparable cell populations. Therefore, we  have started a clinical trial to investigate 
the predictive value of the presence of AR-V7 in CellSearch-enriched CTCs for outcome to 
cabazitaxel as well as to AR-targeted treatments. 
The limitations of our study concern the CellSearch System’s dependency on EpCAM 
expression on CTCs. In breast cancer, EpCAM-negative CTCs have been detected and 
have even been reported to be more strongly predictive of treatment resistance [25,26]. 
Whether this applies to prostate cancer CTCs remains to be investigated. Since only an 
aliquot of the total of isolated RNA could be used for the current study, patients with ≥10 
CTCs – and thus a poor prognosis based on the high baseline CTC count – were selected. 
Patients with insufficient quality and quantity of mRNA were excluded from the analyses. 
Although potentially introducing a selection bias, this assured sufficient epithelial input 
to reliably measure the AR-V7 status. Additionally, patients were recruited from a phase 
2 study investigating cabazitaxel toxicity. As survival was not an end point of the main 
study and PFS was not defined in the study protocol, our PFS analyses were a composite 
of PSA, radiographic, and clinical progression, which were assessed at the discretion 
of the treating physician. This might explain the lack of prognostic value of CTCs for 
PFS. Last, our analyses were exploratory, because no formal power calculations were 
possible at the time of study design and only a small number of patients was included. 
We plan to validate our findings by extending the patient cohort, thereby including 
patients with <10 CTCs. Ultimately, prospective, randomized trials, taking into account 
all other baseline characteristics that might affect outcome, should offer insights into 
the exact role of cabazitaxel in the treatment of AR-V7-positive patients.  
Conclusions
We demonstrated the feasibility of measuring the AR-V7 status of MCRPC patients with 
≥10 CTCs after CellSearch enrichment. We showed that the outcome of cabazitaxel 
treatment in these patients is not associated with the presence of this particular splice 
variant. Our results add important information to the existing evidence that CTCs are 
an invaluable tool for personalizing cancer treatments and improving the prognosis of 
MCRPC patients by allowing optimal treatment sequencing. 
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Supplement 1. 
In- and exclusion criteria for participation in CABARESC trial
Inclusion criteria:
• MCRPC with documented disease progression, defined as: 
• Rising PSA levels: at least two consecutive rises over a reference value and at 
least one week apart, or a PSA rise of ≥2.0 μg/L
and/or
• Appearance of new lesions or documented disease progression on a CT scan or 
bone scan.
• Previous treatment with docetaxel;
• Age ≥18 years;
• WHO performance status ≤1;
• Adequate renal function (serum creatinine ≤1.5 x upper limit of normal (ULN) and/
or MDRD calculated creatinine clearance ≥50 mL/min) and hepatic function (total 
bilirubin ≤1.0 x ULN, alanine aminotransferase and aspartate aminotransferase ≤2.5 
x ULN, or in case of liver metastases ≤5 x ULN, and alkaline phosphatase < 5 x ULN, 
or in case of bone metastases <10 x ULN), within 21 days before randomization;
• Adequate hematological blood counts (absolute neutrophil count ≥1.5 x 109/L and 
platelets ≥100 x 109/L) within 21 days before randomization;
• Castration, either surgically or by continued LHRH agonist therapy;
• Written informed consent according to ICH-GCP;
Exclusion criteria:
• Impossibility or unwillingness to take oral drugs;
• Serious illness or medical unstable conditions requiring treatment, symptomatic 
central nervous system metastases or history of a psychiatric disorder that would 
hinder the understanding and obtaining of informed consent; 
• Use of medications or dietary supplements known to induce or inhibit CYP3A
• Use of hormonal agents other than GnRH agonists;
• Known hypersensitivity to corticosteroids;
• Any active systemic or local bacterial, viral, or fungal infection;
• Ulcerative colitis, Crohn’s disease, or celiac disease (active or in medical history);
• Ostomy;
• Planned/active simultaneous yellow fever vaccine;
• Geographical, psychological, or other non-medical conditions interfering with 
follow-up.
Supplement 2. 
Sample processing, normalization and analysis
Enumeration of CTCs was done from 7.5 mL of blood drawn into a CellSave Preservative 
tube (Janssen Diagnostics). Blood samples were processed within 96 hours using the 
Epithelial Cell Kit on the CellSearch System (both Janssen Diagnostics). In this system, 
epithelial cells are immunomagnetically enriched from whole blood using anti-EpCAM 
antibodies loaded with ferrofluid nanoparticles. Enriched cells are stained with the 
nuclear dye 4’,6-diamidino-2-phenylindole (DAPI), anti-cytokeratin 8/18/19 labeled 
with phycoerythrin (PE), and anti-CD45 labeled with allophycocyanin (APC), followed 
by scanning using the CellTracks Analyzer (Janssen Diagnostics). All cells ≥4 µm, with 
round-to-oval morphology, positive for cytokeratin and DAPI, with at least 50% overlap 
in the DAPI and cytokeratin signal, and negative for CD45 were considered CTCs. All 
samples were analyzed by two independent, trained reviewers. 
For molecular characterization of CTCs, 7.5 mL of blood from an EDTA tube was 
processed using the CellSearch Profile Kit (Janssen Diagnostics) within 24 hours to 
limit mRNA degradation. No staining step was performed after the immunomagnetical 
enrichment. Instead, buffer was aspirated after incubation in a hand magnet and 
enriched cells were lysed in buffer RLT+ (Qiagen, Valencia, CA), followed by storage at 
-80°C until subsequent RNA isolation using the AllPrep DNA/RNA Micro Kit (Qiagen). Of 
the resulting 12 µL with >200 bp RNA, 5 µL was used for the generation of 10.5 µL cDNA 
(RevertAid H Minus First Strand cDNA Synthesis Kit from Thermo Fisher Scientific, 
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Waltham, MA), followed by an RNAse H step (Ambion, Life Technologies) to degrade 
the remaining RNA. Next, 3 µL of the cDNA was used to specifically pre-amplify the 
transcripts generated by the nine Taqman assays depicted in Supplementary Table 
1, which was done in 14 cycles according the protocol supplied by the manufacturer 
of the Taqman PreAmp Master Mix kit (Life Technologies, Carlsbad, CA). Following 
pre-amplification, the resulting 12 µL sample was 15-fold diluted prior to 35 cycles 
of RT-qPCR using an Mx3000P Real-Time PCR System (Agilent, Amsterdam, The 
Netherlands). For each sample, nine individual PCR reactions were performed in duplo 
in a final volume of 20 µL containing 5 µL diluted, pre-amplified cDNA, 30-50% (V/V) 
Taqman Universal Master Mix (4326614, Life Technologies), and 0.5-1 µL Taqman gene 
expression assay, which was done in 35 cycles according the protocol supplied by 
the manufacturer of the Taqman assays. Altogether, 1.5 μL of RNA from the original 
sample was used, which was further diluted for cDNA synthesis and pre-amplification, 
leaving an average aliquot of ~11% of the original starting material to measure the 
expression levels of AR-WT and AR-V7 using Taqman Gene Expression Assays (Applied 
Biosystems, Carlsbad, CA; Supplementary Table 1). The amount of epithelial cell input 
in the aliquot was calculated per patient using the average signal of EPCAM and KRT19 
from the aliquot, which correlated with the CTC count in 7.5 mL blood as assessed 
by the CellSearch System from the parallel CellSave tube  (Spearman r=0.71; P<0.01; 
Supplementary Figure 1A). The final epithelial cell input per patient can be found in 
Supplementary Table 2. To correct for CTC count and epithelial tumor cell input, Cq 
values of AR-V7 and AR-WT were normalized to the average Cq value of the epithelial 
genes EPCAM and KRT19 measured in the same PCR plate as follows: ΔCq AR = average 
Cq value of EPCAM and KRT19 minus Cq value of AR-V7 or AR-WT. Three reference genes 
(GUSB, HMBS, and HPRT1) served as internal control of isolated mRNA and cDNA 
quantity and quality. Samples with an average reference gene Cq value >26.5, indicative 
for low and/or poor RNA/cDNA quality, and/or an average epithelial gene Cq value >26.5, 
indicative for low/no epithelial CTC input in the final RNA/cDNA sample, were excluded 
from the analyses. 
Assay performance was tested through analysis of healthy blood donors (HBD) and cell 
line experiments. All real time PCR assays were equally efficient both before and after 
pre-amplification (108%±4%, Supplementary Table 1). We measured the expression of 
AR-WT and AR-V7 in pure cells of prostate (22RV1, LNCaP, PC3, and VCaP) and breast 
(CAMA1, MDA-MB-415, MDA-MB-453, MPE600, SUM185PE, and ZR75.1) cancer cell 
lines. These were used as negative and positive controls as follows: 22RV1 (WThigh/
V7high), CAMA1 (WTlow/V7neg), LNCaP (WThigh/V7low), MDA-MB-415 (WTlow/V7neg), MDA-
MB-453 (WTlow/V7neg), MPE600 (WTlow/V7neg), PC3 (WTneg/V7neg), SUM185PE (WTlow/V7low), 
VCaP (WThigh/V7high), ZR75.1 (WTlow/V7low). Next, 100 cells of the same cell lines were 
spiked into 7.5 mL HBD blood, followed by CellSearch-enrichment, isolation of RNA, 
synthesis of cDNA, and PCR similar to the patient samples and as described above. In 
Supplementary Table 2 the results from these experiments are reported. To be able 
to assign patients as having AR-V7-positive or -negative CTCs, a cut-off value had to be 
established. As can be deduced from supplementary table 2, the ΔCq value measured in 
the weakly positive breast cancer cell line ZR75.1 was -14.68. To keep a certain margin, 
we decided to set the cut-off for positivity, meaning any detectable AR-V7 signal, at a  
qPCR name
Approved 
Gene Symbol
Slope R² Efficiency
PreAmped PCR on serially diluted cDNA from VCAP cells
AR-V7 AR -3.02 0.98 107%
AR_WT AR -2.97 0.97 109%
AR-WT/fl AR -3.19 0.97 103%
EPCAM EPCAM -2.97 0.99 109%
KRT19 KRT19 -3.13 0.98 104%
GUSB GUSB -3.01 0.99 107%
HMBS HMBS -3.11 0.98 105%
HPRT1 HPRT1 -3.02 0.98 107%
PreAmped PCR on cDNA from leukocytes of different HBDs
CD45 PTPRC -2.71 0.85 117%
Supplementary Table 1. Details of the assays used in the RT-qPCRs.
Continued on next page
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Supplementary Table 1 (continued).
ng cDNA 
input in 
PreAmped 
PCR
# VCAP 
cells input 
in Pre-
Amped 
PCR*
# VCAP 
cells input 
in Pre-
Amped PCR 
(log)
AVG EP-
CAM 
+KRT19  
 
(Cq)
AVG  
AR-WT  
 
 
(Cq)
AR-V7  
 
 
 
(Cq)
2.500 62.50 1.796 12.10 9.16 16.42
0.625 15.63 1.194 14.30 11.79 18.71
0.156 3.91 0.592 15.81 13.07 19.99
0.039 0.98 -0.010 17.18 14.26 21.40
0.020 0.49 -0.311 19.03 16.39 23.53
0.010 0.24 -0.612 19.54 16.83 23.71
* A typical mammalian cell contains 10-30 pg total RNA = 20-60 pg cDNA  = ~40 pg cDNA
www.sabiosciences.com/newsletter/RNA.html
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Supplementary Figure 1. Sensitivity and specificity of the assays. A. Material from 40 MCRPC patients was 
used to evaluate the correlation between the CTC count after CellSearch enrichment and the average Cq value 
of EPCAM and KRT19 in corresponding RNA samples (CTC count = 260466e-0.333*Cq average (EPCAM+KRT19)). B. Data from 
62 individual experiments with input of RNA from 4 to 580 VCAP cells in the RT-qPCR were used to evaluate 
the linear correlation between the Cq value of AR-V7 and the average Cq value of EPCAM +KRT19. Samples with 
an average Cq value of EPCAM + KRT19 below 26.5 Cq were considered to contain a sufficient epithelial signal 
to allow measurement of AR-V7 in these cells. Circles: unspiked VCAP cells; squares: VCAP cells spiked in HBD 
blood. C. Sensitivity and specificity measuring AR-WT and AR-V7 by RT-qPCR in VCAP cells before and after 
spiking in HBD blood, before and after CellSearch enrichment and before and after pre-amplification. Data are 
expressed relative to the average expression of EPCAM + KRT19 (ΔCq) measured in these preparations. Within 
a window of ± 1.1 Cq, both transcripts can be reproducibly measured in material from as little as 2 VCAP cells. 
Dark blue circles: ΔCq AR-WT; squares; light blue circles: ΔCq AR-V7.
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The therapeutic landscape of metastatic castration-resistant prostate cancer 
(MCRPC) has drastically changed over the past decade with the advent of several 
new anti-tumor agents. Oncologists increasingly face dilemmas concerning the best 
treatment sequence for individual patients since most of the novel compounds 
have been investigated and subsequently positioned either pre- or post-docetaxel. 
A currently unmet need exists for biomarkers able to guide treatment decisions 
and to capture treatment resistance at an early stage thereby allowing for an 
early change to an alternative strategy. Circulating tumor cells (CTCs) have in 
this context intensively been investigated over the last years. The CTC count, as 
determined by the CellSearch System (Janssen Diagnostics LLC, Raritan, NJ), is a 
strong, independent prognostic factor for overall survival in patients with MCRPC at 
various time points during treatment and, as an early response marker, outperforms 
traditional response evaluations using serum prostate-specific antigen (PSA) levels, 
scintigraphy as well as radiography. The focus of research is now shifting toward 
the predictive value of CTCs and the use of the characterization of CTCs to guide the 
selection of treatments with the highest chance of success for individual patients. 
Recently, the presence of the androgen receptor splice variant 7 (AR-V7) has been 
shown to be a promising predictive factor. In this review, we have explored the 
clinical value of the enumeration and characterization of CTCs for the treatment 
of MCRPC and have put the results obtained from recent studies investigating the 
prognostic and predictive value of CTCs into clinical perspective. 
ABSTRACT
Introduction
Over the past decade, the advent of new drugs have led to a substantial improvement in 
the treatment of patients with metastatic castration-resistant prostate cancer (MCRPC). 
After the approval of docetaxel in 2004, six more agents have been registered, among 
which the next-generation taxane cabazitaxel, the androgen receptor (AR) antagonist 
enzalutamide, and the CYP17A1 inhibitor abiraterone [1,2]. In view of the preclinical and 
clinical evidence for the emergence of cross-resistance between docetaxel, abiraterone, 
and enzalutamide  [2-6], the optimal treatment sequence yet remains to be determined. 
Importantly, optimal treatment sequencing may be patient-dependent, requiring 
deliberate (tailored) choices of specific agents for specific patients at specific times.
The options for a personalized treatment approach for patients with MCRPC are 
currently limited given the only few prognostic and predictive markers that are available 
for treatment selection and early evaluation of treatment efficacy. An initial Gleason 
score ≥7 and/or a short interval between the start of initial androgen deprivation therapy 
(ADT) and the development of MCRPC may select for patients who will likely benefit 
most from first-line docetaxel instead of AR-targeted treatment [7,8]. Monitoring of 
treatment response is mostly done through the dynamics of serum levels of prostate-
specific antigen (PSA) and changes in bone scintigraphy and/or computed tomography 
(CT). However, these modalities are at most modestly useful and the read-out of efficacy 
needs at least three months after treatment start due to the long half-life and release 
from apoptotic cells of PSA, flare-up phenomena on bone scans, and slow changes in 
combination with inter-observer variability in tumor size on CT scans [2]. 
Circulating tumor cells (CTCs) are tumor cells present in the peripheral circulation of 
patients with different solid malignancies including MCRPC, which have detached from 
tumor sites. Although occurring at very low frequencies in the peripheral blood, CTC 
counts before and during treatment have proven to be an accurate early response 
marker with a strong independent prognostic value at all time-points during treatment 
[9,10]. Also, CTCs have generally been considered as surrogates for metastatic cells and 
the characterization of CTCs may in this respect function as a “liquid biopsy” to aid in 
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the tailoring of treatments [11,12]. In this review, we discuss the progress that has been 
made regarding the use of CTCs as a prognostic and predictive marker for patients with 
MCRPC, thereby focusing on the clinical relevance of CTCs and to what extent they may 
guide treatment decision-making and optimal treatment sequencing in MCRPC. 
Enumeration of CTCs 
In 2008, a landmark paper was published showing the strong, independent prognostic 
value of a CTC count from peripheral blood in patients with MCRPC when taken before 
the start of a new treatment line  [10]. The enumeration of CTCs was done from 7.5 mL of 
blood by the CellSearch System (Janssen Diagnostics, Raritan, NJ). This semi-automated 
system immunomagnetically enriches epithelial cells from peripheral blood using anti-
epithelial cell adhesion molecule (EpCAM)-antibodies bound to ferrofluid nanoparticles. 
Enriched cells, consisting of CTCs and still a thousand-fold of contaminating leukocytes, 
are immunofluorescently stained and manually counted after digital microscopy; 
nucleated (4’,6-diamidino-2-phenylindole (DAPI)pos), cytokeratin (CK)pos, and CD45neg 
cells with a diameter ≥4x4 μm and a round to oval morphology are thereby considered 
CTCs. This way, patients can be stratified as having a favorable CTC count – defined as <5 
CTC/7.5 mL – or an unfavorable CTC count of ≥5 CTC/7.5 mL. It was shown in 231 patients 
that having a favorable CTC count predicted for a significantly improved progression-free 
survival (PFS) and overall survival (OS) compared to an unfavorable count of ≥5 CTCs at 
all time-points before and during treatment [10]. Conversions of the CTC count, from 
unfavorable to favorable or vice versa, during treatment were shown to be associated 
with an improvement or deterioration of the prognosis, respectively, already 2-5 weeks 
after the start of treatment. By contrast, a 30% or 50% decline in PSA only started to 
be of prognostic significance after 6-8 weeks with maximum hazard ratio (HR) after 13-
20 weeks. At all times, the HR of the favorable versus unfavorable CTC count for OS 
was greater than the HR for the PSA reduction. This study led to the Food and Drug 
Administration (FDA)-clearance of the CTC enumeration by the CellSearch System for 
clinical use in patients with MCRPC. Other studies have since confirmed the prognostic 
value of CTC counts as determined by the CellSearch System under different treatments 
(Table 1). 
Reference
N
Treatm
ent
Patients 
w
ith ≥5 CTCs
Prognostic value
D
anila et al. 
(2007) [6
8]
120
A
ny chem
o
therap
y; 
first/seco
nd-line 
57%
B
aseline CTC co
unt stro
ngly asso
ciated w
ith O
S in univariate analysis (P
<0.001)
D
e B
o
no
 et al. 
(2008) [10]
231
A
ny chem
o
therap
y; 
first/seco
nd/third-
line 
57%
B
aseline H
R
 fo
r O
S: 3.3 (95% CI 2.2-5.1, P
<0.0001);
H
R
 after 2-5 w
eeks: 4.5 (95% CI 3.0-6
.7, P
<0.0001);
CTCs w
ere m
o
re stro
ngly p
ro
gno
stic than P
SA
 at all tim
e p
o
ints
G
oodm
an et al. 
(2009) [69]
100
A
ny chem
o
therap
y; 
any line (1-7th) 
N
ot report-
ed
LD
H
 and CTC both independent prognostic factors for O
S;
B
aseline H
R
 o
f the CTC co
unt ≥4 fo
r O
S: 3.6
5, P
<0.001
O
lm
os et al. 
(2009) [70]
119
A
ny chem
o
therap
y; 
any line (1-5th)
50%
B
aseline H
R
 fo
r O
S: 3.25 (95% CI 1.4-7.4, P
=0.005);
Changes in CTC counts during treatm
ent predict a change in prognosis, 
P
<0.0001)
Scher et al. 
(2009) [6
5]
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D
ocetaxel m
ono
-
therapy or com
bina-
tio
n; first-line
54%
B
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R
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r O
S: 1.58 (P
<0.0001);
Changes in CTC counts w
ere strongly associated w
ith O
S at all tim
es, w
hereas 
changes in P
SA
 w
ere o
nly m
o
destly asso
ciated w
ith O
S after 12 w
eeks
D
anila et al. 
(2011) [56
]
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A
b
iratero
ne; 
seco
nd- o
r third-line
73%
U
nfavo
rab
le CTC co
unt after 4 w
eeks o
f ab
iratero
ne w
as asso
ciatio
n w
ith w
o
rse 
O
S (49 versus 122 w
eeks; P
<0.001)
Scher et al. 
(2013) [71]
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Cabozantinib; 
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r m
o
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71%
A
 CTC co
nversio
n fro
m
 unfavo
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le to
 favo
rab
le w
as asso
ciated w
ith im
p
ro
ved 
O
S: H
R
 0.42 (95% CI 0.19-0.92; P
=0.03) 
Thalgott et al. 
(2013) [72]
55
First-line do
cetaxel 
o
r seco
nd-line treat-
m
ent
57%
U
nfavorable baseline CTC counts w
ere associated w
ith w
orse O
S (P=0.003)
Vo
gelzang et al. 
(2013) [73] 
208
D
o
cetaxel ± lenalid-
o
m
ide; first-line 
58%
B
aseline H
R
 fo
r 2-year O
S: 3.5 (P
<0.05); 
H
R
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r an increase in CTCs b
etw
een b
aseline and cycle 4 fo
r O
S: 5.2 (P
=0.03)
G
oldkorn et al. 
(2014) [74]
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D
o
cetaxel ± atrasen-
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51%
A
 decrease o
f CTCs to
 <5 during treatm
ent w
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rrelated to
 P
SA
 resp
o
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3% 
versus 44%; P
=0.01) and R
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o
nse (31% versus 14%; P
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B
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R
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f the CTC co
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n fo
r 2-year O
S: 2.74 (95% CI 1.72-4.37; P
<0.001); 
H
R
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aseline CTCs ≥5 fo
r O
S: 0.53 (95% CI 0.27-1.06
; P
=0.07); 
H
R
 o
f the co
nversio
n favo
rab
le to
 unfavo
rab
le CTC co
unt: 6
.47 (95% CI 1.96
-21.4; 
P=0.002)
Table 1. O
verview
 of the studies investigating the prognostic value of the CTC count as assessed by the CellSearch System
 before and during 
treatm
ent in patients w
ith M
CRPC. 
Continued on next page
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Given the strong, independent 
prognostic value at baseline 
and early moments during 
treatment, the CTC enumeration 
by the CellSearch System has 
been suggested and increasingly 
investigated as a surrogate end-
point for OS in clinical trials. The 
combination of CTC and lactate 
dehydrogenase (LDH) dynamics 
during treatment fulfilled the 
criteria for individual patient-level 
surrogacy, supporting the use 
as a valid trial end-point instead 
of OS [13]. Already, CTC counts 
have been implemented as 
additional end-points in several 
phase I/II trials investigating the 
tolerability and efficacy of new 
treatments [14-19]. The use of 
CTCs as early outcome marker in 
the development track of novel 
drugs in MCRPC will likely improve 
the efficiency of early clinical 
trials through the shortening 
of the necessary follow-up 
time. Consequently, the time to 
registration for newly developed 
compounds can be expected to 
be reduced, as will the costs of 
development. 
Circulating tumor cell characteristics
Besides a mere enumeration, the interrogation of CTCs for specific tumor characteristics 
has drawn major attention over the past few years. The genomic profiles of CTCs have 
been found to be largely comparable to primary tumors and/or metastatic tissue, 
suggesting that CTCs are able to reflect tumor characteristics including the extent of intra- 
and intertumoral heterogeneity [20-25]. However it remains to be established whether 
CTCs represent the characteristics of all the metastases or only of the most invasive 
clones and what influence factors present in the circulation have on the characteristics 
of CTCs.  Moreover, CTCs have been shown to be tumorigenic and capable of forming 
new metastases [26-28]. The half-life of CTCs has been estimated to be in the order 
of hours rather than days [12,29-31], suggesting a real-time representation of tumor 
characteristics at the time of blood draw. Altogether, CTCs offer the opportunity to gain 
a snap-shot of tumor characteristics at a certain point in time and may therefore, as a 
liquid biopsy, harbor important characteristics of metastatic tumor cells in an individual 
patient. Until now, alterations in the expression, function, and localization of AR in CTCs 
and the clinical relevance thereof have mostly been investigated (Table 2).
Subcellular localization of AR 
After activation by androgens, AR translocates from the cytoplasm to the nucleus in 
order to exert its function as a transcription factor for target genes. The presence of AR 
in the nucleus of tumor cells therefore indicates an active AR pathway. In this respect, 
evaluation of the subcellular localization has been suggested as marker for response 
or resistance to treatment, not only to abiraterone and enzalutamide, but also to 
docetaxel. For long, the working mechanism of docetaxel seemed to be the induction 
of mitotic arrest and apoptosis through the stabilization of microtubules. Recently, it 
was discovered that AR also interacts with microtubules for its nuclear transport and 
consequently at least part of the efficacy of docetaxel in MCRPC seems to result from 
an impairment of AR-signaling [3]. Darshan et al. [32] have shown that the absence 
of nuclear AR in patients treated with docetaxel correlates with clinical response, as 
assessed by confocal microscopy of CellSearch-enriched CTCs. In longitudinal samples 
Ta
bl
e 
1 
(c
o
n
ti
n
u
ed
).
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from 14 MCRPC patients during treatment with docetaxel, a shift was observed from 
nuclear AR before treatment to cytoplasmic AR during treatment to again nuclear AR at 
the time of progressive disease (PD). Overall, 71% of the patients who benefitted from 
taxane treatment had cytoplasmic AR whereas 72% of the CTC samples drawn at the time 
of PD showed a nuclear localization of AR. 
To facilitate the characterization of CTCs for expression and localization of AR, a 
protocol has been developed to incorporate AR as an additional marker within the 
CellSearch System, enabling simultaneous characterization and enumeration of CTCs 
[33]. Comparing the intensity of AR staining between abiraterone/enzalutamide-naïve 
patients and patients who had progressed on abiraterone/enzalutamide, no difference 
in the staining intensity or subcellular localization was observed. However, an increase 
in the median intensity of nuclear AR expression compared to baseline was observed 
over sequential samples of five of the eight patients (63%) who progressed during 
abiraterone or enzalutamide [33]. This increase in AR staining intensity in patients 
progressing on abiraterone has also been described by Reyes et al. [34]. Applying a 
combined flowcytometric and microscopic method, the ImageStream X, to assess AR 
staining intensity and the subcellular localization of AR in the CTCs of 20 MCRPC patients, 
they found the median AR staining intensity to be three times higher in the ten patients 
progressing on abiraterone than in the ten patients who were abiraterone-naïve. No 
difference was observed in the subcellular localization of AR though. Interestingly, 
a correlation between high expression of AR, nuclear localization, and more intense 
staining of the proliferation marker Ki-67 in CTCs was found, suggesting active AR 
signaling in CTCs with high nuclear expression of AR.  
Evidence for active AR signaling in CTCs has also been reported by Miyamoto et al. [35]. 
In this study, CTCs were captured using a CTC chip with anti-EpCAM-antibodies covered 
walls followed by characterization by automated fluorescence microscopy. Based on the 
expression of PSA and the membrane bound form of PSA (PSMA), three CTC categories 
with respect to AR-signaling were defined: AR-off (PSAneg/PSMApos), AR-mixed (PSApos/
Reference
N
CTC Isolation; 
characterization
Param
eter
Clinical relevance
M
iyam
oto et al. 
(2012) [35]
14
CTC-chip
; IF
A
R
 signaling p
heno
-
type of single CTCs
A
R
 p
heno
typ
e o
f CTCs w
as highly hetero
geneo
us w
ith an ab
undance o
f the 
“A
R
-o
ff
” p
heno
typ
e. A
n increase o
f “A
R
-o
n” CTCs during ab
iratero
ne w
as 
associated w
ith a decreased O
S.
D
arshan et al. 
(2011) [32]
14
CellSearch or 
density gradient 
separation; IF
A
R
 sub
cellular lo
cal-
ization
The p
resence o
f nuclear A
R
 w
as p
redictive fo
r resistance to
 taxanes.
Reyes et al. 
(2014) [34]
20
Im
ageStream
 X 
(com
bined FC 
and IF)
A
R
 exp
ressio
n and 
subcellular localiza-
tion
H
igher intensity staining o
f A
R
 in CTCs p
o
sitively co
rrelated w
ith the intensi-
ty o
f the p
ro
liferatio
n m
arker K
i-6
7. N
uclear lo
calizatio
n o
f A
R
 also
 co
rrelat-
ed w
ith the exp
ressio
n o
f K
i-6
7. 
D
ago et al. 
(2014) [22]
1
M
icrom
anipu-
lato
r; IF, W
G
A
, 
N
G
S
A
R
 sub
cellular lo
cal-
ization 
AR
 am
p
lificatio
ns
A
R
pos CTCs decreased fro
m
 6
7% b
efo
re to
 11% during ab
iratero
ne to
 96
% at 
the tim
e of PD
. The localization shifted from
 cytoplasm
ic before and during 
ab
iratero
ne to
 nuclear at the tim
e o
f P
D
. A
m
p
lificatio
ns o
f AR disappeared 
during treatm
ent, but reappeared at the tim
e of PD
. 
Crespo et al. 
(2015) [33]
48
CellSearch; IF
A
R
 exp
ressio
n and 
subcellular localiza-
tion
N
o
 diff
erence in the staining intensity o
r lo
calizatio
n o
f A
R
 b
etw
een p
atients 
naïve fo
r versus p
ro
gressing o
n ab
iratero
ne/enzalutam
ide. In 5/8 p
atients 
w
ho
 had p
ro
gressed o
n ab
iratero
ne/enzalutam
ide an increase o
f nuclear A
R
 
expression w
as observed com
pared to baseline.
Shaff
er et al. 
(2007) [47]
9
CellSearch; FISH
AR
 am
p
lificatio
ns
H
igh co
p
y num
b
er gains in 56
% o
f the p
atients; clinical asso
ciatio
ns no
t re-
ported.
A
ttard et al. 
(2009) [45]
33
CellSearch; FISH
AR
 am
p
lificatio
ns
H
igh co
p
y num
b
er gains in 45% o
f the p
atients; clinical asso
ciatio
ns no
t re-
ported.
Leversha et al. 
(2009) [46
]
49
CellSearch; FISH
AR
 am
p
lificatio
ns
H
igh co
p
y num
b
er gains in 35% o
f the p
atients; clinical asso
ciatio
ns no
t re-
ported.
M
agbanua et al. 
(2012) [25]
9
IM
 enrichm
ent 
and FA
CS; W
G
A
 
and aCG
H
AR
 am
p
lificatio
ns
H
igh co
p
y num
b
er gains in 78% o
f the p
atients. O
verall geno
m
ic p
ro
files o
f 
the CTCs w
ere com
parable to the corresponding archival prim
ary tum
ors, 
except for the AR
 am
p
lificatio
ns.
Jiang et al. (2010) 
[42]
35
CellSearch; N
G
S
AR m
utations
In to
tal, 27 m
utatio
ns w
ere identified in 20 (57%) p
atients; clinical asso
cia-
tions not reported.
Continued on next page
Table 2. O
verview
 o
f studies investigating the p
redictive value o
f CTCs b
y characterizing CTCs fo
r the exp
ressio
n and lo
calizatio
n o
f A
R
 and the 
p
resence o
f A
R
 m
utatio
ns, am
p
lificatio
ns, and/o
r sp
lice variants.
| CTCs AS A TOOL TO GUIDE TREATMENT DECISIONS IN MCRPC
 159158
7
CHAPTER 7 |
Re
fe
re
nc
e
N
CT
C 
Is
ol
at
io
n;
 
ch
ar
ac
te
riz
at
io
n
Pa
ra
m
et
er
Cl
in
ic
al
 re
le
va
nc
e
M
iy
am
ot
o 
et
 a
l. 
(2
01
5)
 [
43
]
13
CT
C-
iC
hi
p
, m
i-
cr
om
an
ip
ul
at
or
; 
R
N
A
 s
eq
ue
nc
in
g
A
R
 m
ut
at
io
ns
A
R
 s
p
lic
e 
va
ri
an
ts
 V
1, 
V3
, V
4,
 V
7,
 a
nd
 V
12
Th
e 
A
R
 t
ra
ns
cr
ip
t 
w
as
 e
xp
re
ss
ed
 in
 6
0 
o
f 
th
e 
77
 (
78
%)
 s
in
gl
e 
CT
Cs
 s
e-
q
ue
nc
ed
; o
ne
 A
R
 m
ut
at
io
n 
(T
87
7A
) 
w
as
 d
et
ec
te
d 
in
 5
/9
 C
TC
s 
fr
o
m
 1
/1
3 
(8
%)
 
o
f 
th
e 
p
at
ie
nt
s;
 3
3 
o
f 
73
 (
43
%)
 f
ro
m
 8
/1
1 
(7
3%
) 
ex
p
re
ss
ed
 ≥
1 
A
R
 s
p
lic
e 
va
ri
an
t:
 
AR
-V
7 
(7
3%
 o
f 
th
e 
p
at
ie
nt
s)
, A
rv
56
7e
s/
AR
-V
12
 (
73
% 
o
f 
th
e 
p
at
ie
nt
s)
, o
r 
AR
-V
1/
AR
-V
3/
AR
-V
4 
(4
5%
 o
f 
th
e 
p
at
ie
nt
s)
St
ei
ne
st
el
 e
t a
l. 
(2
01
5)
 [
44
]
37
A
dn
aT
es
t;
 P
CR
A
R
 m
ut
at
io
ns
Pr
es
en
ce
 o
f A
R-
V7
A
R
 m
ut
at
io
ns
 in
 5
% 
an
d 
ex
p
re
ss
io
n 
o
f A
R-
V7
 in
 4
9%
 o
f 
th
e 
p
at
ie
nt
s.
 T
he
 p
re
s-
en
ce
 o
f A
R-
V7
 w
as
 p
os
iti
ve
ly
 c
or
re
la
te
d 
w
ith
 th
e 
nu
m
be
r o
f p
rio
r t
re
at
m
en
t 
lin
es
; t
he
 p
re
se
nc
e 
of
 A
R-
V7
 w
as
 h
ig
hl
y 
pr
ed
ic
tiv
e 
fo
r r
es
is
ta
nc
e 
to
 s
ub
se
-
q
ue
nt
 a
nt
i-A
R
 t
re
at
m
en
t 
o
r 
ch
em
o
th
er
ap
y 
(7
% 
ve
rs
us
 7
1%
 P
SA
 r
ed
uc
ti
o
n 
o
f 
≥5
0%
; P
<0
.0
01
)
A
nt
o
na
ra
ki
s 
et
 
al
. (
20
14
) 
[5
0]
62
A
dn
aT
es
t;
 P
CR
Pr
es
en
ce
 o
f A
R-
V7
AR
-V
7 
w
as
 d
et
ec
te
d 
in
 t
he
 C
TC
s 
o
f 
29
% 
o
f 
th
e 
p
at
ie
nt
s.
 T
he
 p
re
se
nc
e 
o
f A
R-
V7
 w
as
 h
ig
hl
y 
pr
ed
ic
tiv
e 
fo
r a
bi
ra
te
ro
ne
 a
nd
 e
nz
al
ut
am
id
e 
re
si
st
an
ce
 a
nd
 
pr
og
no
st
ic
 fo
r P
FS
 a
nd
 O
S.
A
nt
o
na
ra
ki
s 
et
 
al
. (
20
15
) 
[5
2]
37
A
dn
aT
es
t;
 P
CR
Pr
es
en
ce
 o
f A
R-
V7
AR
-V
7 
w
as
 d
et
ec
te
d 
in
 t
he
 C
TC
s 
o
f 
46
% 
o
f 
th
e 
p
at
ie
nt
s.
 T
he
 p
re
se
nc
e 
o
f A
R-
V7
 w
as
 n
ot
 p
re
di
ct
iv
e 
fo
r r
es
is
ta
nc
e 
to
 ta
xa
ne
s 
an
d 
no
t p
ro
gn
os
tic
 fo
r P
FS
 
an
d 
O
S.
 A
R-
V7
po
s  p
at
ie
nt
s 
tr
ea
te
d 
w
ith
 ta
xa
ne
s 
ha
d 
a 
lo
ng
er
 P
FS
 c
om
pa
re
d 
to
 t
re
at
m
en
t 
w
it
h 
an
ti
-A
R
 t
re
at
m
en
t,
 n
o
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
tr
ea
tm
en
ts
 
w
as
 o
bs
er
ve
d 
fo
r A
R-
V7
ne
g  p
at
ie
nt
s.
N
ak
az
aw
a 
et
 a
l. 
(2
01
5)
 [
51
]
14
A
dn
aT
es
t;
 P
CR
Pr
es
en
ce
 o
f A
R-
V7
Co
nv
er
si
on
s 
in
 A
R-
V7
 s
ta
tu
s 
of
 C
TC
s 
fr
eq
ue
nt
ly
 o
cc
ur
re
d;
 re
ve
rs
io
ns
 o
nl
y 
du
rin
g 
ta
xa
ne
 tr
ea
tm
en
t. 
Th
e 
cl
in
ic
al
 a
ss
oc
ia
tio
ns
 o
f t
he
se
 c
on
ve
rs
io
ns
 a
nd
 
re
ve
rs
io
ns
 w
er
e 
no
t r
ep
or
te
d.
 
O
ns
te
nk
 e
t a
l. 
(2
01
5)
 [
49
]
29
Ce
llS
ea
rc
h;
 P
CR
Pr
es
en
ce
 o
f A
R-
V7
AR
-V
7 
w
as
 d
et
ec
te
d 
in
 t
he
 C
TC
s 
o
f 
55
% 
o
f 
th
e 
p
at
ie
nt
s.
 T
he
 p
re
se
nc
e 
o
f A
R-
V7
 in
 b
as
el
in
e 
CT
Cs
 w
as
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 re
si
st
an
ce
 to
 c
ab
az
ita
xe
l a
nd
 
no
t p
ro
gn
os
tic
 fo
r P
FS
 a
nd
 O
S.
 
PSMApos), and AR-on (PSApos/PSMAneg). In five patients with metastatic prostate cancer 
starting initial ADT, the AR-on phenotype was predominately present. The phenotype 
switched to AR-off during ADT, followed by the disappearance of CTCs after three 
months. By contrast, a wide variety of CTC phenotypes were observed in 14 MCRPC 
patients, with an abundance of the AR-off phenotype. In only 11% of the investigated 
CTCs, the AR-on phenotype was detected. Interestingly, an increase of CTCs with the AR-
on phenotype during abiraterone treatment was found to be associated with a shorter 
median OS, suggesting that the occurrence of this AR-on phenotype may predict for 
resistance to anti-AR treatment. 
AR mutations and amplifications
In addition to the presence and the localization of AR in CTCs, recent studies have 
focused on the specific aberrations of the AR gene as a cause of resistance to established 
treatments. Activating mutations in AR, leading to constitutive activity, have rarely been 
detected in hormone-sensitive tumors [36], but can be found in up to one-third of the 
patients with MCRPC [36-41]. Mutations have also been detected in CTCs from patients 
with MCRPC [42-44]. At the present time, only limited data from retrospective series of 
patients have been reported and prospective data reporting associations with clinical 
outcome remain to be awaited. 
Amplifications of the AR gene resulting in AR protein overexpression and 
hypersensitization of prostate cancer cells to even castrate levels of androgens are a 
second possible mechanism for treatment resistance [38]. Amplifications have been 
detected in up to 50% of the castration-resistant prostate cancers [36-38] as well as in 
the CTCs from MCRPC patients [45-47]. Conveniently, a protocol has been developed 
to combine the CellSearch enumeration and characterization for gene amplifications by 
fluorescence in situ hybridization (FISH) in one CellSearch cartridge [48]. Applying this 
protocol, AR amplifications have been detected in all of the 33 evaluable patients with 
≥4 CTCs starting treatment with abiraterone, with 15 patients (45%) having CTCs with >5 
AR copies [45]. Observed copy number gains were remarkably heterogeneous between 
Ta
bl
e 
2 
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o
n
ti
n
u
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single CTCs in one sample. Similar results, with amplification rates of 50-78%, have 
been reported from studies investigating AR amplifications by FISH on cytospun CTCs 
from CellSearch cartridges [46,47] or by array comparative genomic hybridization on 
immunomagnetically-enriched and fluorescence-activated cell sorted CTCs [25]. Again, 
marked heterogeneity in AR gene copy numbers between single CTCs was observed in 
most patients.
AR splice variants
To date, the potential predictive value of CTC characteristics has best been exemplified 
by recent reports on the association between the presence of the AR splice variant 7 
(AR-V7) – coding for a truncated and constitutively active AR – and treatment outcome 
[44,49-52]. The presence of AR-V7 in CTCs was shown to be highly predictive for 
resistance to anti-AR treatments [44,50]. From 31 patients starting abiraterone and 31 
patients starting enzalutamide, CTCs were isolated and characterized for the presence 
of AR-V7 by the polymerase chain reaction (PCR)-based AdnaTest [50]. The overall 
prevalence of AR-V7 at baseline was 29%. None of the patients with AR-V7pos CTCs had a 
50% PSA response rate (PSA-RR) compared to 53% and 68% of the patients with AR-V7neg 
CTCs receiving enzalutamide or abiraterone, respectively (P=0.004 for both treatments). 
The presence of AR-V7 in CTCs was an independent prognostic factor for OS with a HR of 
6.9 (95% confidence interval (CI) 1.7-28.1, P=0.002) for the enzalutamide cohort and HR 
12.7 (95% CI 1.3-125.3; P=0.006) for the abiraterone cohort. 
In a second report by the same investigators applying the same methodology, the 
presence of AR-V7 was detected in the CTCs of 46% of the 37 patients from a different 
cohort starting taxane treatment (docetaxel, N=30, or cabazitaxel, N=7) [52]. In this 
study, the PSA-RR was not significantly different between the AR-V7pos and the AR-
V7neg patients (41% versus 65%, respectively; P=0.19) and the presence of AR-V7 was not 
prognostic for PFS (HR 2.7; 95% CI 0.8-8.8; P=0.11) and OS (HR 0.7; 95% CI 0.1-3.8; P=0.66). 
A significant interaction between the presence of AR-V7 and the type of treatment was 
observed; while the prognosis of the AR-V7neg patients was comparable, the PFS of the 
AR-V7pos patients treated with taxanes seemed to be longer compared to the patients 
treated with abiraterone or enzalutamide from the first cohort. However, this indirect 
comparison of the different cohorts has to be interpreted with caution, amongst others 
since the patients treated with taxanes had more advanced disease. 
From 21 of the 37 taxane treated patients, a secondary CTC sample during treatment was 
available. A conversion from AR-V7neg to AR-V7pos was observed in only 1/8 (11%) patients, 
but vice versa was the case in 7/12 (58%). Conversions have also been investigated over 
sequential treatment lines, where 70 CTC samples from 14 patients undergoing a total 
of 37 therapies were selected and analyzed using the AdnaTest [51]. Three patients 
remained AR-V7pos over multiple treatment lines. In the other 11 patients, changes in the 
AR-V7 status of the CTC samples were observed. Interestingly, conversions from AR-V7pos 
to AR-V7neg only occurred during taxane and not anti-AR treatment. Although the results 
from this study suggest that the expression of AR-V7 is influenced by the treatment 
given, the predictive value of the conversions in AR-V7 status remains to be established. 
Also, it is unclear whether the observed changes in the AR-V7 status are true conversions 
or the result of the disappearance of CTCs in the blood sample tested. In the work-up of 
the AdnaTest, cells are lysed and the enumeration of CTCs is not possible (See Table 3 for 
the characteristics of the AdnaTest versus the CellSearch System). The number of CTCs 
present in a sample was therefore not taken into account in the analyses and may be a 
confounder for the prognostic value of AR-V7 in CTCs.  
Given the constitutive activity of AR-V7 as a result of the missing ligand-binding domain, 
treatments with AR-independent mechanisms of action such as cabazitaxel may remain 
effective. With this hypothesis, we measured the expression levels of AR-V7 by RT-qPCR 
in 29 patients with PD after having been treated with at least docetaxel and starting 
cabazitaxel [49]. Data were collected as a part of a prospective phase II trial, for which 
the enumeration of CTCs formed part of the secondary objectives [49]. To ensure 
reliable CTC-derived signals as well as to avoid confounding by CTC count, we normalized 
the expression of AR-V7 to the average of the epithelial genes KRT19 and EPCAM, which 
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showed to correlate with the CTC count as derived from the parallel enumeration tube. 
The presence of AR-V7 was detected in 16 patients (55%) at baseline and was more 
frequent in patients who had received prior abiraterone (100% versus 35%, P=0.009). No 
associations were found between the presence of AR-V7 in baseline CTCs and response 
to cabazitaxel in terms of the CTC-RR or the PSA-RR. In the preliminary survival analyses 
in 29 patients, OS was not impacted by the presence of AR-V7 (HR 1.6 (95% CI 0.6-4.4; 
P=0.45)). 
AdnaTest
(Qiagen, Hannover, GE)
CellSearch System
(Janssen Diagnostics LLC, 
Raritan, NJ)
Regulatory approval CE certification, no clinical 
validation
FDA clearance for clinical use 
of the CTC enumeration
Input  5 mL whole blood 7.5 mL whole blood
Enrichment method Immunomagnetical Immunomagnetical
Enrichment markers EpCAM and HER2 EpCAM
Detection method PCR-based after lysis of en-
riched cells
Immunofluorescence staining 
of fixed and permeabilized 
enriched cells
Detection markers PSMA, PSA, EGFR CK8/18/19
Detection criteria Concentration of ≥10 ng/µL 
for one or more of the detec-
tion markers in the presence 
of a sufficient actin signal
Intact cell of ≥4 µm with a 
round to oval morphology 
and a nucleus overlapping the 
cytokeratin for ≥50%; DAPI-
pos, CK8/18/19pos, CD45neg
CTC quantification Not possible Count per 7.5 mL blood
Characterization possibilities Limited to PCR for tumor-as-
sociated genes
Extensive; for example immu-
nofluorescence staining of 
an additional marker, FISH of 
enriched cells, PCR for tu-
mor-associated genes
Single CTC characterization 
possible
No, CTCs and contaminating 
leukocytes are lysed in a 
sample
Limited to the assessment of 
immunofluorescence staining 
of individual CTCs in the car-
tridge
Table 3. Comparison of the characteristics of the two enrichment methods that have been used in the studies 
investigating the prognostic and predictive value of the presence of AR-V7 in CTCs: the AdnaTest and the 
CellSearch System. Many other detection, enrichment and characterization assays based on the different 
biological and physical properties of CTCs have been developed; these have been reviewed in [12].
Lastly, Miyamoto et al. [43] determined the AR splice variants 1, 3, 4, 7, and 12 in single CTCs 
by RNA sequencing after isolation on the CTC-iChip and picking by a micromanipulator. 
Heterogeneous expression levels of the different splice variants were observed both 
between and within patients. In 33 of the 73 (43%) single CTCs from 8 of the 11 patients (73%) 
at least one alternative splice variant was detected. This most frequently concerned AR-
V7 in 36% of the CTCs and 73% of the patients, followed by ARv567es/AR-V12 in 25% and 73%, 
and AR-V1/V3/V4 in 10% and 45% of the CTCs and the patients, respectively. Importantly, 
splice variants were not detected in corresponding primary prostate tumors, suggesting 
that alternative splicing occurs during disease progression. The prognostic value of all 
splice variants and the clinical relevance of the changes during treatment remain to 
be investigated and in this respect, several prospective clinical trials have been or will 
shortly be intiated (e.g. the CARVE (NCT02621190), the PRIMCAB (NCT02379390), and 
the ARMOR3 trial (NCT02438007). 
Other predictive factors?  
Besides AR, other factors regulating cancer-related pathways may contribute to disease 
progression and treatment resistance and may be clinically relevant to measure in CTCs 
(Table 4). One well-known example are the TMPRSS2:ERG rearrangements, resulting in 
fusion of an ERG oncogene with the AR-driven TMPRSS2 promotor. Rearrangements 
have been detected in >50% of the hormone-sensitive prostate cancers and seem to be 
conserved during tumor progression and evolution [36,37,53]. The recent finding that 
patients with specific ERG rearrangements may be more sensitive to treatment with 
abiraterone makes the presence of this rearrangement a potential predictive factor [54]. 
Rearrangements have been detected in CTCs in frequencies ranging between 21-60% 
[29,45,55-59]. Overall, the rearrangement status of CTCs was homogeneous between 
different CTCs in one sample [45] and concordant with the primary tumor when assessed 
by FISH [45], while discordances have been described when comparing expression 
levels by RT-qPCR [29,56]. Whether technical issues or biological processes cause these 
discordances remains to be investigated. Two trials so far have investigated the predictive 
value of the presence of ERG rearrangements in CTCs for response to abiraterone in a 
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prospective-retrospective manner. Although both studies used the CellSearch System to 
enrich CTCs from whole blood, the subsequent characterization method differed, which 
may contribute to the conflicting results obtained. In the first study by Attard et al. [45], 
the CTCs from 49 patients with ≥4 CTCs at baseline and matching tumor tissue from 
38 patients were characterized by FISH. Patients who were positive for TMPRSS2:ERG 
rearrangements responded better to abiraterone in terms of a ≥90% PSA response 
than the patients in whom no rearrangements were found (80% versus 32%, P=0.001). 
However, in the second study by Danila et al. [56] expression levels of TMPRSS2:ERG in 
CTCs were measured by RT-qPCR in the baseline CTCs from 41 MCPRC patients who had 
started abiraterone treatment. Herein, no associations with PSA response or OS were 
observed. To allow for prospective evaluation of the predictive value of TMPRSS2:ERG 
rearrangements for abiraterone sensitivity, the observed discordances between the 
results obtained by FISH and by PCR will have to be clarified first.
The expression of the proliferation marker Ki-67 has been detected in variable levels 
in CTCs and was shown to be positively correlated to the expression levels and nuclear 
localization of AR [34] as well as to more advanced stages of prostate cancer [29]. The 
presence of Ki-67-positive CTCs during treatment has been suggested as a marker of 
treatment resistance [29,34]. Similarly, the activity of telomerase – an enzyme that 
lengthens and protects the caps of the chromosomes and this way may protect tumor 
cells from apoptosis – has been investigated in CTCs. Telomerase activity was not only 
detected in CTCs, but was also shown to be an adverse prognostic factor in patients with 
a baseline CTC count of ≥5 as assessed by the CellSearch System [60]. Conversely, the 
presence of the apoptosis marker M30 – a neo-epitope of cytokeratin-18 emerging after 
cleavage of cytokeratin-18 by caspases – in CTCs during treatment has been suggested 
as a marker of treatment response [61]. The characterization of CTCs for the presence 
of other putative predictive factors, such as the loss of PTEN [45,59], expression of the 
enhancer of zeste homolog 2 (EZH2) [62], the epidermal growth factor receptor (EGFR) 
[47], or the insulin-like growth factor 1 receptor (IGF1R) [63], or the presence of transcripts 
for steroidogenic enzymes in CTCs [64] have been reported in several proof-of-principle 
Reference
N
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Table 4. Selectio
n o
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R
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Continued on next page
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studies. The clinical relevance of these 
factors for treatment decision-making 
and sequencing of currently available 
treatments remain to be established.  
Discussion
The treatment landscape for MCRPC 
has become increasingly dense with the 
emergence of several new treatment 
options over the past years. The lack of 
reliable biomarkers precludes deliberate 
treatment choices to select the most 
appropriate therapy for individual patients. 
Efforts have been made to identify 
prognostic and predictive factors to guide 
clinical decisions and the enumeration and 
characterization of CTCs from peripheral 
blood by the CellSearch System have 
shown to be promising in this context. 
By the cut-off of ≥5 CTCs/7.5 mL of blood, 
patients with MCRPC can be subdivided 
into a favorable (<5 CTCs) or unfavorable 
prognostic group (≥5 CTCs) [10]. Given 
this strong, independent prognostic 
value, CTCs deserve to be incorporated 
in randomized clinical trials as surrogate 
end-point for OS and as baseline factor 
to ascertain that the treatment arms are 
well balanced. Additionally, CTC dynamics 
during treatment are a superior response 
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evaluation marker over serum PSA levels and radiographic evaluations [10,65]. As such, 
the enumeration of CTCs has already increasingly been incorporated into clinical trials. 
Hopefully, the employment of CTCs will result in an acceleration in drug development 
and at the same time a diminution of the costs of development. 
In parallel to the prognostic value, the predictive value of CTC characteristics in guiding 
up-front treatment decisions is being explored. Amongst others, the presence of 
mutations, amplifications or splice variants of AR have been assessed in CTCs with the 
aim to predict resistance to targeted treatments. Indeed, the presence of AR-V7 in CTCs 
was shown to be able to predict resistance to abiraterone and enzalutamide  [50], but 
not taxanes [49,66]. This way, baseline characterization of CTCs may support the choice 
of anti-AR-treatment or chemotherapy for an individual patient and save patients from 
ineffective treatments with accompanying unnecessary side-effects. Consecutive CTC 
enumerations and characterizations may help to keep track with the development of 
resistance during treatment, as a rising CTC count with shifts in the characteristics of the 
CTC pool may indicate outgrowth of a resistant clone and allow for early intervention 
through a change of treatment. Altogether, CTCs may help to increase treatment 
effectiveness and lower health-care costs. 
Although encouraging results have been obtained over the past few years, there still is 
some way to go for CTCs to be implemented into standard clinical care. The detection 
rate of CTCs in patients with MCRPC lies around 80%, but not all patients with active 
disease have detectable CTCs in their blood, as would be expected. The CellSearch 
System relies on the expression of EpCAM and cytokeratin for the isolation and detection 
of CTCs, making that cells negative for EpCAM and/or cytokeratin will be missed. Indeed, 
cytokeratin-negative CTCs have been found and were shown to exhibit AR amplifications 
supporting their malignant origin [33]. To enable the detection of these cells,  isolation 
and detection methods have been developed exploiting the physical and biological 
characteristics of CTCs, for example the size and deformability of CTCs compared to 
leukocytes or the expression of other cell surface markers besides EpCAM on CTCs [11]. 
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However, each of the approaches brings its own intrinsic limitations. Knowledge about 
the biology and the behavior of tumor cells in the circulation has to be improved in order 
to allow for the development of more sensitive and specific assays to reliably capture 
CTCs preferably in a single cell manner.   
Technical issues in the detection and isolation of CTCs also hinder the clinical applicability 
of the CTC characterization for use as a liquid biopsy to guide treatment decisions. 
Currently, characterization assays have to deal with the rarity of CTCs in the blood 
stream and have to be very sensitive and specific. For example, interrogation of CTCs 
for the presence of AR amplifications by FISH was only successful in 33 of 89 patients 
(37%) with ≥4 CTCs [45] and although single cell sequencing has proven to be feasible, 
sufficient quality DNA samples could only be retrieved from 12 of the 99 CTCs detected 
(12%) [67]. No validated characterization assays exist at this stage and consequently 
many different methods have been applied, limiting the possibilities for comparison of 
the results obtained from the different studies.  
In conclusion, CTCs are a promising tool to help select the optimal treatment for individual 
patients with MCRPC. Whereas a CTC enumeration allows for early and reliable treatment 
response monitoring, CTC characterization may provide a comprehensive overview of 
tumor characteristics at real-time. A clear image of possible resistance mechanisms may 
be obtained through the evaluation of for example the AR mutation, amplification, and 
splice variant status. The expression and phosphorylation of other proteins beyond 
AR will in the future likely further improve the predictive value of CTCs and extend the 
possibilities for tailoring of treatment. While the clinical relevance of sequential CTC 
counts during treatment for use as an early response evaluation marker has clearly been 
shown, the value of a CTC characterization to guide treatment decisions in the clinic 
remains to be investigated. Future prospective clinical trials will have to prove whether 
CTCs can truly function as a liquid biopsy and shed light in the current dense treatment 
landscape for individual patients with MCRPC.
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CTCs as a tool for precision medicine in oncology
The work described in this thesis exemplifies the progress that has been made regarding 
the use of circulating tumor cells (CTCs) as a tool for precision medicine in oncology. Upon 
the commercial availability of the CellSearch System in 2004 and the subsequent US Food 
and Drug Administration (FDA) clearance for the clinical use of the CTC count for patients 
with metastatic breast cancer (MBC) in 2004 [1], for metastatic colorectal cancer (MCRC) 
patients in 2007 [2], and for metastatic castration-resistant prostate cancer (MCRPC) 
patients in 2008 [3], research on the clinical applicability of CTCs has gained momentum. 
While the initial focus was on the prognostic value of the CTC count to stratify patients 
into prognostic subgroups, over the years this has shifted to the predictive value of CTC 
characteristics to guide treatment decision-making by oncologists. 
The need for tools to guide clinical decisions is urgent. Recent research on tumor biology 
has extended our knowledge of tumor progression and has identified several key 
oncogenic factors allowing for therapeutic interventions. For example, 80-85% of the 
gastro-intestinal tumors (GISTs) have been found to carry a c-KIT mutation, which results 
in a constitutive active protein product driving malignant behavior of this tumor type 
[4]. The advent of a specific inhibitor of this protein – imatinib mesylate – has improved 
the median survival of patients with advanced or metastatic GIST from <1 years to >5 
years [5]. Attempts have been made to identify such factors in other tumor types, but, 
unfortunately, most oncogenic molecular aberrations have been detected in much lower 
frequencies. In fact, >90% of targetable alterations identified so far have been found in 
<5% of the patients with a specific tumor type [6], stressing the need to identify driver 
oncogenic factors for individual patients before selecting specific targeted treatments. 
Furthermore, molecular aberrations have been shown not to be static, but rather 
follow a dynamic pattern, which constantly evolves during the course of the disease 
and under the pressure of treatments. The heterogeneity in molecular characteristics 
both between and within patients may have several important implications for the clinic: 
i) in order to select the most effective targeted treatment, molecular alterations in an 
individual tumor will have to be determined; ii) the actual molecular profile of a tumor 
will have to be determined at the time of treatment decision-making; iii) changes in a 
tumor’s molecular profile will have to be followed up in order to capture the emergence 
of treatment resistance early-on and to adjust treatment (Figure 1). As a result, minimally 
invasive methods to molecularly characterize tumor cells throughout a patient’s 
treatment trajectory are highly desired. Representing the smallest comprehensive unit 
of a tumor, CTCs provide the opportunity to facilitate these molecular analyses.  
Figure 1. The concept of precision medicine in oncology. During a patient's treatment trajectory (represented 
by the arrow), the molecular make-up of tumor cells changes (represented by the different colors) due to 
spontaneous tumor evolution and/or under the pressure of administrered treatments. As a consequence of 
the molecular changes, tumors may become resistant to treatments they may have responded to before. To 
ascertain that the most effective treatment is given at any given point in time and to improve the prognosis of 
individual patients, well-informed treatment decisions based on a tumor's actual characteristics will have to be 
made and treatment may frequently have to be adapted based on the changes that have occurred (represented 
by the color matched pills). Assessment of tumor characteristics can be done on tumor tissue that has been 
obtained through for example a needle biopsy (represented by the black needles). However, minimally 
invasive tests are to be prefered to preserve the quality of life over repeated analyses. The characterization of 
CTCs from peripheral blood (represented by the blood tubes containing tumor cells) provides opportunities 
for use as a liquid biopsy.   
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Technical issues
Technical difficulties hamper research on the predictive value of CTCs and, consequently, 
their usage as a liquid biopsy. The low prevalence amongst hematological cells requires 
extremely sensitive and specific assays to detect, capture, and characterize CTCs from 
whole blood. Although the CellSearch System is able to detect 1 CTC amidst the billions 
of erythrocytes, leukocytes, and thrombocytes in 7.5 mL of blood, it only does so in 70-
80% of the patients with MBC or MCRPC [7], 50% of the patients with MCRC [7], and even 
less in other carcinomas such as hepatocellular carcinoma (30%) [8], non-small cell lung 
carcinoma (24%) [9], pancreatic cancer (21%) [10], and ovarian cancer (14%) [11]. 
Sampling site
Differences in the biological behavior of tumors may be responsible for the observed 
differences in the prevalence of detectable CTCs by the CellSearch System. For example, 
ovarian cancer has the tendency to spread intra-abdominally and does not or only at 
late stages disseminate hematologically, which may explain the low occurrence of CTCs 
in the blood stream of patients with even high stage disease [12]. A large proportion of 
the CTCs from patients with MCRC may become trapped in the small capillaries of the 
liver and the lungs through which they travel before reaching the systemic peripheral 
circulation, as may be evidenced by the higher prevalence of CTCs in the portal vein 
compared to the hepatic vein and the occurrence of tumor micro-emboli in the pulmonary 
microcirculation [13, 14]. Also, CTC counts have been found to be higher in the central 
than in the peripheral circulation in patients with MBC [15], again suggesting filtration of 
CTCs from the circulation in the pulmonary microvasculature. Depending on the tumor 
type, we may thus have to consider different sources to capture CTCs. 
Sampling volume 
Increasing the sample volume to be tested for the presence of CTCs may results in 
improved CTC detection rates [16, 17]. Based on the CTC enumerations by the CellSearch 
System from the peripheral blood of 836 patients with MBC, MCRC, and MCRPC, it has 
been calculated that 99% of the patients would have ≥1 CTC in their circulation but that 
up to 5 L of blood would have to be filtered to detect ≥1 CTC in all patients [16]. As such, 
alternative enrichment and detection methods have been developed, such as diagnostic 
leukapheresis [18] and an in vivo enrichment through a peripheral venous catheter-based 
medical wire (CellCollector, GILUPI, Potsdam, GE) [19]. However, these approaches are 
less patient-friendly compared to drawing a tube of blood and, importantly, will have 
to be investigated in large-scale clinical trials in a similar way as has been done for the 
CellSearch System before eventual clinical implementation. 
New enrichment markers
Even when present, current isolation assays may lack the sensitivity to detect all or part 
of the CTCs in a sample. In MBC, our group has shown that a subset of CTCs does not 
express the epithelial cell adhesion molecule (EpCAM), which is the surface molecule 
necessary for the enrichment of CTCs by the CellSearch System (Introduction page 14, 
Figure 2)  [20, 21]. Based on preliminary cell line data and a pilot study in MBC patients, 
melanoma cell adhesion molecule (MCAM, CD146) was identified as an alternative 
enrichment marker for EpCAM-negative CTCs [20]. The clinical relevance of the CTC 
enumeration by a combined EpCAM and MCAM enrichment approach has prospectively 
been tested in the clinical trial described in chapter 2. The aim for this study was to 
improve the sensitivity of the CellSearch System for the detection of CTCs in patients 
with locally advanced breast cancer (LABC) in order to improve the prognostic value 
and to facilitate downstream characterization of the isolated CTCs. Unfortunately, 
our primary objective to increase the capture rate of ≥1 CTC from 7.5 mL blood from 
the current 20% to 40% of the patients with LABC was not met. Still, a significant 
increase to 30% was observed. No correlation was found between the presence of 
EpCAM-postive CTCs and achievement of pathological complete response (pCR) to 
neoadjuvant chemotherapy (NAC). Remarkably, however, none of the patients with 
MCAM-positive CTCs reached a pCR to NAC compared with 23% of the patients without 
MCAM-positive CTCs. Although this difference was not statistically significant, survival 
data will have to be awaited to further conclude on the prognostic value of MCAM- and 
EpCAM-positive CTCs. Meanwhile, a study has been started to investigate the clinical 
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relevance of MCAM-positive CTCs in patients with MBC (IMPACT-MBC; NCT01957332). 
Besides the improvement in the detection of CTCs, a secondary aim of this study is to 
molecularly characterize the isolated MCAM-positive CTCs and to compare these to 
the EpCAM-positive CTCs. Since MCAM has been identified as an inducer of epithelial-
to-mesenchymal-transition (EMT) [22, 23] – the process during which CTCs lose their 
epithelial phenotype to acquire a more mesenchymal phenotype as a means to survive 
in the circulation and to migrate to distant sites [22, 23] – it may well be that MCAM 
enriches for a more aggressive counterpart of CTCs. Recently, it has been shown that 
the overall pool of CTCs comprises a spectrum of phenotypes ranging from full epithelial 
to full mesenchymal CTCs and hybrid epithelial/mesenchymal phenotypes in between 
(Figure 2) [24]. Increases in mesenchymal CTCs during treatment have been found to be 
more strongly predictive of treatment resistance than increases in epithelial CTCs [24], 
which supports further investigation into the associations between the presence of 
MCAM-positive CTCs and the lack of pCR in patients with LABC as observed in our study. 
Other enrichment and detection methods
In an attempt to overcome the limitations formed by the EpCAM-dependency of the 
CellSearch System a plethora of CTC enrichment and detection methods exploiting 
different phenotypical and physical properties of CTCs have been developed over the 
recent years [25]. However, no assay is currently able to directly isolate pure CTC fractions 
without contamination of leukocytes. To discriminate CTCs from the contaminating 
leukocytes, a secondary CTC detection step remains necessary. In the CellSearch System, 
CTCs are identified based on morphological and phenotypical criteria using fluorescence 
microscopy. A cell is considered a CTC when it has i) an intact, round or oval-shaped 
morphology; ii) a size of ≥4 x 4 µm; iii) positivity for 4'6-diamidino-2-phenylindole 
(DAPI), indicating the presence of double-stranded DNA in a cell nucleus, which should 
overlap ≥50% with the cytoplasm and be smaller than the cytoplasm, which is indicated 
by; iv) positive fluorescence staining for cytokeratin (CK); and v) negative staining for 
leukocyte marker CD45 (Introduction page 14, Figure 3). However, the selection based 
on positive staining for CK has been subject of recent debate, since CK-negative CTCs 
Figure 2. Epithelial-to-mesenchymal transition (EMT). After the detachment of CTCs from a solid tumor mass 
and under influence of factors in the blood circulation, the expression of epithelial markers such as EpCAM 
and CK may be downregulated or even lost and mesenchymal markers such as vimentin and N-cadherin may 
be upregulated. The total CTC pool in the blood hence comprises a spectrum of phenotypes ranging from fully 
epithelial (A.) to hybrid epithelial/mesenchymal (B.) to fully mesenchymal (C.). Mainly the loss of EpCAM (red 
markers) and CK (red dashed line) cause for a subset of CTCs to go undetected by most currently available 
detection methods.  
have been shown to exist [24-26]. Like EpCAM, CK is downregulated during the process 
of EMT, meaning that even after enrichment these CTCs would remain undetectable 
if not recognized due to absent CK staining (Figure 2) [24, 26]. A proposed alternative 
marker from in vitro experiments to be used instead of CK is CD49f [27], although this 
marker remains to be tested on clinical samples. Alternative enrichment and detection 
Cytokeratin
EpCAM / CD326
Mesenchymal marker
CD45
A.
B.
C.
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markers instead of or next to EpCAM and CK must be identified in order to detect, 
enumerate, and characterize the full spectrum of CTCs, including the subsets that are 
currenly frequently missed. The characterization of MCAM-positive CTCs will hopefully 
result in the identification of alternative enrichment and detection markers to improve 
the CTC detection rate.
Clinical relevance of the CTC receptor status in MBC
An improvement in the CTC detection rate will likely further boost research on the 
clinical relevance of the characterization of CTCs and the use of CTCs as a tool for tailored 
treatments based on the presence of predictive factors on/in CTCs. Already, promising 
results have been obtained concerning the expression of the estrogen receptor (ER) 
and the human epidermal growth factor receptor 2 (HER2) in CTCs from patients with 
MBC. As summarized in Chapter 3, different studies have investigated the discordances 
in receptor status of CTCs compared to the primary tumor. Although the results from 
the studies have to be compared with caution due to the differences in applied isolation 
and characterization assays, receptor status conversions have consistently been 
observed. Whereas the probability of a loss or gain of the expression of HER2 on CTCs in 
comparison to the primary tumor seems to be equal, the trend for ER is a loss in patients 
with initial ER-positive tumors. Although the frequencies of discordances in receptor 
status between CTCs and the primary tumor are difficult to estimate at this stage due to 
the methodological differences of the studies, it seems to affect a significant proportion 
of the patients. Given the potential direct therapeutic consequences – either inadequate 
treatment in patients in whom a negative conversion occurred or missing out on an 
effective treatment option in patients with a positive conversion – the clinical relevance 
of the receptor status of CTCs must be prospectively investigated. 
As also described in chapter 3, the presence of HER2-positive CTCs has been found to be 
an adverse prognostic factor. Already, the first prospective clinical trials investigating the 
prognostic and predictive value of the expression of HER2 on CTCs have been reported 
[28-31]. Also, we have started a prospective, multicenter, multinational clinical trial to i) 
test the efficacy of the HER2-targeted monoclonal antibody trastuzumab in MBC patients 
with an HER2-negative primary tumor and HER2-positive CTCs (CAREMORE-trastuzumab, 
NTR5115); and ii) test the impact of the expression of HER2 on CTCs on the efficacy of 
endocrine treatment in MBC patients with an initial ER-positive/HER2-negative primary 
tumor (CAREMORE-AI study; NTR5121). The results from these ongoing studies will have 
to be awaited.   
Reflection of tumor characteristics by CTCs
While awaiting the results from prospective trials, studies are trying to shed light on the 
biology of CTCs. Although generally assumed, it has not been proven that CTCs derive 
from different metastatic sites and this way truly reflect the characteristics of the entire 
tumor load including the extent of heterogeneity between tumor clones. Mouse studies 
have shown that certain CTCs have acquired the capability of forming new metastases 
[32-34], suggesting that the characteristics of CTCs at least to some extent reflect the 
characteristics of the metastasis they have formed and are again derived from. However, 
the impact of the detachment from a solid mass and of factors present in the circulation 
on the characteristics of CTCs remain largely unknown. 
In the study described in chapter 4, we have investigated to what extent the molecular 
profiles of the CTCs from 62 patients with MBC resembled the primary tumor, which 
was resected at median 33 months before the CTC blood draw. Using the gene panel 
of 35 CTC-specific genes that had been established in a prior study [35], we observed 
discordant overall profiles in 48% of the patients and in the expression of ESR1 – the gene 
transcript coding for ER – in 24% of the patients. These discordances were not correlated 
with clinicopathological parameters. Only a gain of ER was of prognostic significance in 
our exploratory analyses; the discordances in overall gene expression profiles had no 
impact on survival. Unfortunately, tissue from distant metastatic sites was not available 
in this retrospective study and we were not able to investigate the resemblance with 
a metastasis to investigate whether CTCs best resemble the tumor that is present at 
the time of blood sampling. This would have been of particular interest for the patients 
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with discordant CTC versus primary tumor profiles, where the hypothesis is that CTCs no 
longer resemble the primary tumor due to changes that have occurred to the molecular 
tumor profile of the metastases and that they instead reflect the characteristics of the 
metastases. 
In the prospective trial described in chapter 5, we applied a similar approach as in the 
study described above and compared the molecular profiles of CTCs from patients with 
MCRC to the primary tumor, and in this case also to a liver metastasis. Resection of liver 
metastases has become common practice for MCRC patients with metastases confined 
to the liver and hence metastatic tissue is readily available in this setting. From the 23 
patients that were included in our study, blood was sampled at the time of liver surgery 
and tissue from the primary tumor and a liver metastasis were collected. In all samples, 
the expression of 25 MCRC-associated, CTC-specific genes were measured by RT-qPCR 
and the three resulting profiles were mutually compared. Interestingly, the profiles of 
the CTCs correlated with the liver metastasis in 74% of the patients, but with the primary 
tumor in only 57% of the patients. In another 57% of the patients, the correlation of the 
CTC profile with the liver metastasis profile was stronger than the correlation of the CTC 
profile with the primary tumor profile. Comparing the expression of the 25 individual 
genes between the three tumor compartments over the 23 patients revealed nine 
genes to be downregulated in the CTCs compared to the primary tumor and/or the 
liver metastasis. Most of these genes have been described as tumor-suppressors or to 
be involved in cell-adhesion or EMT, suggesting a functional reason for these genes to 
be downregulated. Altogether, our study has provided evidence that CTCs reflect the 
characteristics of the metastases better than the characteristics of the primary tumor 
and our data suggest that CTCs can indeed be used as surrogates for metastatic tissue.  
The predictive value of CTC characteristics for patients with MCRPC
The use of CTCs as a minimally invasive means to investigate the changes in molecular 
characteristics occurring in a tumor has become of particular interest for patients with 
MCRPC. Over the last decade, several new compounds have been brought to the market, 
among which the new generation taxane cabazitaxel, the CYP17A1-inhibitor abiraterone, 
and the androgen receptor (AR)-antagonist enzalutamide [36, 37]. Both abiraterone and 
enzalutamide have been found to be effective treatment options when placed before 
and after standard treatment with docetaxel chemotherapy [36, 37]. Recent reports 
on the emergence of cross-resistance – mainly between docetaxel, abiraterone, and 
enzalutamide [38, 39] – have further stressed the need to define the optimal treatment 
sequence and to keep track with the development of resistance mechanisms in tumor 
cells. The fact that a CTC represents the smallest yet integral unit of a tumor, which 
still contains information on many aspects of the tumor that may cause treatment 
resistance, such as chromosomal amplifications and translocations, DNA mutations, the 
upregulation of certain signaling pathways, and the expression of proteins, makes them 
an invaluable source in this context. 
The promise of the characterization of CTCs to guide treatment decision-making has well 
been illustrated by a recent study showing a strong predictive value of the presence 
of the AR splice variant 7 (AR-V7) in CTCs for resistance to the AR-targeted treatments 
abiraterone and enzalutamide [40]. In this study, the presence of AR-V7 transcripts in 
CTCs was measured using the clinically non-validated AdnaTest (Qiagen, Hannover, GE) 
in 62 patients with MCRPC. Both PFS and OS were shown to be significantly impacted by 
the presence of AR-V7 in CTCs. Importantly, none of the 18 patients with AR-V7-positive 
CTCs responded to treatment compared to 27 of the 44 (61%) of the patients with AR-
V7-negative CTCs (P=0.004). This led us to design the study that has been described in 
chapter 6. Herein, we have set up an assay to assess the presence of AR-V7 in CTCs after 
CellSearch enrichment to test the predictive value of the presence of AR-V7 in CTCs for 
response to cabazitaxel. Our hypothesis was that cabazitaxel would remain effective 
in patients with AR-V7-positive CTCs given its AR-independent mechanisms of action. 
The presence AR-V7 was detected in the CTCs from 16 of the 29 patients included (55%). 
Indeed, the CTC response rates – defined as a decrease from ≥5 CTCs before the start 
of to <5 CTCs during treatment [3] – to cabazitaxel were 20% in both the patients with 
AR-V7-positive and AR-V7-negative CTCs at baseline, and survival was not impacted by 
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the presence of AR-V7. Although our study has shown that the AR-V7 status of CTCs is no 
prognostic factor for patients that had received cabazitaxel – in contrast to abiraterone 
or enzalutamide – the true predictive value can only be established by prospective 
clinical trials, which have in the mean-time been initiated. Currently, we are testing the 
logistics and the feasibility to report the AR-V7 status of CTCs back to the clinics within 
10 days and before the start of a new treatment line (PRELUDE trial). These logistics will 
be used in the future multicenter, prospective CARVE trial, which will further investigate 
the predictive value of the presence of AR-V7 in CellSearch-enriched CTCs for response to 
abiraterone/enzalutamide and cabazitaxel. 
This thesis concludes with chapter 7, in which the clinical relevance of the CTC enumeration 
and characterization for the management of MCRPC was discussed. A liquid biopsy 
through CTC counts and characteristics may fill the gap caused by the lack of tools to 
enable the selection of the most optimal treatment for an individual patient at a specific 
point in time during his treatment trajectory. The enumeration of CTCs is able to indicate 
the aggressiveness of the disease before the start of treatment and CTC dynamics 
during treatment is a superior response evaluation marker over PSA and imaging [3]. 
The characteristics of CTCs mainly with regard to mutations and amplifications of AR and 
the presence of AR splice variants may predict which treatment would have the highest 
chance of success, thereby preventing ineffective treatments with unnecessary side-
effects. This way, CTCs will help to improve the treatment of individual patients with 
MCRPC, ultimately improving the prognosis of the entire group of MCRPC patients and 
rendering the treatment for MCRPC more cost-effective.
Future perspectives
With the ever ongoing advancements in the biomedical technical field, further progress 
in the research on both the prognostic and the predictive value of CTCs can be foreseen. 
Already, genomic analysis of single cell CTCs has proven to be feasible [41, 42]. For 
the future, more efficient techniques to obtain pure CTC samples with the ability to 
analyze a multitude of genomic and proteomic factors in a single cell fashion can be 
anticipated. Other biomarkers, such as circulating tumor DNA (ctDNA) from peripheral 
blood and exosomes that have been released from tumor cells into the blood plasma, 
may complement the CTC analyses. However, given the comprehensive tumor picture 
a CTC as unit provides with information on the DNA, RNA, and protein level including 
heterogeneity between single CTCs, these assays will likely not replace CTCs. 
Future studies will have to focus on the biology of CTCs, in addition to further unravel the 
predictive value of CTC characteristics. Pure CTCs samples without the contamination of 
leukocytes will have to shed light on the changes that CTCs undergo while circulating. 
The process of EMT and the reverse process of MET must be studied to identify detection 
and isolation markers allowing for the capture of all CTC subsets present in the peripheral 
blood, including the putative most aggressive subset of CTCs that have fully undergone 
EMT. Only then can the true prognostic and predictive power of CTCs be established. 
This may also provide new targets for treatment, for example by inhibiting initiators 
of EMT or blocking the reverse process of MET in order to prevent the formation of 
(new) metastases. Studies in patients with metastatic disease will further have to focus 
on the extent to which CTCs truly reflect the characteristics of the metastases and the 
information on tumor heterogeneity they carry. Preferably, multiple clones from multiple 
metastases would be sequenced and compared to single CTCs to establish whether CTCs 
derive from all the tumor clones present or from a subset of the most invasive clones. 
The results obtained through yet to be initiated comprehensive large-scale trials 
investigating the characteristics of CTCs at the DNA, mRNA, and protein level will yield 
a wealth of information that will help us extract the best ways to treat tumors early-
on. Already, large-scale sequencing efforts of metastatic tissues have been started, for 
example by the Dutch Center for Personalized Cancer Treatment. These efforts will help 
us to identify actionable genomic factors and tumor-specific signaling pathways, but will 
only to a limited extent give insight into the escape mechanisms, which may develop in 
tumors under treatment pressure. Also, genomic analyses will not be fully informative 
for the epigenetic changes, alternative mRNA splicing, or protein-related changes, such 
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The studies that have been described in this thesis focus on improvement of the 
prognostic and predictive value of circulating tumor cells (CTCs) by optimization of the 
detection, capture, and characterization of CTCs from the peripheral blood of patients 
with different forms of cancer. In chapter 2 we investigated a new approach to increase 
the yield of CTCs in patients with locally advanced breast cancer (LABC) by combining 
the usual epithelial cell adhesion molecule (EpCAM)-based CTC enrichment with an 
experimental melanoma cell adhesion molecule (MCAM, CD146)-based enrichment on 
the CellSearch System. In a prior project, our group has shown that a subset of CTCs does 
not express EpCAM and identified MCAM as an alternative enrichment marker for EpCAM-
negative CTCs. We prospectively tested the clinical relevance of the CTC enumeration by 
EpCAM and MCAM with the aim to improve the sensitivity of the CellSearch System for 
the detection of CTCs in patients with LABC in order to improve the prognostic value 
and to facilitate downstream characterization of the isolated CTCs. Unfortunately, our 
primary objective to increase the capture rate in LABC patients from the current 20% 
to 40% was not met. Still, a significant increase to 30% was observed. We investigated 
the correlation between the presence of EpCAM-positive and MCAM-positive CTCs and 
the response to neoadjuvant chemotherapy (NAC) and found that none of the patients 
with MCAM-positive CTCs reached a pathological complete response (pCR) to NAC 
compared with 23% of the patients without MCAM-positive CTCs. This difference was 
not statistically significant, though. The survival data have to be awaited in order to 
investigate the association of the presence of EpCAM-positive and MCAM-positive CTCs 
with disease-free survival (DFS) and overall survival (OS) data. 
An improvement in the CTC detection rate will likely further boost research on the clinical 
relevance of the characterization of CTCs and the use of CTCs as a tool to tailor treatments 
based on the presence of predictive factors on/in CTCs. Chapter 3 contains a review article 
discussing the possibilities for and the clinical relevance of the characterization of CTCs 
from patients with metastatic breast cancer (MBC) mainly focusing on the expression of 
the human epidermal growth factor receptor 2 (HER2) and the estrogen receptor (ER). 
Receptor status conversions between primary tumors and CTCs have frequently been 
observed, although the results obtained from different studies have to be compared 
with caution due to the differences in methodology mainly caused by the different CTC 
detection and characterization assays. Nonetheless, the probability of a loss or gain of 
the expression of HER2 on CTCs in comparison to the primary tumor seems to be equal, 
whereas the trend for ER is a loss in patients with initial ER-positive tumors. The presence 
of HER2-positive CTCs has been found to be an adverse prognostic factor for DFS, 
progression-free survival (PFS), and OS and is now subject of several prospective clinical 
trials investigating the predictive value of the expression of HER2 on CTCs, irrespective 
of the HER2 status of the primary tumor. 
The main hypothesis regarding CTCs is that they are derived from different tumor 
sites that are present at the time of blood sampling and that CTCs this way reflect the 
characteristics of the entire tumor load, including the extent of heterogeneity between 
different tumor sites. In the study described in chapter 4, we have investigated to 
what extent the molecular profiles of the CTCs from 62 patients with MBC resembled 
the primary tumor, which was resected at median 33 months before the CTC blood 
draw. After comparison of the expression levels of 35 CTC-specific genes, we observed 
discordant overall profiles in 48% of the patients and in the expression of ESR1 – the gene 
transcript coding for ER – in 24% of the patients. These discordances were not correlated 
with clinicopathological parameters. Only a gain of ER was of prognostic significance in 
our exploratory analyses; the discordances in overall gene expression profiles had no 
impact on survival. 
In the prospective trial described in chapter 5, we applied a similar approach to compare 
the molecular profiles of CTCs from patients with MCRC to the primary tumor, and in 
this case also to a liver metastasis. Blood from 23 patients was sampled at the time of 
liver surgery and tissue from the primary tumor and a liver metastasis were collected. In 
all samples, the expression of 25 MCRC-associated, CTC-specific genes were measured 
by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and the 
resulting profiles were mutually compared. The profiles of the CTCs correlated with the 
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liver metastasis in 74% of the patients, but with the primary tumor in only 57% of the 
patients. In 57% of the patients the correlation of the CTC profile with the liver metastasis 
profile was stronger than the correlation of the CTC profile with the primary tumor 
profile. Comparing the expression of the 25 individual genes between the three tumor 
compartments over the 23 patients revealed nine genes to be downregulated in the 
CTCs compared with the primary tumor and/or the liver metastasis. Most of these genes 
have been described as tumor-suppressor or to be involved in cell-adhesion or epithelial-
to-mesenchymal-transition (EMT), suggesting a functional reason for these genes to 
be downregulated. Altogether, our study has provided evidence that CTCs reflect the 
characteristics of the metastases better than the characteristics of the primary tumor 
and our data suggest that CTCs can be used as surrogates for metastatic tissue.  
In chapter 6 we investigated the prognostic and predictive value of the presence of 
androgen receptor splice variant 7 (AR-V7) transcripts in the CTCs from patients with 
metastatic castration-resistant prostate cancer (MCRPC). For this purpose, we set up 
an assay to measure the expression of AR-V7 in CTCs after CellSearch enrichment and 
we investigated the association between the presence of AR-V7 in CTCs and response 
to cabazitaxel. Our hypothesis was that cabazitaxel would remain effective in patients 
with AR-V7-positive CTCs given its androgen receptor (AR)-independent mechanisms 
of action in contrast to the AR-targeted treatments abiraterone and enzalutamide. The 
presence AR-V7 was detected in the CTCs from 16 of the 29 patients included (55%) and 
the CTC response rates – defined as a decrease from ≥5 before the start of to <5 CTCs 
during treatment – to cabazitaxel were 20% in both the patients with AR-V7-positive and 
AR-V7-negative CTCs at baseline. Survival was also not impacted by the presence of AR-
V7. Our study suggests that cabazitaxel would thus remain a valid treatment option for 
patients with AR-V7-positive CTCs. 
This thesis concludes with chapter 7, in which the clinical relevance of the CTC enumeration 
and characterization for the management of MCRPC is discussed. Studies investigating 
the clinical relevance of the CTC enumeration and characterization for patients with 
MCRPC are summarized and put into perspective. In short, the enumeration of CTCs may 
help to estimate the aggressiveness of the disease before the start of treatment and CTC 
dynamics during treatment can be used as a superior early response evaluation marker 
over PSA and imaging. The characteristics of CTCs mainly with regard to mutations and 
amplifications of AR and the presence of AR splice variants may predict which treatment 
would have the highest chance of success, thereby preventing the administration of 
ineffective treatments with unnecessary side-effects. This way, CTCs may improve the 
treatment of individual patients with MCRPC and ultimately the prognosis of the whole 
group of patients with MCRPC.
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Circulerende tumorcellen
Het werk dat in dit proefschrift beschreven is, geeft de voortgang weer van het 
onderzoek naar het gebruik van circulerende tumorcellen (CTC’s) als hulpmiddel voor 
een persoonsgerichte “therapie op maat” in de oncologie. Sinds het commercieel 
verkrijgbaar worden van het CellSearch Systeem (Janssen Diagnostics LLC, Raritan, 
NJ) in 2004 en vervolgens de goedkeuring door de Amerikaanse Food and Drug 
Administration (FDA) voor het klinisch gebruik van een CTC telling bij patiënten met 
uitgezaaide borstkanker in 2004 [1], uitgezaaide darmkanker in 2007 [2] en uitgezaaide 
prostaatkanker in 2008 [3] is het onderzoek naar CTC’s in een stroomversnelling geraakt. 
Hoewel de focus in eerste instantie met name op de prognostische waarde van de CTC 
telling lag, is dit de laatste jaren verschoven naar de predictieve waarde van CTC’s en het 
gebruik van CTC’s ter ondersteuning van behandelbeslissingen door de oncoloog. 
CTC's als hulpmiddel in de kliniek
Hulpmiddelen om klinische beslissingen te ondersteunen zijn dringend nodig. Recent 
onderzoek naar de biologie van tumoren heeft onze kennis over de groei van tumoren 
vergroot en heeft ertoe geleid dat we verschillende factoren hebben kunnen identificeren 
die benodigd zijn bij deze groei en die kunnen dienen als aangrijpingspunt voor gerichte 
therapie. Bijvoorbeeld, 80-85% van de gastro-intestinale stromatumoren (GIST’s) draagt 
een mutatie in het cKIT oncogen, wat resulteert in een abnormaal en continu actief 
eiwitproduct met groei van de tumor als gevolg [4]. Behandeling met een remmer van 
dit abnormale eiwit – imatinib mesylaat – heeft de mediane overleving van patiënten 
met een GIST verbeterd van <1 jaar naar ≥5 jaar [5]. Ook in andere tumoren is en wordt 
gezocht naar moleculaire afwijkingen die op een gelijke manier tumorgroei veroorzaken. 
Echter, over het algemeen wordt de aanwezigheid van groeibevorderende factoren in 
veel lagere frequenties per tumorsoort gedetecteerd: 90% van de bekende oncogene 
mutaties worden gedetecteerd in <5% van de patiënten met een specifiek tumortype 
[6]. Er lijken dus bij veel tumorsoorten niet één maar vele verschillende factoren 
betrokken te zijn bij de groei van de tumor. Het bepalen van een moleculair profiel 
om de aanwezigheid van oncogene factoren in de tumor van individuele patiënten te 
onderzoeken zal daarom noodzakelijk zijn om de meest effectieve behandeling op een 
bepaald moment te kunnen selecteren. 
Naast de verschillen tussen patiënten blijkt het moleculaire tumor profiel van een 
individuele patiënt over de tijd niet constant te zijn; tumoren zijn onderhevig aan 
veranderingen en evolutie gedurende het ziekteproces en onder de toegediende 
behandelingen. Hierdoor ontstaan verschillen in de eigenschappen van een tumor, 
wat ook wel heterogeniteit wordt genoemd (pagina 11, figuur 1). Deze heterogeniteit 
is zichtbaar te maken in moleculaire profielen en kan zowel tussen patiënten als in een 
individuele patiënt bestaan. Heterogeniteit heeft verschillende implicaties voor de 
kliniek: i) de selectie van de meest effectieve behandeling dient te gebeuren op geleide 
van het moleculaire profiel van de tumor; ii) het moleculaire profiel dient actueel te zijn 
en zal daarom bepaald moeten worden direct vóór de te starten behandeling; en iii) 
veranderingen in het moleculaire profiel van een tumor zullen vervolgd moeten worden 
om het ontstaan van resistentie tegen de ingestelde behandeling op een zo vroeg mogelijk 
moment te kunnen ondervangen en de behandeling aan te kunnen passen (pagina 179, 
figuur 1). Minimaal invasieve methoden om tumorcellen gedurende het behandeltraject 
van een patiënt herhaaldelijk moleculair te kunnen onderzoeken zijn hierbij van groot 
belang. Aangezien CTC’s eenvoudig te verkrijgen zijn middels een simpele bloedafname 
en een CTC de kleinste integrale eenheid van een tumor vertegenwoordigt, heeft een 
bloedafname voor de telling en karakterisatie van CTC’s de potentie om een belangrijk 
hulpmiddel te worden voor de moleculaire tumor analyses. 
Technische hindernissen
Het onderzoek naar de klinische waarde van CTC’s en het gebruik als zogenaamd 
“vloeibaar biopt” wordt echter bemoeilijkt door technische obstakels. De zeer lage 
prevalentie van CTC’s tussen de vele hematologische cellen vereist extreem sensitieve 
en specifieke methoden om de cellen te detecteren en te vangen uit volbloed om ze 
vervolgens te karakteriseren voor de moleculaire eigenschappen. Hoewel het CellSearch 
Systeem in staat is om 1 CTC te detecteren temidden van de miljarden rode bloedcellen, 
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witte bloedcellen en bloedplaatjes die aanwezig zijn in 7,5 mL bloed, gebeurt dit 
slechts in 70-80% van de patiënten met uitgezaaide borst- en prostaatkanker [7], 50% 
van de patiënten met uitgezaaide darmkanker [7] en zelfs nog minder frequent in 
andere tumortypes zoals leverkanker (30%) [8], niet-kleincellig longkanker (24%) [9], 
alvleesklierkanker (21%) [10] en eierstokkanker (14%) [11]. 
Plaats van afname
De verschillen die bestaan in het biologische gedrag van de tumoren kan een verklaring 
zijn voor de verschillende frequenties waarin CTC’s door het CellSearch Systeem in het 
bloed worden gedetecteerd. Bijvoorbeeld, eierstokkanker is een ziekte die voornamelijk 
in de buikholte groeit en niet of slechts in vergevorderde stadia via het bloed uitzaait 
[12]. Dit zou mogelijk het lage percentage van patiënten met detecteerbare CTC’s bij dit 
tumortype kunnen verklaren. Bij darmkanker gaan de CTC’s eerst door de bloedvaten 
van de lever en de longen alvorens ze in de grote bloedsomloop komen. Filtratie van 
een groot deel van de CTC’s in de lever en in de kleine vaatjes  van de longen kan in 
dit geval zorgen voor een lager aantal CTC’s bij patiënten met uitgezaaide darmkanker. 
Onderbouwing voor deze hypothese kan ook gevonden worden in het hogere aantal 
CTC’s dat gedetecteerd werd in het bloed uit de poortader ten opzichte van bloed uit de 
leverader [13] alsmede het voorkomen van klompjes van tumorcellen in het vaatbed van 
de longen [14]. Daarnaast zijn verhoogde aantallen CTC’s gevonden in bloedafnames uit 
de centrale, grote circulatie ten opzichte van de perifere circulatie bestaande uit kleinere 
bloedvaten [15], wat opnieuw aanwijzingen geeft voor het optreden van filtratie van 
CTC’s. Mogelijk is de plaats van afname van de CTC's dus van belang en kan dit verschillen 
tussen de tumor typen.   
Volume
Het vergroten van het volume dat onderzocht wordt voor de aanwezigheid van CTC’s 
kan ook een manier zijn om de CTC detectie te verbeteren [16, 17]. Gebaseerd op de CTC 
tellingen bij 836 patiënten met uitgezaaide borst-, prostaat- en darmkanker is berekend 
dat 99% van de patiënten ≥1 CTC(’s) in het bloed heeft, maar dat tot 5 L bloed onderzocht 
moet worden om daadwerkelijk 1 CTC in al deze patiënten te detecteren. Om deze reden 
zijn alternatieve verrijkings- en detectiemethoden ontwikkeld, waaronder diagnostische 
leukaferese [18] en een in vivo verrijking middels een vergulde medische draad die via 
een infuus in de bloedbaan gebracht wordt (CellCollector, GILUPI, Potsdam, GE) [19]. 
Echter, deze methoden zijn minder patiënt-vriendelijk dan een reguliere bloedafname. 
Daarnaast zal het van groot belang zijn deze methoden eerst te onderzoeken in 
grootschalige klinische studies en de CTC telling en/of karakterisatie klinisch te valideren 
op eenzelfde manier als voor het CellSearch Systeem is gedaan alvorens over te gaan tot 
klinische implementatie. 
Nieuwe detectie merkers
Een te lage sensitiviteit van de huidige detectiemethoden kan een andere verklaring 
zijn voor het lage aantal CTC’s dat momenteel gedetecteerd wordt. Onze groep heeft in 
uitgezaaide borstkanker laten zien dat er een subgroep van CTC’s bestaat welke geen of 
slechts zeer laag het eiwit EpCAM tot expressie brengt. Aangezien dit membraaneiwit 
door het CellSearch Systeem gebruikt wordt om CTC’s uit volbloed te vangen, worden de 
EpCAM-negatieve CTC’s met de huidige methode gemist (pagina 14, figuur 2). Gebaseerd 
op in vitro cellijn experimenten werd het eiwit MCAM (CD146) geïdentificeerd als een 
mogelijke alternatieve detectie merker voor EpCAM-negatieve CTC’s [20, 21]. De klinische 
relevantie van een CTC telling middels zowel EpCAM als MCAM is prospectief getest in 
de klinische studie die beschreven is in hoofdstuk 2. Het doel van deze studie was om 
de sensitiviteit van het CellSearch Systeem te verbeteren voor de detectie van CTC’s 
bij patiënten met lokaal gevorderde borstkanker. Uiteindelijk zou dit kunnen helpen 
de prognostische waarde van CTC’s te versterken en de erop volgende karakterisatie 
te vergemakkelijken. Helaas werd het primaire doel van de studie – om de detectie 
van ≥1 CTC/7,5 mL bloed te verbeteren van de huidige 20% van de patiënten met lokaal 
gevorderde borstkanker naar een beoogde 40% – niet behaald. Desalniettemin werd een 
significante verbetering naar 30% van de patiënten in onze studie gevonden. Opvallend 
genoeg bereikte geen van de patiënten met MCAM-positieve CTC’s een pathologisch 
complete respons op neo-adjuvante chemotherapie tegenover 23% van de patiënten 
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zonder MCAM-positieve CTC’s. Hoewel dit verschil niet statistisch significant was, 
zullen de overlevingsdata afgewacht moeten worden om een definitieve conclusie te 
kunnen trekken over de prognostische waarde van MCAM- en EpCAM-positieve CTC’s 
bij de patiënten in onze studie. In de tussentijd is een studie gestart waarin de klinische 
relevantie van MCAM-positieve CTC’s bij patiënten met uitgezaaide borstkanker verder 
wordt onderzocht (IMPACT-MBC; NCT01957332). Naast de verbetering in de detectie 
van CTC’s is een secundair doel van deze studie om geïsoleerde MCAM-positieve CTC’s 
moleculair te karakteriseren en deze te vergelijken met de EpCAM-positieve CTC’s. 
Aangezien MCAM geïdentificeerd is als een van de factoren die betrokken zijn bij 
epitheliale-naar-mesenchymale transitie (EMT; een proces waarin CTC’s hun epitheliale 
fenotype kwijtraken en een meer mesenchymaal fenotype verkrijgen om op deze manier 
in de bloedstroom te kunnen overleven en naar weefsels op afstand te kunnen migreren) 
[22, 23] isoleert de MCAM verrijking mogelijk voor een agressievere subset van CTC’s. 
Onlangs is aangetoond dat de gehele CTC fractie een spectrum aan fenotypes omvat 
dat reikt van volledig epitheliaal naar volledig mesenchymaal en gemengde epitheliaal-
mesenchymale fenotypes daartussen  (pagina 183, figuur 2) [23]. Een toename in het 
aantal mesenchymale CTC’s gedurende de behandeling bleek sterker predictief te zijn 
voor resistentie tegen de ingestelde behandeling dan een toename van de epitheliale 
subset [24]. Deze resultaten steunen verder onderzoek naar de verbanden tussen de 
aanwezigheid van MCAM-positieve CTC’s en het uitblijven van pathologisch complete 
respons op neo-adjuvante chemotherapie zoals gevonden werd bij de patiënten met 
lokaal gevorderde borstkanker in onze studie. 
Andere detectiemethoden
Recente inspanningen om de beperkingen van het CellSearch Systeem, welke met 
name gevormd worden door de EpCAM-afhankelijkheid voor het detecteren en vangen 
van CTC’s, te ondervangen hebben geleid tot een veelvoud aan CTC verrijkings- en 
detectiemethoden. Hoewel de verschillende methoden uitgaan van verschillende 
eigenschappen van CTC’s – naast de aanwezigheid van membraaneiwitten onder 
andere ook de grootte en vervormbaarheid van de cellen ten opzichte van bloedcellen 
– heeft iedere methode ook zijn eigen nadelen. Geen enkele methode is op dit moment 
in staat om pure CTC fracties te isoleren uit volbloed zonder “bijvangst” van witte 
bloedcellen. Om de CTC’s van de witte bloedcellen te kunnen onderscheiden is altijd nog 
een vervolgstap nodig. Het CellSearch Systeem maakt hiervoor naast kenmerken in de 
vorm van de cellen gebruik van fluorescente antistoffen om de aan- of afwezigheid van 
bepaalde eiwitten te visualiseren. Een cel wordt beschouwd als een CTC als deze i) intact 
en rond of ovaal van vorm is; ii) een minimale grootte van 4 x 4 µm heeft; iii) positief is 
voor 4'6-diamidino-2-phenylindool (DAPI), wat de aanwezigheid van dubbelstrengs DNA 
in een celkern zichtbaar maakt, deze kleuring moet voor tenminste 50% binnen de cel 
liggen; iv) positieve fluorescente aankleuring van cytokeratine; en v) geen aankleuring 
voor de witte bloed cel merker CD45 laat zien (pagina 14, figuur 3). Recentelijk is de 
aankleuring van cytokeratine als criterium om een cel een CTC te noemen echter 
onderwerp van discussie geworden, nadat het bestaan van cytokeratine-negatieve CTC’s 
werd aangetoond [24-26]. Net als EpCAM wordt de expressie van cytokeratine omlaag 
gebracht tijdens het proces van EMT, wat betekent dat deze cellen niet gedetecteerd 
kunnen worden wegens afwezige cytokeratine aankleuring zelfs al worden ze gevangen 
[24, 26]. Een mogelijke alternatieve merker voor cytokeratine zou CD49f kunnen zijn [27], 
hoewel deze merker alleen nog afkomstig is uit cellijn experimenten en getest dient te 
worden op patiënten materiaal. Al met al zullen alternatieve merkers voor de verrijking 
en detectie van CTC’s in plaats van of naast EpCAM en cytokeratine geïdentificeerd moet 
worden om de detectie en telling van CTC’s, inclusief de subset van CTC’s die met de 
huidige methoden niet of moeilijk detecteerbaar is, uit volbloed te optimaliseren en de 
CTC karakterisatie te faciliteren. Het onderzoek naar het vóórkomen en de eigenschappen 
van MCAM-positieve CTC’s zal hopelijk resulteren in nieuwe merkers die de CTC detectie 
kunnen verbeteren.
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CTC's en de behandeling van patiënten met uitgezaaide borstkanker
Een verbetering in de CTC detectie kan een nieuwe impuls geven aan het onderzoek 
naar de klinische relevantie van de karakterisatie van CTC’s en het gebruik van CTC’s 
als hulpmiddel voor therapie op maat, gebaseerd op de eigenschappen van CTC’s. 
Veelbelovende resultaten zijn al behaald waar het de expressie van de oestrogeen 
receptor (ER) en de humaan epidermale groeifactor receptor 2 (HER2) – beide 
belangrijke aangrijpingspunten voor de behandeling van patiënten met borstkanker – in 
CTC’s bij patiënten met uitgezaaide borstkanker betreft. In hoofdstuk 3 is een overzicht 
gegeven van de frequentie van discordante expressie van ER en HER2 tussen de CTC’s 
en de primaire borsttumor, welke onderzocht zijn in verschillende studies. Hoewel 
de resultaten op dit moment moeilijk vergelijkbaar zijn door de grote verschillen in 
de toegepaste CTC isolatie en karakterisatie methoden, zijn conversies in de receptor 
status van CTC’s ten opzichte van de primaire tumor consistent geobserveerd. Waar de 
waarschijnlijkheid van het verliezen of verwerven van HER2 op CTC’s in vergelijking met 
de primaire tumor vergelijkbaar lijkt te zijn, is de trend voor ER een verlies bij patiënten 
met een oorspronkelijk ER-positieve tumor. Hoewel exacte frequenties van discordante 
expressie op dit moment moeilijk aan te geven zijn door de grote verschillen tussen de 
studies, lijkt het om een significant deel van de patiënten te gaan. Gezien dat dit mogelijk 
directe therapeutische consequenties met zich meebrengt – ofwel het geven van een 
inadequate behandeling bij patiënten waar de receptor verloren is gegaan ofwel het niet 
overwegen van een effectieve behandeling bij patiënten waar een receptor in eerste 
instantie niet aanwezig was – is het van groot belang om de klinische relevantie van 
de receptor status van CTC’s nader te onderzoeken in prospectieve klinische studies. 
Zoals ook beschreven in hoofdstuk 3 is de aanwezigheid van HER2 op CTC’s prognostisch 
gebleken voor slechte overleving. De eerste prospectieve klinische studies die de 
prognostische en predictieve waarde van de HER2 status van CTC’s hebben onderzocht 
zijn inmiddels ook gepubliceerd [28-31]. Op dit gebied heeft ook onze groep een 
prospectieve, multicenter, multinationale klinische studie gestart om i) de effectiviteit 
te testen van het anti-HER2 monoclonale antilichaam trastuzumab bij patiënten met 
uitgezaaide borstkanker met een HER2-negatieve primaire borsttumor en HER-positieve 
CTC’s (CAREMORE-trastuzumab, NTR5115); en ii) de impact te testen van de expressie van 
HER2 op CTC’s op de effectiviteit van hormonale therapie bij patiënten met uitgezaaide 
borstkanker met een oorspronkelijk ER-positieve/HER2-negatieve primaire borsttumor 
(CAREMORE-AI study; NTR5121). De resultaten van deze nog lopende studies zullen 
afgewacht moeten worden. 
CTC's versus de primaire tumor versus een uitzaaiing
In afwachting van de resultaten uit de lopende prospectieve klinische studies gaat het 
onderzoek naar de biologie van CTC’s onverminderd door. Hoewel in het algemeen 
aangenomen, is nooit bewezen dat CTC’s ook daadwerkelijk afkomstig zijn van de 
verschillende uitzaaiingen die aanwezig kunnen zijn bij een patiënt en dat CTC’s op deze 
manier de eigenschappen van de gehele tumormassa weergeven, inclusief de mate van 
heterogeniteit. Studies in muizen hebben aangetoond dat bepaalde CTC’s in staat zijn om 
nieuwe uitzaaiingen te vormen [32-34], wat suggereert dat CTC’s tot op zekere hoogte 
de eigenschappen weergeven van de uitzaaiing die ze hebben gevormd en waar ze 
opnieuw van afkomstig zijn. De effecten van het loskomen van een tumor massa en van 
factoren uit de bloedbaan op de eigenschappen van CTC’s blijven echter nog onbekend. 
In de studie die beschreven is in hoofdstuk 4 is onderzocht in welke mate de moleculaire 
profielen van de CTC’s van 62 patiënten met uitgezaaide borstkanker lijken op die van 
de primaire borsttumor, welke mediaan genomen 33 maanden eerder chirurgisch 
was verwijderd. Gebruik makend van het panel van 35 CTC-specifieke genen zoals 
gedefinieerd in een eerdere studie [35], vonden wij discordante profielen in 48% van de 
patiënten. De expressie van ESR1 – het gen dat codeert voor ER – was discordant in 24% 
van de patiënten. De gevonden discordanties waren niet gecorreleerd aan klinische en 
pathologische parameters. Enkel het verwerven van ER had significante prognostische 
waarde in onze exploratieve analyses; discordantie over het gehele genpanel had 
geen gevolgen voor overleving. Helaas was weefsel van een uitzaaiing op afstand niet 
beschikbaar voor de patiënten uit deze retrospectieve studie waardoor we niet in staat 
waren om het CTC profiel te vergelijken met die van een uitzaaiing en te onderzoeken of 
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CTC’s beter lijken op de tumor die op het moment van de bloedafname nog daadwerkelijk 
bij de patiënt was. Dit zou met name van toegevoegde waarde zijn voor de patiënten uit 
onze studie waar de CTC versus primaire tumor profielen discordant waren en waar de 
hypothese is dat de CTC’s niet meer lijken op de primaire tumor door veranderingen die 
zijn ontstaan in de uitzaaiingen gedurende de tijd en dat de CTC’s deze veranderingen 
weergeven. 
In hoofdstuk 5 is een prospectieve studie beschreven waarin eenzelfde aanpak is gevolgd 
als in het onderzoek dat hierboven beschreven is. In dit geval is het moleculaire profiel van 
de CTC’s van patiënten met uitgezaaide darmkanker vergeleken met die van de primaire 
darmtumor alsook met het profiel van een leveruitzaaiing. Het operatief verwijderen van 
leveruitzaaiingen is standaard zorg geworden voor patiënten waar de uitzaaiingen zich 
beperken tot de lever en hierdoor is weefsel van een uitzaaiing op afstand makkelijker 
verkrijgbaar geworden voor deze patiëntengroep. Van de 23 patiënten die geïncludeerd 
waren in de studie werd bloed afgenomen direct voorafgaand aan de leveroperatie en 
werd weefsel van een leveruitzaaiing en de primaire tumor verzameld. In zowel de CTC’s 
uit het bloed als de tumorweefsels werd de expressie van een panel van 25 CTC-specifieke 
genen gemeten middels reverse transcription quantitative polymerase chain reaction (RT-
qPCR) en deze werden onderling vergeleken. Interessant genoeg bleken het profiel van 
de CTC’s overeen te komen met de leveruitzaaiing bij 74% van de patiënten, maar met 
de primaire darmtumor maar bij 57% van de patiënten. Bij 57% van de patiënten was de 
correlatie tussen het profiel van de CTC’s en de leveruitzaaiing sterker dan die tussen de 
CTC’s en de primaire darmtumor. Het vergelijken van de expressie van de 25 individuele 
genen over de 23 patiënten tussen de drie tumorcompartimenten resulteerde in negen 
genen die significant verlaagd tot expressie kwamen in de CTC’s ten opzichte van de 
leveruitzaaiing en de primaire tumor. Over het algemeen zijn deze genen beschreven als 
zijnde tumor suppressor of betrokken bij celadhesie en/of EMT. Dit suggereert dat het 
verlagen van de expressie van deze genen door de tumorcellen een functionele reden 
heeft. Alles tezamen laat onze studie zien dat de eigenschappen van CTC’s het beste 
lijken op de uitzaaiing op afstand in plaats van op de primaire darmtumor en suggereren 
de data dat CTC’s inderdaad gebruikt kunnen worden als surrogaat voor weefsel van 
uitzaaiingen. 
CTC's en de behandeling van patiënten met uitgezaaide prostaatkanker
Het gebruik van CTC’s als een minimaal invasieve manier om veranderingen in de 
moleculaire eigenschappen van een tumor te onderzoeken heeft recentelijk veel aandacht 
getrokken voor de behandeling van patiënten met uitgezaaide castratie-resistente 
prostaatkanker. De laatste jaren zijn er veel nieuwe behandelingen beschikbaar gekomen, 
waaronder de nieuwe generatie taxaan cabazitaxel, de CYP17A1-remmer abiraterone 
en de androgeen receptor (AR)-antagonist enzalutamide [36, 37]. Zowel abiraterone 
als enzalutamide zijn effectieve behandelopties gebleken voor en na behandeling met 
docetaxel chemotherapie, wat de optimale behandelvolgorde onduidelijk maakt [36, 
37]. Het aantonen van het bestaan van kruisresistentie tegen behandelingen – met 
name tussen docetaxel, abiraterone en enzalutamide [38, 39] – onderstreept het belang 
van weloverwogen, geïnformeerde beslissingen over de meest optimale therapie op 
een specifiek moment. Het feit dat CTC’s de kleinste volledige eenheid van een tumor 
vertegenwoordigen, waarbij informatie beschikbaar blijft aangaande velerlei aspecten 
van een tumor welke resistentie kunnen veroorzaken – zoals chromosomale amplificaties 
en translocaties, DNA mutaties, opregulatie van specifieke signaalpaden in de tumor en 
de aanwezigheid van eiwitten – maakt deze cellen van onschatbare waarde. 
Dat de karakterisatie van CTC’s ter ondersteuning van klinische behandelkeuzes 
veelbelovend is, werd recent geïllustreerd door een studie die aantoonde dat de 
aanwezigheid van de AR splice variant 7 (AR-V7) in CTC’s van sterk ongunstige 
prognostische waarde is voor patiënten die behandeld werden met de anti-AR gerichte 
middelen abiraterone en enzalutamide [40]. In deze studie werden de CTC’s van 62 
patiënten met uitgezaaide prostaatkanker gedetecteerd en gekarakteriseerd voor 
de aanwezigheid van AR-V7 middels de klinisch niet-gevalideerde AdnaTest (Qiagen, 
Hannover, GE). De AR-V7 status van CTC’s had een significant negatief effect op zowel 
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de progressie-vrije als totale overleving (respectievelijk PFS en OS). Opvallend was dat 
geen van de 18 patiënten met AR-V7-positieve CTC’s respondeerde op de behandeling 
versus 27 van de 44 patiënten (61%) met AR-V7-negatieve CTC’s (P=0.004). De resultaten 
uit deze studie leidden ons ertoe om de studie beschreven in hoofdstuk 6 op te 
zetten. In deze studie hebben wij een methode opgezet om de aanwezigheid van AR-
V7 te meten in CTC’s die door de CellSearch gedetecteerd zijn. Het doel van de stdie 
was om de predictieve waarde van de aanwezigheid van AR-V7-positieve CTC’s voor 
respons op cabazitaxel te onderzoeken. Onze hypothese was dat behandeling met 
cabazitaxel chemotherapie effectief zou blijven onafhankelijk van de aanwezigheid 
van AR-V7 in CTC’s gezien de merendeels AR-onafhankelijke werkingsmechanismen van 
cabazitaxel. Bij 16 van de 29 patiënten in onze studie (55%) werden AR-V7-positieve CTC’s 
gedetecteerd. Zoals verwacht werd geen verschil waargenomen in de CTC respons – 
gedefinieerd als een afname van ≥5 CTC’s voor start van de cabazitaxel naar <5 CTC’s 
gedurende de behandeling [41] – op cabazitaxel; deze was 20% bij zowel de AR-V7-
positieve als AR-V7-negatieve patiënten. Tevens werd geen effect van de aanwezigheid 
van AR-V7 op overleving waargenomen. Hoewel onze studie laat zien dat de AR-V7 status 
van CTC’s geen prognostische waarde heeft onder behandeling met cabazitaxel – in 
tegenstelling tot abiraterone en enzalutamide – kan de werkelijke predictieve waarde 
alleen bevestigd worden middels prospectieve klinische studies, welke in de tussentijd 
zijn gestart. Zo hebben wij de PRELUDE studie gestart om de logistieke pijplijn te testen 
en de haalbaarheid te toetsen van het terug rapporteren van de AR-V7 status van CTC’s 
naar de kliniek binnen 10 dagen na bloedafname. Deze logistiek zal vervolgens ingezet 
worden voor de toekomstige multicentrische, prospectieve CARVE studie, welke de 
predictieve waarde zal onderzoeken van de aanwezigheid van AR-V7 in door CellSearch 
gedetecteerde CTC's van patiënten met uitgezaaide castratie-resistente prostaatkanker 
die gaan starten met behandeling met ofwel abiraterone/enzalutamide ofwel cabazitaxel. 
Dit proefschrift besluit met hoofdstuk 7, waarin de klinische relevantie van het tellen en 
karakteriseren van CTC’s voor de behandeling van patiënten met uitgezaaide castratie-
resistente prostaatkanker bediscussieerd wordt. Een vloeibaar biopt middels CTC telling 
en eigenschappen kan mogelijk het gat opvullen dat gevormd wordt door het ontbreken 
van hulpmiddelen die de selectie mogelijk maken van de meest optimale behandeling 
voor een individuele patiënt op een specifiek tijdspunt gedurende zijn behandeltraject. 
Het tellen van CTC’s informeert over de agressiviteit van de ziekte voor start van een 
behandeling; het veranderen van het aantal CTC’s gedurende de behandeling kan iets 
zeggen over het wel of niet aanslaan van die behandeling [3]. De responsevaluatie 
middels herhaalde CTC tellingen is superieur gebleken aan de huidige evaluatiemethoden 
die bestaan uit het meten van het prostaat-specifieke antigeen (PSA) in het bloed en 
beeldvorming in de vorm van een CT-scan en/of een botscan. De eigenschappen van 
CTC’s, met name met het oog op de aanwezigheid van AR mutaties en amplificaties en de 
aanwezigheid van AR splice varianten, kunnen mogelijk voorspellen welke behandeling 
de grootste kans van slagen heeft op een specifiek moment. Daarbij worden ineffectieve 
behandelingen met onnodige bijwerkingen voorkomen. Op deze manier kunnen CTC’s 
bijdragen aan een verbeterde prognose voor de gehele groep van patiënten met 
uitgezaaide prostaatkanker en tevens de behandeling meer kosten-effectief maken. 
Perspectief voor de toekomst
Met de immer doorgaande ontwikkelingen in het biomedisch technische vakgebied kan 
meer voortgang verwacht worden in het onderzoek naar zowel de prognostische als de 
predictieve waarde van CTC’s. Het is nu al mogelijk gebleken om het DNA van individuele 
CTC’s te analyseren [41, 42]. In de toekomst zullen naar verwachting meer efficiënte 
technieken ter beschikking komen om een veelvoud aan genetische en eiwit-gerelateerde 
factoren te meten in een enkele CTC. Andere biologische merkers, zoals het circulerend 
tumor DNA (ctDNA) uit bloed en exosomen – minipartikels uitgescheiden door cellen – in 
plasma, kunnen de CTC analyses mogelijk aanvullen. Echter, gezien het complete beeld 
dat CTC’s van een tumor kunnen geven aangaande informatie vanuit DNA, RNA en eiwit 
niveau inclusief de mate van heterogeniteit in deze eigenschappen tussen verschillende 
CTC’s is het niet aannemelijk dat deze merkers CTC’s zullen vervangen. 
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Voor de toekomst zal de focus van studies moeten liggen op de biologie van CTC’s als 
aanvulling op het onderzoek naar de predictieve waarde. Onderzoek in pure CTC fracties 
zonder bijvangst van bloedcellen zal moeten ophelderen welke veranderingen CTC’s 
ondergaan wanneer ze circuleren in het bloed. Het proces van EMT en het tegengestelde 
proces van mesenchymale-naar-epitheliale-transitie (MET) moet worden bestudeerd 
om tot detectiemerkers te komen die het mogelijk maken om alle CTC’s die aanwezig 
zijn in het bloed te vangen, inclusief de subset van CTC’s die volledige EMT hebben 
ondergaan. Pas dan kan de echte prognostische en predictieve waarde van CTC’s worden 
vastgesteld. Bovendien kan dit nieuwe aangrijpingspunten voor behandeling opleveren, 
bijvoorbeeld door de factoren die EMT in gang zetten te remmen of het tegengestelde 
proces van MET tegen te gaan zodat er geen (nieuwe) uitzaaiingen gevormd kunnen 
worden. Studies bij patiënten met uitgezaaide ziekte zullen moeten uitwijzen tot op 
welke hoogte de eigenschappen van CTC’s overeenkomen met de uitzaaiingen en of 
ze werkelijk iets kunnen zeggen over de mate van heterogeniteit tussen verschillende 
uitzaaiingen. Hiervoor zou bij voorkeur het DNA uit verschillende tumorklonen van 
verschillende uitzaaiingen genetisch onderzocht moeten worden, waarna dit vergeleken 
zou moeten worden met het genetische profiel van verschillende losse CTC’s om vast te 
kunnen stellen of CTC’s afkomstig zijn van alle tumorklonen die aanwezig zijn of van een 
selectie van de meest agressieve tumorklonen. 
Resultaten verkregen uit nog te starten, veelomvattende en grootschalige klinische 
studies naar de eigenschappen van CTC’s op het niveau van het DNA, RNA en eiwit zullen 
een schat aan informatie opleveren, welke zal helpen om de beste manier te bepalen 
om tumoren vanaf een zo vroeg mogelijk stadium te behandelen. Inmiddels zijn zulke 
studies reeds gestart, waarbij weefsel afkomstig van een uitzaaiing wordt onderzocht, 
bijvoorbeeld het onderzoek zoals dat uitgevoerd wordt door het Nederlands Centrum 
voor Persoonsgerichte Behandeling van Kanker (Center for Personalized Cancer 
Treatment, CPCT). Deze inspanningen zullen ons verder op weg helpen om tumor-
specifieke genetische factoren en signaalpaden te identificeren die als aangrijpingspunt 
voor therapie kunnen dienen. Echter, het onderzoeken van een uitzaaiing op een 
specifiek tijdspunt zal weinig inzicht geven in het ontstaan van mechanismen die een 
tumor kan aanwenden om onder de druk van een behandeling uit te komen. Daarnaast 
geven puur genetische analyses niet alle informatie over de veranderingen die in een 
tumor kunnen optreden. Bijvoorbeeld epigenetische veranderingen, alternatieve 
splitsing van gen transcripten, of eiwit-gerelateerde veranderingen zoals fosforylatie 
worden niet meegenomen in de genetische analyses. Middels herhaalde bepalingen van 
de eigenschappen van CTC’s kunnen veranderingen van een tumor gedurende de tijd en 
over verschillende behandelingen potentieel zichtbaar gemaakt worden. Doel hierbij is 
om alle moleculaire eigenschappen in aanvulling op de DNA afwijkingen in ogenschouw 
te nemen om zo vroeg mogelijk te kunnen acteren op het ontstaan van resistentie tegen 
de ingestelde behandeling. Uitgaande van dit scenario zullen CTC’s een onmisbaar 
hulpmiddel voor de oncoloog kunnen gaan worden om ofwel het ontstaan van 
uitzaaiingen te voorkomen bij patiënten die zich presenteren met lokale ziekte ofwel de 
groei van de ziekte tegen te gaan bij patiënten die zich presenteren met reeds gevorderde 
ziekte. Uiteindelijk zal kanker op deze manier een chronische, goed te behandelen ziekte 
kunnen worden, gebaseerd op weloverwogen en goed geïnformeerde behandelkeuzes 
aan de hand van herhaalde analyses van de eigenschappen van CTC’s.
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AC Adriamycin + cyclophosphamide combination chemotherapy
ALP Alkaline Phosphatase
APC Allophycocyanin
AR Androgen Receptor
AR-V7 Androgen Receptor splice Variant 7
AR-WT Wild-Type Androgen Receptor
BR Bloom & Richardson grade
BRAF B-RAF Proto-oncogene, serine/threonine kinase
GUSB Gluceronidase beta; gene involved in regular cell metabolism
CD Cluster of Differentiation molecule
cDNA Complementary DeoxyriboNucleic Acid
CEC Circulating Endothelial Cell
CEER Collaborative Enzyme Enhanced Reactive (assay)
cfDNA Cell-Free DeoxyriboNucleic Acid
CI Confidence Interval
CK CytoKeratin
cKIT KIT proto-oncogene receptor tyrosine kinase
CMF Cyclophosphamide, Methotrexate and Fluorouracil combination chemotherapy
CRPC Castration-Resistant Prostate Cancer
Cq Cycle threshold for quantification
CT Computed Tomography
CTC(s) Circulating Tumor Cell(s)
ctDNA Circulating Tumor DeoxyriboNucleic Acid
DAPI 4’,6-DiAmidino-2-Phenylindole
DFS Disease-Free Survival
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DMFS Distant Metastasis-Free Survival
DNA DeoxyriboNucleic Acid
DSB Double Strand Break
DTC Disseminated Tumor Cell
EDTA Ethylenediaminetetraacetic acid
EGFR Epidermal Growth Factor Receptor
EMT Epithelial-to-Mesenchymal Transition
EpCAM Epithelial Cell Adhesion Molecule
ER Estrogen Receptor alpha
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2, gene coding for HER2
ERCC1 Excision Repair Cross-Complementing protein 1
ESR1 Estrogen Receptor 1, gene coding for the ER-alpha protein
FEC Fluorouracil, Epirubicin and Cyclophosphamide combination che-motherapy
FDA Food and Drug Administration (United States)
FGFR Fibroblast Growth Factor Receptor
FITC Fluorescein IsoThioCyanate 
FISH Fluorescence In Situ Hybridization 
FF Fresh-Frozen
FFPE Formalin-Fixed Paraffin-Embedded
FU Follow-Up
GIST Gastro-Intestinal Stromal Tumor
HBD Healthy Blood Donor
HE hematoxylin and eosin (staining)
HER2 Human Epidermal growth factor Receptor 2
HMBS Hydroxymethylbilane synthase; gene involved in regular cell me-tabolism
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HPRT1 Hypoxanthine Phosphoribosyltransferase 1; gene involved in reg-ular cell metabolism
HR Hazard Ratio 
IF ImmunoFluorescence
IQR InterQuartile Range
KRT19 Gene coding for cytokeratin-19
KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog
LABC Locally-Advanced Breast Cancer 
LDH Lactate DeHydrogenase
LHRH Luteinizing Hormone-Releasing Hormone
LNM Lymph Node Metastasis
M Metastasis
MAI Mitotic Activity Index
MBC Metastatic Breast Cancer
MCAM Melanoma Cell Adhesion Molecule
MCRC Metastatic ColoRectal Cancer
MCRPC Metastatic Castration-Resistant Prostate Cancer
MET Mesenchymal-to-Epithelial Transition
Metachr Metachronous (metastasis)
mRNA Messenger RiboNucleic Acid
MUC1 Mucin 1
NAC NeoAdjuvant Chemotherapy
NR Not Reported
NRAS Neuroblastoma RAS Viral Oncogene Homolog
OS Overall Survival
PBC Primary Breast Cancer
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pCR Pathological Complete Response
PCWG2 Prostate Cancer Working Group 2
PD Progressive Disease
PE PhycoErythrin
PFS Progression-Free Survival
pHER2 Phosphorylated HER2
PI3K Phosphoinositide 3-Kinase 
PR Progesterone Receptor
PSA Prostate-Specific Antigen
PT Primary Tumor
RECIST Response Evaluation Criteria in Solid Tumors
ROC receiver operating characteristics
RR Response Rate
RT-(q)PCR Reverse Transcription (Quantitative) Polymerase Chain Reaction
sd standard deviation
Synchr Synchronous (metastasis)
TAC Taxotere (docetaxel)/Adriamycine (doxorubicin)/ Cyclophosphamide combination chemotherapy
TTS Time-to-Treatment Switch
Uk Unknown
ULN Upper Limit of Normal 
WHO World Health Organization
WT Wild-type
ZA Zoledronic Acid
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Zoals alle andere is ook dit proefschrift niet zonder de hulp van velen tot stand 
gekomen. Graag wil ik dan ook een ieder bedanken die geholpen heeft bij het opzetten 
van de studies, het verkrijgen en analyseren van alle resultaten en het schrijven van de 
manuscripten. Een aantal personen wil ik graag bij naam noemen. 
Mijn promotoren, prof.dr. Stefan Sleijfer en prof.dr. John Foekens. Beste S, ik kan bij 
niemand anders beginnen dan bij jou. Via jou kwam ik op het toenmalige lab Medische 
Tumor Immunologie terecht dat je samen met dr. Jan-Willem Gratama wetenschappelijk 
leidde. Op dit lab deed ik in eerste instantie mijn afstudeeronderzoek om na de co-
schappen terug te keren in de Daniël den Hoed Kliniek en mijn promotie onderzoek aan te 
vangen. Ik heb de afgelopen jaren heel veel van je mogen leren; onder jouw begeleiding 
is mijn wetenschappelijk fundering gelegd. Ik hoop dit in de toekomst verder uit te 
kunnen breiden, hopelijk daarbij verder gebruik makend van jouw waardevolle input 
en indrukwekkende kennis van de oncologie. Die rare tic om artikelen te onthouden 
op tijdschrift, volume- en paginanummer neem ik alleen niet van je over. Buiten het 
wetenschappelijke wil ik je ook zeer bedanken voor je support en de gesprekken die we 
hebben gevoerd. En ik zei toch, het komt goed! ;)
Beste John, de eerste jaren zijn we elkaar niet zoveel tegen gekomen buiten onze 
“CTC besprekingen” daar we beiden aan een andere kant van de Maas zaten, jij in 
het Josephine Nefkens Instituut en ik in de Daniël den Hoed. De afgelopen twee jaar, 
sinds onze verhuizing naar het JNI, zijn we buren en is tussentijds overleg makkelijker 
geworden. Dit heeft gezorgd voor meer inbreng vanaf de niet-klinische kant in de 
klinische projecten, iets wat ik zeer gewaardeerd heb. De combinatie van klinische en 
niet-klinische onderzoekers in onze groep heeft interessante discussies en benaderingen 
van onderzoeksvragen opgeleverd en mij geleerd meer vanuit de tumor biologie te 
denken. Daarnaast dank ik je voor het zorgvuldige nalezen van mijn manuscripten. Als jij 
er doorheen bent gegaan, weet je zeker dat de laatste spelfouten eruit zijn!
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Mijn co-promotor dr. J.W.M. Martens. Beste John, alvorens je te bedanken moet ik 
misschien eerst beginnen met sorry te zeggen? Misschien was onze verhuizing naar het 
JNI voor jou minder voordelig; of in ieder geval was het daarna minder rustig. Sorry voor 
alle overlast en voor mijn pesterijen. Maar ja, door zo snel op de kast te gaan zitten, 
vraag je er ook wel een beetje om… Daarnaast dank ik je voor de vele wetenschappelijke 
discussies die we hebben gevoerd, waarbij jij het zeker niet altijd met me eens was 
(of was het andersom??). Deze discussies hebben me vaak aan het denken gezet en 
me uitgenodigd om mijn kennis te verdiepen en problemen van een andere kant te 
benaderen. Ik heb veel kunnen leren van jouw enorme kennis over de tumor biologie op 
het gebied van zowel DNA, RNA als eiwit. Ik hoop onze discussies voort te kunnen blijven 
zetten binnen het Center for Personalized Cancer Treatment en hoop dat daar nog mooie 
projecten uit mogen ontstaan. 
Geachte dr. J.W. Gratama, beste Jan-Willem, jij nam me aan als geneeskunde student 
om op het lab Medische Tumor Immunologie onderzoek te gaan doen naar circulerende 
endotheelcellen. Na die vijf maanden, waarin ik meer ELISA’s heb gedaan dan me lief 
was, vroeg je me te blijven om promotie onderzoek te komen doen. Ondanks dat ik eerst 
mijn co-schappen ben gaan lopen, is mijn plekje toch vrij gebleven en kon ik direct daarna 
aan de slag. Bedankt voor alles wat ik heb mogen leren over de immunologie en flow 
cytometrie en voor het zorgvuldige nalezen van mijn manuscripten, die mede door jouw 
commentaar verbeterden. 
De leden van de kleine commissie – prof.dr. Ronald de Wit, prof.dr. Guido Jenster en dr. 
Luc Dirix – en de grote commissie – prof.dr. Leon Terstappen en prof.dr. Edwin Cuppen 
– dank ik hartelijk voor het aannemen van de uitnodiging om plaats te nemen in de 
commissie en voor de tijd en moeite die de beoordeling van het proefschrift hebben 
gevraagd.
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Geachte dr. M.E.L. van der Burg, beste Maria, jij verdient hier zeker een plek. Ik had graag 
gewild dat je bij de grote dag had kunnen zijn. Aan deze dag en aan dit proefschrift heb 
jij zeker bijgedragen. Vanaf het trialbureau Interne Oncologie, waar we samen orde in de 
TURBO chaos zijn gaan scheppen, is onze samenwerking verder uitgegroeid en dit heeft 
onder andere geresulteerd in twee mooie publicaties. Helaas heb je de laatste niet meer 
kunnen zien, maar ik ben trots op het eindresultaat en weet zeker dat jij dat ook zou zijn 
geweest. Ik heb mijn belofte aan je gehouden, het is af! 
Dr. Jaco Kraan, beste J, van wie anders dan van jou kon ik het beste leren hoe de wereld 
van de flow cytometrie in elkaar steekt?! Dat deze experimenten niet geleid hebben tot 
een hoofdstuk in dit proefschrift ligt zeker niet aan jouw technische en theoretische 
support. Qua morele ondersteuning moet ik toch nog wel even een kritische noot 
plaatsen. Zeggen dat “wij” het goed hebben gedaan als iets goed gelukt is, maar dat 
ík geprutst heb als de uitkomsten niet helemaal naar verwachting waren, is niet goed 
voor het moreel van een beginnend AIO. Beloven dat het nu jouw beurt is om koffie te 
gaan halen na het afronding van het proefschrift (ref: proefschrift J. Kraan, bladzijde 165, 
paragraaf 4) en het vervolgens niet doen, evenals niet terugpraten als ventilatie hoog 
nodig is, is niet goed voor het moreel van een AIO in de afrondende fase. Ondanks dit 
alles blijf je toch mijn favoriete (en voor de onwetende lezer, tevens enige) roomie. Ik zal 
niet tegen Annemarie zeggen dat je dat oude vest nog steeds aan doet op onze kamer. 
Dr. A.M. Sieuwerts, beste Anieta, dank je wel voor alles wat je me bijgebracht heb over 
PCR’s, gen expressies en de analyses. Alles wat ik hiervan weet komt van jouw grote 
kennis en praktische vaardigheden. Ik heb goede herinneringen aan het weekendwerk 
op het lab en de drankjes die we hebben gedaan. Gelukkig ligt er nog wat werk op de 
plank en kunnen we onze samenwerking nog even voortzetten.
Petra van der Spoel, Patricia van den Broek, Mai Van, Zahra Alawi, Joan Bolt, Mieke 
Timmermans en alle andere analisten van het voormalige laboratorium Medische Tumor 
Immunologie en het huidige laboratorium Translational Cancer Genomics and Proteomics, 
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bedankt voor alle hulp bij de experimenten! Zonder jullie had het tot stand komen van dit 
proefschrift nog minstens vier jaar langer geduurd. Bedankt ook voor alle gezelligheid 
op het lab.
Marcel Smid, dank je wel voor je hulp bij de diverse analyses die zeker niet altijd 
gemakkelijk gingen. Je bent nooit te beroerd even mee te denken of iets na te zoeken. 
Wat de rest betreft; het anti-dankwoord werd te lang en is daarom slechts als bijlage 
op aanvraag beschikbaar. Maar we hebben het er al over gehad; niet bedankt voor alle 
keren dat je me onderuit haalde en voor al je sarcasme en grove (en tevens slechte) 
grappen. 
Prof.dr. P. Berns, beste Els, via Maria leerde ik jou kennen en maakte ik kennis met het 
translationele onderzoek bij het ovariumcarcinoom. Jouw energie en enthousiasme voor 
het onderzoek werken aanstekend en motiveren om steeds weer op zoek te gaan naar 
verdere antwoorden. Daarnaast heb je me laten zien hoe leuk het geven van onderwijs 
is. Dankzij jouw grote inzet is de Junior Med School vanuit de oncologie jaar op jaar weer 
een succes. Dank je wel ook voor alle steun en advies. 
Alle mede-promovendi door de jaren heen: Arjen, Bianca, Esther, Nick, Ellen, Annemieke, 
Sander (CPCT buddy), Marjolein, Inge, Lisanne, Lindsay. Bedankt voor alle gezelligheid 
en de fijne werkomgeving die we met z’n allen gecreëerd hebben (Be-414, onthoud: 
koffie na de lunch is een verplicht onderdeel van de AIO opleiding!). Bianca, van jou 
nam ik het onderzoek over, iets wat niet zomaar gedaan was. Jij hebt een belangrijke 
rol gehad in het opzetten van de CTC werkgroep en aan mij was de taak om dit over te 
nemen en voort te zetten. Bedankt voor al je werk en de gelegde fundamenten voor mijn 
projecten. Het is goed om te zien dat je hart nog steeds bij het CTC onderzoek ligt en dat 
je actief betrokken wilt blijven bij het onderzoek. Ik hoop dat je in de toekomst vanuit de 
kliniek een waardevolle rol kunt gaan spelen. 
Ook goed om te zien is dat de groep AIO’s behoorlijk is uitgebreid de laatste jaren. Het 
onderzoek naar de liquid biopsies (en die mito dingen) is succesvol en belooft veel voor 
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de toekomst van de oncologie. Fantastisch om te zien dat we daar vanuit Rotterdam in 
kunnen bijdragen. 
Esther, dr. E, my partner in crime. De kleine zeemeermin reciteren, selfies maken op de 
follow-you scanner, spandoeken knutselen om een bepaalde collega aan te moedigen; 
hoe is het ons überhaupt gelukt die proefschriften af te krijgen?? Het is significant 
rustiger nu jij niet meer dagelijks rondloopt op de afdeling en dat is niet per sé een 
goed ding. Gelukkig ben je er nog af en toe om ons op de hoogte te houden van laatste 
ontwikkelingen op welk gebied dan ook. Wanneer doen we de ASCO samen in Chicago 
nog eens over? Dit keer graag mét rodeostier in dat ene café (hoe heette dat ook alweer, 
S?). Ik draag het stokje aan jou over; succes met de laatste loodjes van jouw proefschrift! 
Goed onderzoek komt bij uitstek tot stand door samenwerking tussen afdelingen en 
disciplines. In ons geval is de samenwerking met het Center for Oncological Research van 
het Sint-Augustinus Ziekenhuis/Universiteit van Antwerpen hier een goed voorbeeld van. 
Onder leiding van prof.dr. Steven van Laere en dr. Luc Dirix zijn al heel wat gezamenlijke 
projecten van de grond gekomen en met iedere inter-lab meeting komen er weer nieuwe 
ideeën bij. Beste Luc, mede hierom vind ik het mooi dat u plaats heeft willen nemen in 
mijn leescommissie. Beste Dieter en Bram, bedankt voor de prettige samenwerking op 
de verschillende mammacarcinoom en prostaatcarcinoom projecten en voor het heen 
en weer reizen als er weer eens stalen opgehaald of langsgebracht moesten worden. 
Een samenwerking aan de meer technische kant van CTC verrijking, detectie en 
karakterisatie is die met de Medical Cell BioPhysics groep van de Universiteit van Twente. 
Geachte prof.dr. L.W.M.M. Terstappen, beste Léon, bedankt voor alle ondersteuning 
en input vanaf deze voor mij toch wat ingewikkeldere kant van het verhaal. Tevens 
bedankt voor de goede week in Athene en natuurlijk voor het plaatsnemen in mijn grote 
commissie. 
Binnen het Erasmus MC is de samenwerking met de afdelingen Interne Oncologie, 
Chirurgie, Urologie en Pathologie van het Erasmus MC van groot belang geweest. 
Om die reden wil ik graag alle oncologen bedanken voor het meewerken aan al onze 
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studies en het vragen van patiënten voor hun toestemming voor deelname. Hoewel 
er vele studies lopen en de bomen het bos soms niet meer lieten zien, was er altijd de 
bereidheid om mee te denken in oplossingen en verbeteringen. Carolien van Deurzen, 
bedankt voor de beoordeling van al die paraffine blokjes van de mammatumoren. Guido 
Jenster en Wytske van Weerden, bedankt voor jullie input en specifieke kennis over het 
prostaatcarcinoom. 
Mijn dank gaat zeker ook uit naar de oncologen uit de diverse externe centra die mee 
hebben gewerkt aan onze studies. Specifiek wil ik hierbij dr. Paul Hamberg en dr. Felix de 
Jongh benoemen. Beste Paul, jouw inzet voor het onderzoek vanuit het Sint Franciscus 
Gasthuis is onovertroffen. Onderzoek naar CTC’s, circulerend tumor DNA, genetisch 
onderzoek in biopten, we kunnen altijd bij je terecht. Bedankt ook voor het kritisch 
nalezen van de manuscripten en de suggesties ter verbetering. Beste Felix, bedankt 
voor al die patiënten die trouw vanuit het Ikazia Ziekenhuis aangemeld bleven worden. 
Hopelijk kan deze vruchtbare samenwerking in de toekomst voortgezet worden. 
Alle research verpleegkundigen uit het Erasmus MC en de externe centra (Anita van 
der Poel, Karin Wensing, Linda de Hoog, Suraya van Broekhoven, Corry Leunis) hartelijk 
dank voor jullie inzet om al die bloedafnames steeds maar weer op tijd te organiseren 
en realiseren.
Alle patiënten en hun familie, alsmede de bloedbankdonoren, bedankt voor de belangrijke 
en belangeloze bijdrage aan het wetenschappelijk onderzoek. Al lijkt het soms slechts de 
afname van een extra buisje bloed, ik heb respect voor de medewerking in vaak zware 
en emotionele tijden waarin al genoeg gebeurt. Deze medewerking is essentieel om de 
behandeling voor toekomstige patiënten met kanker te kunnen verbeteren. 
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Mijn nieuwe collega’s bij Hartwig Medical Foundation, bedankt voor de nieuwe uitdaging 
die jullie me bieden. In een relatief korte tijd is een indrukwekkende sequencing faciliteit 
opgezet met een enthousiast, betrokken en bekwaamd intern team onder aansturing 
van Hans van Snellenberg. Beste Hans, captain Kirk, bedankt dat je me binnengehaald 
hebt bij het moederschip. Ik voel me trots en vereerd om deel uit te mogen maken van 
de bemanning. Prof.dr. Edwin Cuppen, beste Edwin, bedankt voor de samenwerking tot 
nu toe; ik hoop mijn kennis op het gebied van sequencing en genetica nog wat uit te 
kunnen breiden in de nabije toekomst.
Mijn paranimfen, lieve Lieke en lieve Annemarie, wat ben ik blij om jullie naast en achter 
me te mogen hebben. Dank jullie wel dat jullie mijn paranimfen willen zijn en mij willen 
helpen er een onvergetelijke dag van te maken. Dank jullie wel dat jullie er altijd voor 
me zijn en op ieder moment van de dag voor me klaar willen staan, maar ook voor alle 
gewoon gezellige avonden, theetjes en etentjes (An, awesome!). 
Mijn lieve vriendinnen, bedankt! Lieke, Annemarie, Ilse, Tanja, Merlijn, Petra, Anke; 
bedankt voor alle gezellige avondjes en goede gesprekken. Ik hoop dat er nog veel 
etentjes, bezoekjes aan musea, theater, en gewoon gezellige bijklets avondjes met 
thee of wijn zullen volgen. Ilse, je bent een topper en ik heb bewondering voor je 
doorzettingsvermogen. Tanja, dank je wel voor alles wat je voor me hebt betekend!! 
Vanaf het bijzondere begin van onze vriendschap tot onze etentjes nu en alle appjes 
tussendoor. Ik vind onze vriendschap heel bijzonder en ik waardeer je enorm. Merlijn, 
mijn oud-collegaatje van het trialbureau Interne Oncologie in de Daniël die ook nog eens 
bij mij in de buurt bleek te wonen. We hebben heel wat samen gefietst en hard gelopen. 
Inmiddels doen we allebei iets anders, maar is de vriendschap gelukkig gebleven. Ik hoop 
dat dit nog lang zo mag blijven. Peet, wat gaan de jaren snel voorbij; we zijn toch heel 
wat verder nu. Ik ben trots op ons! Anke, al is het misschien niet zo vaak, onze bijklets-
avondjes zijn altijd gezellig en vol van nieuwe verhalen over de opleiding en de laatste 
reizen; wat mij betreft mag ik die nog vaak horen. Ennuh… You’re next! 
Lieve familie, dit proefschrift is voor jullie. Het devies hard werken en nooit opgeven om 
te kunnen bereiken waar je van droomt heb ik van jullie; wij zijn vechters en doorzetters 
en komen alles te boven. Pa & ma, ik weet dat jullie altijd achter me hebben gestaan en 
altijd achter me zullen staan. Pap, ik vind het een eer dat je mijn voorkant hebt gemaakt. 
Liefste broer, hoe trots ben ik op jou! Ik zeg het niet genoeg, maar jullie betekenen de 
wereld voor me. Lieve o & o, één! Meer hoef ik niet te zeggen toch? Ik had graag gewild 
dat u dit had kunnen meemaken, opa, maar ik weet dat u heel groos op me bent. In 
gedachten bent u erbij.
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General Courses Year ECTS
BROK course on clinical research, legislation and organization 2008 1.5
BROK recertification 2014 1
Biomedical English Writing 2012 2
NiHes Winter Programme:
• Clinical epidemiology
• Biostatistics for clinicians
• Regression analysis for clinicians
• Survival analysis for clinicians
2012 5
Workshop Successful Grant Writing 2012 0.3
BKO training Teach the Teacher 2012 1
Workshop Adobe Photoshop and Ilustrator CS6 2013 0.15
Workshop Adobe Indesign CS6 2014 0.15
Workshop How to teach groups of students 2014 0.15
Workshop Individual Interviews with Students 2014 0.15
Masterclass Cambridge Advanced General English 
(two semesters)
2015
2016
3
Specific Courses Year ECTS
MolMed Course Introduction to Biomedical Research Techniques 2011 1.6
NVVO Introduction course into Fundamental and Clinical Oncology 2011 1.5
Veridex CellSearch Training 2011 1.5
Oral presentations Year ECTS
Medical Oncology Research Meeting, EMC, Rotterdam Annually 1
Josephine Nefkens Institute Oncology Meeting, Rotterdam Annually 1
A Sister’s Hope Brilliant Minds Together Meeting, Amsterdam 2012 0.2
Dutch Uro-Oncology Studygroup (DUOS) symposium, Utrecht 2012 0.2
Molecular Tools Group meeting, Uppsala University, Sweden 2012 0.2
European Organization for Research and Treatment of Cancer (EORTC) 
Gynaecologic Cancer Group General Assembly and Business Meeting, 
Brussels
2013 0.2
Scientific meeting of Department of Medical Oncology, EMC, Rotterdam 2013 0.2
DUOS symposium, Utrecht 2012 0.2
Sint Franciscus Gasthuis Research Meeting, Rotterdam 2015 0.2
Janssen Academy, Rotterdam 2016 0.2
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Poster presentations Year ECTS
The European Cancer Congress, Amsterdam 2013 1
American Society of Clinical Oncology, Chicago, Illinois 2014 1
The European Cancer Congress, Vienna, Austria 2015 1
(Inter)National conferences and Symposia Year ECTS
Scientific Meeting of the Department of Medical Oncology, Rotterdam Annually 0.5
Novel Treatments in Gynaecological Cancer, Amsterdam 2011 0.2
EORTC 50th Anniversary Meeting, Leuven, Belgium 2012 0.4
Advances in Circulating Tumor Cells, Athens, Greece 2012 1
Borstkanker Behandeling Beter, Rotterdam 2013 0.2
American Society of Clinical Oncology, Chicago, Illinois 2013 1
Scientific Meeting of the Erasmus Medical Center, Rotterdam 2014 0.2
Center for Personalized Cancer Treatment (CPCT) Symposium 2015 0.2
Teaching Year ECTS
Lecture Junior Med School class Annually 0.2
Lecture third-year medical students, Minor Oncology Annually 0.2
Supervision of four-week Junior Med School Medical Oncology lab program 2011 1.5
Development and coordination of four-week Junior Med School Medical 
Oncology lab program 2013 2
Co-supervision medical master student 2012 2
Supervision University College student 2014 0.5
Tutor first-year medical students 2014 1
Lecture second-year medical students in Honours Class 2015 0.2
Extended tutorate first-year students 
(Kennismaking Beroeps Praktijk)
2016 0.5
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Wendy Onstenk werd geboren op 13 april 1984 te Schiedam. Zij volgde middelbaar onderwijs aan het 
Stedelijk Gymnasium te Schiedam. Vanaf de vierde klas in 2000 participeerde zij één à twee dagen 
per week in onderzoek naar embryogenese en congenitale afwijkingen aan de afdeling Plastische 
en Reconstructieve Chirurgie van het Erasmus MC onder supervisie van dr. A.J.M. Luijsterburg en 
dr. C. Vermeij-Keers. Dit resulteerde in een profielwerkstuk over craniosynostoses, waarvoor zij 
een prijs ontving. In 2002 behaalde zij cum laude haar VWO-diploma aan het Stedelijk Gymnasium 
te Schiedam, waarna zij direct begon met de studie Geneeskunde aan de Erasmus Universiteit te 
Rotterdam. Vanaf 2004 werkte zij als medisch student bij de afdeling Interne Oncologie van het 
Erasmus MC, in eerste instantie als medisch typiste en vanaf 2007 als datamanager bij het trialbureau 
Interne Oncologie. Hier werkte zij als lokaal en regionaal datamanager aan verschillende fase I, II 
en III studies binnen de oncologie. In dit kader behaalde zij ook haar Good Clinical Practice diploma 
in 2008. In 2009 deed zij haar wetenschapsstage van 21 weken aan het Laboratorium Medische 
Tumor Immunologie in de Daniël den Hoed Kliniek onder supervisie van dr. Michiel Strijbos en 
dr. Jan-Willem Gratama. Na afronding van de scriptie Biomarkers in Clinical Oncology behaalde zij 
haar doctoraal diploma. Vanaf 2009 tot 2011 volgden twee jaar co-schappen, welke afgesloten 
werden met een oudste co-schap bij de afdeling Interne Geneeskunde in het Ikazia Ziekenhuis 
onder supervisie van dr. A. Dees. Gedurende de co-schappen werkte zij door aan een eerder 
gestart onderzoek bij patiënten met eierstokkanker in samenwerking met dr. M.E.L. van der Burg 
en prof.dr. P.M.J.J. Berns, wat resulteerde in twee publicaties. Na de co-schappen legde zij in 2011 
het artsexamen cum laude af en startte zij met het promotie-onderzoek aan de afdeling Interne 
Oncologie van het Erasmus MC Kankerinstituut onder supervisie van prof.dr. S. Sleijfer, prof.dr. 
J.A. Foekens en dr.ir. J.W.M. Martens, zoals beschreven in dit proefschrift. Tijdens het promotie-
onderzoek heeft zij in 2012 een laboratorium stage van twee maanden gevolgd bij de Molecular Tools 
Research Group aan de Universiteit van Uppsala in Zweden onder supervisie van dr. O. Söderberg. 
Deze stage werd mogelijk gemaakt door het verwerven van een persoonsgebonden reisbeurs 
via het Koningin Wilhelmina Fonds. In 2014 won zij een Conquer Cancer Foundation of the Americal 
Society of Clinical Oncology Merit Award voor het ingediende onderzoek voor het ASCO congres 
van dat jaar. Gedurende het promotie-onderzoek heeft zij mogen presenteren op (inter)nationale 
congressen en schreef zij mee aan enkele gehonoreerde subsidie aanvragen, onder andere door 
Pink Ribbon en A Sister’s Hope. Tevens was zij actief betrokken bij het onderwijs aan Junior Med 
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School, eerste-, tweede- en derdejaars geneeskunde en master studenten. Per 1 april 2015 startte 
zij als postdoctoral fellow aan de afdeling Interne Oncologie van het Erasmus MC Kankerinstituut 
en werkte zij aan de Center for Personalized Cancer Treatment (CPCT)-02 studie. Vanaf 1 april 2016 
werkt zij tevens in dienst van Hartwig Medical Foundation om grootschalige moleculaire analyse 
van tumoren te faciliteren.
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